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ABSTRACT 
Overeating is believed to be the primary factor responsible for the increasing prevalence 
of human obesity. A proportion of people develops a chronic obsessive/compulsive 
relationship to foods that is defined as food addiction (FA). The degree that FA contributes 
to obesity in the general population, and the key factors involved in FA, are unknown. The 
aims of the thesis were to assess and to find: 1) The prevalence of FA in the general 
population; 2) If clinical symptom counts of FA were significantly correlated with body 
composition measurements; 3) If food addicts were significantly more obese than controls, 
4) If any macronutrient intake is associated with FA, 5) The link of hormones and 
neuropeptides that regulate appetite and metabolism with FA, 6) The differences of dietary 
nutrient intakes (micro- and macro-nutrients) between obese individuals with FA (FAO) 
or without FA (NFO), and 7) Discovery of novel FA associated candidate genes. 
The current thesis consists of three phases. In phase I, I found that the prevalence of FA in 
the general NL population was 5.4% and women had double the prevalence relative to men. 
FA was significantly associated with obesity (vs normals). Additionally, FA was positively 
correlated with severity of obesity. 
In phase II, compared to NFO, FAO individuals had lower levels of TSH, TNF-α, and 
amylin, but higher levels of prolactin. The total calorie intake, the dietary intake of fat and 
the percent calorie intake from fat and carbohydrates was higher in the FAO. FAO subjects 
consumed more sugar, minerals (including sodium, potassium, calcium and selenium), fat 
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and its components, omega 3 and 6 fatty acids, vitamin D and gamma-tocopherol than 
NFO. 
The phase III by combining exome sequencing technology with genetic association 
analysis in 2 equally obese but with opposite extreme phenotype of FA, we discovered and 
validated two FA candidate genes: DRD2 and TIRAP. Our discoveries suggest that FA 
may represent a sub-group of obese individuals with unique nutritional, hormonal and 
genetic factors. 
  
iv 
 
ACKNOWLEDGEMENTS 
I would like to thank, first and foremost, my supervisor, Dr. Guang Sun, for giving me the 
opportunity to deeply develop my skill in obesity research, for teaching me how to think 
as a researcher and how to apply my knowledge in a productive way.  You are not only my 
mentor, but also a role model for my career in the future. I sincerely appreciate you for 
giving me the confidence and freedom to grow as a research scientist and to actively 
contribute towards the training of other students in our laboratory.  
I would also like to thank my committee members, Dr. Guangju Zhai and Dr. Sudesh 
Vasdev, for their supports, guidance, and their brilliant suggestions and comments 
throughout the course of my Ph.D.  
I would like to thank Ms. Hongwei Zhang, our wonderful laboratory technician, for being 
always ready to help and support me. During my Ph.D., we spent many hours together to 
teach each other. She is a very hard working person and very patient as a teacher.   
I would also like to especially thank Dr. Wayne Gulliver, for encouraging me in my 
research and for all of his valuable comments on all parts of my projects during my Ph.D. 
During the past 4 years, he has taught me something new in every meeting that we had.  I 
always wish to be as productive and knowledgeable as he is. 
To Dr. Shabnam Asghari- Thanks for believing me and giving this opportunity to work 
with you. In this short period of time, I learned tremendously from you. I really enjoyed 
v 
 
the way that you approach research and I am tremendously honored to be a small part of 
your team.  
To my wonderful sister, Panteha- Thank you so much for being such a positive influence 
in my life. You have always encouraged me to follow my dream. Thank you for always 
being available to support me and be part of my success.   
To my husband and my best friend, Farzad- You cannot imagine how much your supports 
means to me. Thank you for caring so much and inspiring me. I sincerely appreciate you 
to always be the first person who pushes me to follow my dream.  
And finally, to my parents. I am tremendously grateful to you for encouraging me, for 
supporting me and teaching me how to work hard.  You have been always my role model 
since I was a kid. Thanks for raising me with a love of science and the principle of hard 
work. Without your unconditional support the achievement of this degree would not have 
been possible.  
 
 
 
 
 
 
  
vi 
 
Table of Contents 
ABSTRACT ........................................................................................................................ ii 
ACKNOWLEDGEMENTS ............................................................................................... iv 
Table of Contents ............................................................................................................... vi 
List of Tables ..................................................................................................................... ix 
List of Figures .................................................................................................................... xi 
List of Abbreviations ........................................................................................................ xii 
Chapter 1. Introduction ..................................................................................................... 17 
1.1 Prevalence and Health Consequences of Obesity ................................................... 18 
1.2 Definition of obesity................................................................................................ 21 
1.3 Etiology of obesity .................................................................................................. 22 
 Environmental Factors ...................................................................................... 25 
 Genetics ............................................................................................................ 25 
 Unbalanced Diet ............................................................................................... 31 
 Dietary intake assessment ......................................................................... 34 
 Overeating ........................................................................................................ 35 
 Food Addiction ................................................................................................. 36 
 Clinical and behavioral similarities between food addiction and substance 
dependence ............................................................................................................ 37 
 Neurobiological similarities between food addiction and substance 
dependence ............................................................................................................ 40 
 Assessment of food addiction ................................................................... 41 
1.4 Approaches to Understanding the Etiology of Food Addiction .............................. 42 
 Appetite-Regulating Hormones ........................................................................ 42 
 Hedonic Aspects of Food intake ............................................................... 43 
 Homeostatic aspects of food intake .......................................................... 44 
 Dietary Intake ................................................................................................... 51 
 Genetics ............................................................................................................ 52 
1.5 Rationale.................................................................................................................. 54 
vii 
 
References ......................................................................................................................... 58 
Chapter 2. Food Addiction: Its Prevalence and Significant Association with Obesity in 
the General Population ...................................................................................................... 74 
2.1 Introduction ............................................................................................................. 75 
2.2 Materials and Methods ............................................................................................ 77 
2.3 Results ..................................................................................................................... 81 
2.4 Discussion ............................................................................................................... 88 
Author Contributions..................................................................................................... 91 
References ......................................................................................................................... 92 
Chapter 3. Hormonal and Dietary Characteristics in Obese Human Subjects with and 
without Food Addiction .................................................................................................... 95 
3.1 Introduction ............................................................................................................. 96 
3.2 Experimental Section .............................................................................................. 98 
3.3 Results ................................................................................................................... 103 
3.4 Discussion ............................................................................................................. 110 
3.5 Conclusions ........................................................................................................... 114 
Author Contributions................................................................................................... 114 
References ....................................................................................................................... 116 
Chapter 4. Two novel candidate genes identified in adults from the Newfoundland 
population with addictive tendencies towards Food ....................................................... 121 
4.1 Introduction ........................................................................................................... 122 
4.2 Method .................................................................................................................. 124 
4.3 Results ................................................................................................................... 130 
4.4 Discussion: ............................................................................................................ 143 
4.5 Conclusion ............................................................................................................. 148 
Author Contributions................................................................................................... 149 
Supplementary ................................................................................................................ 150 
I.S1. SNPs with significant difference of allele frequencies in genes associated with 
psychological disorders among the three groups ........................................................ 150 
viii 
 
I.S2. SNPs with significant difference of allele frequencies in genes associated with 
energy metabolism and obesity or obesity-related disease among the three groups ... 157 
I.S3. SNPs associated with the genes related to cancer and the genes with unknown 
function or with other diseases out of the aforementioned disease ............................. 164 
References ....................................................................................................................... 165 
Chapter 5. Conclusions, Limitations, and Future Directions .......................................... 178 
5.1 Concluding remarks .............................................................................................. 179 
5.2 Limitations of the present work ............................................................................ 182 
5.3 Future direction ..................................................................................................... 182 
APPENDIX 1 - MANUSCRIPTS PUBLISHED DURING PHD .................................. 184 
APPENDIX 2 – RESEARCH GRANTS DURING PHD .............................................. 186 
A2.1 The role of food addiction and gut hormones in obese Newfoundland children 187 
A2.2 The Association of Dietary Selenium Intake and Level of Serum Selenium with 
Childhood Obesity....................................................................................................... 189 
A2.3 The Association of Dietary Calcium Intake and Level of Serum Calcium with 
Obesity and Insulin Resistance in NL Children .......................................................... 191 
APPENDIX 3 – PUBLISHED ABSTRACTS & PRESENTATIONS DURING PHD . 193 
APPENDIX 4 – POSTERS PRESENTED AT INTERNATIONAL CONFERENCES 197 
A4.1 Hormonal and Dietary Characteristics in Obese Human Subjects with and without 
Food Addiction ............................................................................................................ 198 
A4.2 Metabolomics Characteristics in Obese Human Subjects with Food Addiction 204 
A4.3 Serum GLP-1, PYY, ghrelin, amylin and TNFα are significantly associated with 
the severity of Childhood Obesity ............................................................................... 208 
A4.4 The Associations of Dietary Selenium Intake and Level of Serum Selenium with 
Childhood Obesity....................................................................................................... 212 
A4.5 Negative associations of dietary and serum selenium with insulin resistance in 
children ........................................................................................................................ 216 
 
  
ix 
 
List of Tables 
Table 1-1 BMI classification based on WHO ................................................................... 24 
Table 1-2 Obesity status based on Bray criteria ............................................................... 24 
Table 2-1 Characteristics of Study Participants ................................................................ 83 
Table 2-2 Prevalence of food addiction according to sex and obesity status ................... 84 
Table 2-3 The proportion of food addiction according to obesity status .......................... 84 
Table 2-4 Correlation between food addiction clinical symptom counts with obesity 
measurements .................................................................................................................... 85 
Table 2-5 Obesity measurements and macronutrient intake characteristics of food 
addiction and non-food addiction ..................................................................................... 87 
Table 3-1 Characteristics of the study participants . ....................................................... 104 
Table 3-2 Hormonal and neuropeptide characteristics in food-addicted and non-food-
addicted overweight/obese . ............................................................................................ 105 
Table 3-3 Macronutrient intake characteristics in food addiction and non-food addiction 
overweight/obese groups  ............................................................................................... 108 
Table 3-4 Significant differences of selected micronutrient intakes between food addicts 
(FAO) and non-food addicts (NFA) of overweight/obese groups  ................................. 109 
Table 4-1 Characteristics of study participants in the two stages ................................... 131 
Table 4-2 SNPs with significantly different frequencies that are associated with 
addiction-related genes between FAO and NFO  ........................................................... 133 
Table 4-3 SNPs with significantly different frequencies associated with addiction-related 
genes between FAO and Ctrl .......................................................................................... 134 
Table 4-4 SNP with significantly different frequencies associated with addiction-related 
genes between NFO and healthy Ctrl ............................................................................. 135 
Table 4-5 SNPs with significantly different frequencies associated with addiction-related 
genes between NFO and NFO+Ctrl ................................................................................ 136 
Table 4-6 Comparisons of allelic and the genotypic frequencies of the SNPs located in 
addiction genes................................................................................................................ 137 
Table 4-7 Significant association between SNPs and food addiction ............................. 141 
x 
 
Table 4-8 SNPs with significant association to food addiction in the subjects categorized 
solely based on symptom counts..................................................................................... 142 
 
Table S1. SNPs with significantly different frequencies associated with psychological 
disorders related genes between FAO and NFO ............................................................. 151 
Table S2. SNPs with significantly different frequencies associated with psychological 
disorders related genes between FAO and Ctrl ............................................................... 153 
Table S3. SNPs with significantly different frequencies associated with psychological 
disorders related genes between NFO and Ctrl ............................................................... 154 
Table S4. SNPs with significantly different frequencies associated with psychological 
disorders related genes between FAO and NFO+Ctrl .................................................... 156 
Table S5. SNPs with significantly different frequencies associated with the genes related 
energy metabolism and obesity or obesity-related disease between FAO and NFO  ..... 158 
Table S6. SNPs with significantly different frequencies associated with the genes related 
energy metabolism and obesity or obesity-related disease in between FAO and Ctrl .... 159 
Table S7. SNP with significantly different frequencies associated with the genes related 
energy metabolism and obesity or obesity-related disease between NFO and healthy Ctrl
......................................................................................................................................... 161 
Table S8. SNPs with significantly different frequencies associated with the genes related 
energy metabolism and obesity or obesity-related disease between FAO and NFO+Ctrl
......................................................................................................................................... 162 
 
  
xi 
 
List of Figures 
 
Figure 1-1 Map of the prevalence of obesity in Canadian Adults according to body mass 
index (BMl ≥30.0 kg /m2) ................................................................................................. 20 
  
xii 
 
List of Abbreviations 
 
Abbreviation 
 
Full name 
%AF  Android fat percentage 
%BF  Body fat percentage 
%GF  Gynoid fat Percentage 
%TF  Trunk fat Percentage 
α-MSH  Alpha-melanocyte-stimulating hormone 
AACE  American Association of Clinical Endocrinologists  
ACTH  Adrenocorticotropic hormone 
ADHD  Attention Deficit Hyperactivity Disorder  
ADP  
 
Air displacement plethysmography 
AGRP  Agouti-related peptide 
ANCOVA 
 
Analysis of covariance 
BDNF  Brain-derived neurotrophic factor, 
BED   Binge Eating Disorder 
BIA 
 
Bioelectrical impedance analysis 
BMI 
 
Body mass index 
C-peptide  Connecting peptide 
CART  Cocaine and amphetamine regulated transcript 
CCK 
 
Cholecystokinin 
CFI  Canada Foundation for Innovation 
CHR  Chromosome  
xiii 
 
CIHR  Canadian Institutes of Health Research 
CNS 
 
Central nervous system 
CNTF  Ciliary neurotrophic factor 
CODING 
 
Complex Diseases in the Newfoundland Population: 
Environment and Genetics 
CRF  Corticotropin releasing factor 
Ctrl  Control 
CT  Computerized tomography 
DXA 
 
Dual-energy X-ray absorptiometry 
DSM-IV TR  Diagnostic and Statistical Manual IV, Text Revision 
ENPPl  Ectonucleotide pyrophosphatase/phosphodiesterase I 
ELISA  
 
Enzyme-linked immunosorbent assay 
FA  Food addiction 
FAO  Food addicted obese  
FFQ 
 
Food frequency questionnaire 
Freq  Minor allele frequencies 
FSH  Follicle-stimulating hormone 
FTO 
 
Fat mass and obesity-associated gene 
GABA 
 
Gamma-aminobutyric acid  
GAD2  Glutarnate decarboxylase 2 
GHS-R  Growth hormone secretagogue receptor 
GIP  Gastric inhibitory polypeptide 
GLP-1 
 
Glucagon-like peptide-1 
xiv 
 
GWAS 
 
Genome-wide association study 
HDL  High-density lipoprotein 
HOMA 
 
Homeostatic model assessment 
HOMA-β 
 
Homeostatic model assessment-β-cell function 
HOMA-IR 
 
Homeostatic model assessment-insulin resistance 
HREA 
 
Health research ethics authority 
HSC  High symptom count 
HWE  Hardy-Weinberg Equilibrium  
LDL  Low-density lipoprotein 
LEP  Leptin 
LEPR  Leptin receptor 
LH  Luteinizing hormone 
LSC  Low symptom counts 
m-YFAS  Modified YFAS  
MC4R 
 
Melanocortin receptor 4 
MCP  Monocyte chemotactic protein-1 
mRNA 
 
Messenger RNA 
MCH  Melanin-concentrating hormone 
MLGP  Multilocus genetic profile score  
MRI  
 
Magnetic resonance imaging 
NAc  Nucleus Accumbens 
NFO  Non-food addicted obese 
NGS  Next-generation sequencing  
xv 
 
NHANES  National Health and Nutrition Examination Survey  
NL 
 
Newfoundland and Labrador 
NPY 
 
Neuropeptide Y 
NTRK2  Neurotrophic Receptor Tyrosine Kinase 2 
OFC  Orbitofrontal Cortex 
OR  Odds ratio 
PAI-1  Plasminogen activator inhibitor-1 
PCSK1  Proprotein Convertase Subtilisin/Kexin type 1 
POMC 
 
Pro-opiomelanocortin 
PP 
 
Pancreatic polypeptide 
POMC  Pro-OpioMelanoCortin 
PYY 
 
Peptide tyrosine tyosine (peptide YY) 
SBE  Single base extension 
SIM1  Single-Minded homolog 1 
SD 
 
Standard deviation 
SLC6A14 
 
solute carrier family 6 (amino acid transporter), 
member 14 
SNP  Single-nucleotide polymorphism 
T2D 
 
Type 2 diabetes 
TG 
 
Triacylglycerol 
TNF-α 
 
Tumor necrosis factor alpha 
TSH  Thyroid-stimulating hormone 
VTA  ventral tegmental area  
xvi 
 
WHO 
 
World Health Organization 
YFAS  Yale Food Addiction Scale 
   
 
 
17 
 
 
 
1 
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1.1 Prevalence and Health Consequences of Obesity  
Overweight and obesity are the abnormal or excessive accumulation of adipose tissue 
generally resulting from a chronic positive energy imbalance (1, 2). Globally the prevalence 
of obesity has dramatically increased over the past three decades. Based on the most recent 
estimation of the World Health Organization (WHO), among the adult population (18 years 
of age or older) 1.9 billion people are overweight and 600 million are obese. In another 
word, 39% of world adult population is overweight and the global prevalence of obesity in 
adults is about 13% (2). In Canada, it has been estimated that 5.3 million adults are obese 
which means over one out of five Canadians are affected by obesity (3). Furthermore, it is 
projected that by 2019 about 50.4% of the adult population in Canada will be categorized 
as either overweight or obese (4). Based on a report published by Statistics Canada in 2014, 
Newfoundland and Labrador (NL) has the second highest obesity rate (30.4%) among the 
Canadian provinces, trailing only the Northwest Territories (3). The prevalence of obesity 
in NL is 10% higher than the national average indicating the existence of a substantial 
health problem in the province (Figure 1.1). 
Excessive adiposity in the body is identified as a major factor that escalates the risk of many 
diseases such as type 2 diabetes (5, 6), cardiovascular disease (7, 8), stroke (9, 10), 
dyslipidemia (11), hypertension (12, 13), asthma (14), several type of cancers (15, 16) ,etc..  
There are also evidence that demonstrates the fact that obesity causes a decrease in the 
quality of the life (17, 18) and overall life expectancy (19, 20).  Obesity has been estimated 
as the second most preventable cause of death in the United States and globally as the fifth 
principal cause of death (2, 21).  
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In consequence of the high prevalence of obesity and its associated comorbidities, a 
significant fiscal burden is engaging on health systems. Medical costs linked to obesity 
were estimated to be $147 billion in 2008 (22). A 2010 report estimated that direct costs of 
overweight and obesity represented $6 billion – 4.1 % of Canada’s total health care budget 
(23). 
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Figure 1-1 Map of the prevalence of obesity in Canadian Adults according to body mass 
index (BMl ≥30.0 kg /m2; ref 3) 
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1.2 Definition of obesity  
Many methods can be used to categorize an individual as normal weight, overweight or 
obese. The most widely used method to determine obesity status is body mass index (BMI): 
dividing a person’s weight in kilograms by the square of his/her height in meters (kg/m2). 
According to the World Health Organization, a BMI > 25 kg/m2 is classified as overweight, 
while a BMI > of 30 kg/m2 is classified as obese (Table 1-1; ref 24). Simplicity, 
accessibility, and low cost are the main reasons that the majority of epidemiology studies 
employ the BMI (25). However, some disadvantages have been attributed to BMI including 
inaccuracy in representing body composition due to the inability to distinguish fat mass 
from fat-free mass (muscle and bone; refs 26-30). Furthermore, while sex differences in 
body fat percentage have been well documented, the BMI is unable to consider the sexual 
dimorphism of adiposity (31-33). In addition, there is no variation of accumulation of body 
fat with age or the inter-individual difference of body fat percentage among people within 
the same BMI category (30). Therefore, World Health Organization now admits that 
caution must be taken when utilizing BMI to classify obesity status because it may not 
correspond to the same degree of fatness in different individuals (2). 
As a result, recent works have focused on identifying tools that are better able to predict 
disease risk. In terms of anthropometric measurements, waist circumference measurements 
and the ratio of waist to hip circumferences have been utilized to estimate central adiposity, 
a known contributor to cardiovascular, insulin resistance  and other obesity-related diseases 
(34-36). Although these anthropometric classifications have proven useful in large-scale 
population studies, they are not without limitations. For instance, large interindividual 
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variation in visceral fat exists in individuals with the same waist circumference (37). 
Underwater weighing (hydro densitometry) has long been used as the traditional gold 
standard for quantifying body fat (38). Skinfold measures using caliper (39), air 
displacement plethysmography (ADP; ref 40), magnetic resonance imaging (MRI; ref 41), 
and bioelectrical impedance analysis (BIA; ref 42) have also been used to estimate body 
fat. However, now greater precision and simplicity are found using dual-energy X-ray 
absorptiometry (DXA). The DXA scanner uses two X-ray beams of different energies to 
distinguish between bone, muscle, and adipose tissue. Bone, lean mass, and fat all have 
different densities (bone > muscle > fat) which the scanner uses to tell the tissues apart 
from one another. Still, more accurate measures are evident when using MRIs (43) and CT 
scans (44), but due to the expensive operative costs, these are not usually employed in 
large-scale studies. Therefore DXA is considered as the gold standard for measuring body 
composition (45).  
Another criteria for individual classification into different obesity status is recommended 
by Bray. These criteria can determine the individuals based on body fat percentage (%BF) 
according to age and sex specific (Table 1-2; refs 27, 46). 
1.3 Etiology of obesity 
The American Association of Clinical Endocrinologists (AACE) has recently identified 
obesity as a disease (5, 6). Obesity is a complex, multifactorial disease and the etiology has 
not been completely understood (47). Generally, obesity is the result of weight gain due to 
a chronic positive caloric balance: energy intake (caloric intake) is greater than energy 
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expenditure (basal metabolic rate, thermic effect of food/adaptive thermogenesis, and 
physical activity; ref 48). Although a lack of physical activity and/or the increased 
accessibility/consumption of calorie dense foods are the primary contributing factors to 
obesity development, however, genetics (49, 50), endocrine function (51, 52), behavioral 
patterns (53, 54) and environmental determinants (55) play a fundamental role in the 
development of obesity. The implications of this complexity impose significant challenges 
to researchers in order to understand the etiology of obesity  
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Table 1-1 BMI classification based on WHO*(24) 
Classification BMI (kg/m2) 
 
Principal cut-off 
points 
Additional cut-off 
points 
Underweight < 18.50 < 18.50 
   Severe thinness < 16.00 < 16.00 
   Moderate thinness 16.00 – 16.99 16.00 – 16.99 
   Mild thinness 17.00 – 18.49 17.00 – 18.49 
Normal range 18.50 – 24.99 
18.50 – 22.99 
23.00 – 24.99 
Overweight ≥ 25.00 ≥ 25.00 
   Pre-obese 25.00 – 29.99 
25.00 – 27.49 
27.50 – 29.99 
   Obese ≥ 30.00 ≥ 30.00 
      Obese Class I 30.00 – 34.99 
30.00 – 32.49 
32.50 – 34.99 
      Obese Class II 35.00 – 39.99 
35.00 – 37.49 
37.50 – 39.99 
      Obese Class III ≥ 40.00 ≥ 40.00 
*BMI, Body Mass Index; WHO, World Health Organization  
 
 
 
Table 1-2 Obesity status based on Bray criteria (27) 
  Women (%BF)* Men (%BF) 
Age 
(years) 
Underweight 
Normal 
weight 
Overweight Obese 
 
Underweight 
Normal 
weight 
Overweight Obese 
20-39 <21 21-32 33-38 39+  <8 8-20 21-25 26+ 
40-59 <23 23-34 35-40 41+  <11 11-22 23-28 29+ 
60-79 <25 25-37 38-42 43+  <13 13-24 25-30 31+ 
%BF, Body Fat Percentage   
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 Environmental Factors 
The rapid weight gain in the population over the last three decades is largely due to the 
environmental changes (56). Various environmental cues including the weather, culture, 
sedentary life style, industry marketing, portion size, the price of food, good tasting, and 
energy-dense foods have been thought to have a role in the increasing prevalence of obesity 
(57, 58). Food is also heavily advertised, and it has become acceptable to eat food 
everywhere (59). Rapid developments in technology have created a new world in which 
life has become much easier for most people. As a culture of pre-packaged and fast food, 
watching television, playing video games and surfing the Web has triumphed, a lifestyle of 
minimum physical activity is emerged (57). These factors result in a chronic excessive 
energy intake (calorie intake) and low energy expenditure and consequently to a chronic 
positive caloric balance. 
 Genetics  
Genetic predisposition is a key factor responsible for the large individual difference in body 
weight, body fat and other obesity-related aspects (60, 61). In the 1960’s the ‘thrifty gene’ 
hypothesis was proposed, whereby genes that predispose to obesity would have had a 
selective advantage in populations that frequently experienced starvation. People who 
possess these genes in today’s obesogenic environment might be those that ‘overreact’ not 
just becoming slightly overweight, but extremely obese (62, 63). This can be seen in certain 
high-risk groups, such as Pima Indians and Pacific Islanders, and recent studies in the 
United States have shown that there is also a disproportionate level of obesity in African-
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Americans and Hispanic-Americans compared with Caucasians. These differences cannot 
be explained by lifestyle, economic or environmental factors alone, indicating an important 
role of genetics (64). The discovery of ob gene and leptin contributed to promoting a 
significant progress in the knowledge and understanding on the genetic component of body 
weight regulation (65, 66). The role of leptin was first discovered in studies of severely 
obese ob/ob mice, which harbor mutations in the ob gene resulting in a complete lack of its 
protein product leptin which is derived from adipose tissue. Administration of recombinant 
leptin reduces the food intake and body weight of leptin-deficient ob/ob mice and corrects 
all their neuroendocrine and metabolic abnormalities (66-68) 
When considering obesity, clearly heritability is not a fixed entity, as the proportion of the 
phenotype that can be explained by the genotype will be influenced by the varying exposure 
to obesogenic environmental factors in different individuals and families (68). 
Consequently estimates of the heritable variation contributing to obesity range from 30–
60% in family studies to 60–80% in twin studies (69, 70). 
Based on genetic and phenotypic characteristics, three types of obesity forms can be 
considered: monogenic non-syndromic obesity, monogenic syndromic obesity, and 
polygenic (common) obesity that is caused by the interaction between multiple genes and 
the environment (64, 71). 
Monogenic forms of non-syndromic obesity result from an alteration of a single gene and 
are rare, affecting in total about 5 % of the population (68, 71).  The mutations in genes 
that encode proteins with likely roles in appetite regulation are responsible for Mendelian 
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disorders in which obesity is the most obvious phenotype (64). There are more than 200 
types of human obesity that are associated with homozygous forms of a single gene 
mutation (70, 71). Interestingly, all these mutations can be found in only 11 genes (70). 
There are six well-known genes with mutations in monogenic non-syndromic form of 
obesity explaining up to 10 % of cases with early-onset extreme obesity, affecting leptin 
gene (LEP), Leptin receptor (LEPR), Pro-OpioMelanoCortin (POMC), Proprotein 
Convertase Subtilisin/Kexin type 1(PCSK1), Neurotrophic Receptor Tyrosine Kinase 2 
(NTRK2) and Single-Minded homolog 1 (SIM1; refs 68, 71, 72).  
In monogenic syndromic obesity, at least 20 rare syndromes are caused by discrete genetic 
defects or chromosomal abnormalities (both autosomal and X-linked) characterized by 
obesity (64). Such as Prader-Willi syndrome (which involves a mutation or deletion of the 
paternally contributed chromosome 15qll-q13; ref 73), and Bardet Biedl syndrome 
(associated with mutations in at least twelve different loci; ref 74).  
The genetic profile of polygenic or common form of obesity results from the effects of 
many altered genes (70). In theory, the genetic basis of polygenic obesity implies that the 
specific set of variants relevant for obesity vary considerably from one obese person to the 
next (75). In this model, many genes have a small influence on the adiposity status of a 
given individual (76). According to the latest installment of the Obesity Gene Map, more 
than 600 genes, markers, and chromosomal regions have been associated with obesity 
phenotypes (70). In contrast with monogenic obesity, in polygenic obesity each 
polymorphism leads to a variant that confers susceptibility, requiring additionally the 
presence of other variants and an obesogenic environment to determine the obese 
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phenotype (71). In the common form of obesity, there is no observable simple Mendelian 
inheritance pattern. There are a few exceptions to this, namely melanocortin 4 receptor 
(MC4R) and brain-derived neurotrophic factor (BDNF), with variants originally identified 
as causing rare monogenic obesity but now known to be frequent enough to account for a 
measurable proportion of common obesity cases (77).  
The study of common obesity is far more complicated and challenging. However, the 
advent of new techniques facilitated this study by allowing the analysis of several loci at 
the same time (71). There are some approaches used in the detection and analysis of a 
candidate gene in body weight regulation: linkage studies, genome-wide association 
(GWA) studies, and candidate gene approach. Their objective is to determine whether an 
association between a genetic variation and an obesity-related trait do exist (71).  
- Linkage studies: Positional cloning based on linkage results has identified a small 
number of possible candidates, including glutarnate decarboxylase 2 (GAD2, ref 78), 
ectonucleotide pyrophosphatase/phosphodiesterase I (ENPPl) (79), and solute carrier 
family 6 (amino acid transporter), member 14 (SLC6A14; refs 80, 81).  
- Genome-wide association studies: To date, GWAS had identified more than 52 loci 
associated with obesity-related traits (71). The first loci identified through GWAS was 
the fat mass and obesity-associated (FTO) gene, and until now more than 50 genetic 
loci have been identified as being associated with at least one obesity-related trait (71, 
82). A common variant in FTO was unequivocally associated with BMI and increased 
risk for obesity simultaneously by two groups. The effect size of FTO polymorphism 
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on BMI is modest, with homozygous individuals for the risk allele (in this case the A 
allele) weighing on average 3 kg more than those homozygous for the protective allele 
(in this case the T), with the difference representing approximately, 0.36 kg/m2 (71, 
83). Variation in FTO was estimated to account for approximately 1% of the total 
heritability of BMI. Although this is a relatively small effect on total adiposity, 
countless other groups have confirmed these initial findings (84-86). Additional 
candidates have since been identified through GWAS such as MC4R, NCPI, MAF, 
PTER, KCTDI5, MTCH2, NEGRI, SH2BI, and TMEMI8 (87-90). To date, more than 
35 loci have been found associated with the increase of BMI (explaining ~1–3 % of the 
variance in BMI), while other loci correlate with abdominal obesity, establishing 13 
loci associated with it, assessed by the waist-to-hip circumference ratio (71, 91). 
- Candidate gene association studies: this approach can analyze genes involved in key 
metabolic pathways or those that have been shown to be important for obesity 
development in animal or human studies (65). This approach can be defined as the study 
of genetic influences on a complex trait by identifying variants, such as single 
nucleotide polymorphisms (SNPs), in or near a candidate gene that may have a role in 
the etiology of the disease (92). Selection of obesity candidate genes is typically based 
on prior knowledge of their known physiological role in pathways related to energy 
intake (INS, LEP, MC4R, NPY, POMC, AGRP, CARTPT, FTO or LEPR; refs 93, 94), 
energy expenditure (CLOCK, ADRB2, ADRB3, UCP1, UCP2 or UCP3; refs 95, 96), 
as well as or adipose tissue growth and development (PPARG2, CEBPA, IL6, FABP4, 
CD36, PNAPLA3 or PLPIN5; refs 65, 97, 98). In addition, candidate genes may also 
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be chosen on the basis of previous evidence of association with obesity-related traits in 
other populations. Candidate gene studies take advantage of both the increased 
statistical efficiency of association analysis of complex diseases and the biological 
understanding of the phenotype, tissues, genes and proteins that are likely to be 
involved in the disease (92). 
- Exome sequencing studies: In complex trait genetics, exome sequencing studies bring 
to light rare coding variants that are undetected by microarray-based genome-wide 
association studies. Exome sequencing provides a complementary approach to 
comprehensively assessing the role of all coding variation, both common and rare. 
Therefore, the strong interest in exome sequencing stems from three factors: the 
potential to identify many genes underlying complex traits, straightforward functional 
annotation of coding variation, and cost being substantially lower (around 5 times) than 
whole-genome sequencing (99). 
- The recent developments in the automated DNA sequencing instruments, which utilize 
modern advancements in engineering, chemistry, molecular biology and software 
development, has opened up new exciting opportunities. Currently, molecular diagnosis 
based on Sanger’s sequencing is restricted to only a few genes as this technology is 
expensive, time-consuming, and labor-intensive. With the help of the next-generation 
sequencing (NGS) technology, a new molecular diagnosis method has been developed 
that makes it possible to perform the sequencing of the whole genomes or exomes, or 
several genes simultaneously. The NGS based innovative and cost-efficient genetic 
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testing methods portray a promising landscape for sensitive obesity multi-gene 
screening (71). 
 Unbalanced Diet  
Poor diet caused by micronutrient deficiencies and the consumption of insufficient calories 
has been always as a global burden and contributed to diet-related health issues (100, 101). 
Until about 50 years ago poor health caused by overweight and obesity was a negative 
consequence of a wealthy lifestyle.  Now, however, the adverse effects of “over-nutrition” 
far exceed the problems caused by “under-nutrition” and create a double burden in low- 
and middle-income countries (101). The average energy supply has been estimated that 
increased from 2250 calories per person per day in 1961 to 2750 calories per person per 
day in 2007 (101). In general, during the last decades, the total food supply and 
consequently, total energy intake has increased (102, 103). One of the reasons is the shift 
of predominant dietary away from traditional foods prepared within the community towards 
ultra-processed and packaged food products. These type of food are most often nutritionally 
poor but dense in energy (101). Daily diet in North America, on average consists of about 
15% protein, 35% fat, and 50% carbohydrates (104). Data from the National Health and 
Nutrition Examination Survey (NHANES) in the United State show parallel increases in 
the percentage of energy from carbohydrate sources over the last 30 years (101, 105).  
The role of diet macronutrients (protein, carbohydrate and fat) in the development of 
obesity has been long debated (106). In many studies, the effects of different macronutrients 
intake level on both weight gain and weight loss have been assessed (101). The total fat, 
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carbohydrate and protein intake has not shown consistent associations with weight gain 
(102).  Nevertheless, from the available data it appears that “a calorie is a calorie” 
regardless of its macronutrient source and there is a physiological support for this 
proposition, but over the time, changing the macronutrient composition of the diet may play 
a role in weight change (101).  
- Fat: the role of dietary fat intake in weight loss or weight gain is controversy. The 
majority of the studies show a positive association between dietary fat intake and BMI 
in children, and adults (107-109). Several mechanisms may explain the relationship 
between high fat intake and greater body fat: 1) dietary fat is the most energy-dense 
macronutrient in the diet with providing approximately 38 kJ/g vs. 17 kJ/g for 
carbohydrate and protein which could lead to overconsumption of energy if food 
volume is unregulated; 2) fats could increase food consumption by lending greater 
flavour and palatability to food; and 3) carbohydrate produce a greater thermogenic 
effect than fat, suggesting that dietary fat may be utilized more efficiently and 
accumulate as body fat (107).  
In general, for preventing weight gain and obesity, the evidence supports that low-fat 
diets are an optimal choice. In addition, there is a positive association between weight 
loss and reduction of consumed percentage of the calorie from fat (110). In animal 
studies, as a rule, eating low-fat diet does not lead to become obese. When animals are 
exposed to different levels of dietary fat, there is a dose–response curve with a threshold 
of about 25% dietary fat which suggests that levels of dietary fat need to exceed 25% 
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in the diet before obesity develops (108). In human, a 10% reduction in dietary fat is 
predicted to produce a 4-5 kg loss in an individual with a BMI of 30 kg/m2 (110). 
- Carbohydrate:  foods with a high energy percentage of carbohydrates can range from a 
low (for example, raw vegetables and fruits) to a high (for example, sugary candy) 
energy density (111). The evidence in the case of carbohydrate intake in relation to 
weight loss or weight gain is also controversy (111, 112).  Several reports indicate a 
rapid weight loss after low-carbohydrate diet in the short period and this impact is even 
greater than a low-fat diet (113-116). However, this was not observed in all studies 
(112, 117). Thus, whether a reduction in carbohydrate intake offers any benefit beyond 
energy restriction alone is unclear (112). Several mechanisms may explain the 
relationship between low carbohydrate intake and weight loss: 1) the ketogenic effect 
of very low carbohydrate intake may facilitate weight loss through urinary excretion of 
ketones or even suppression appetite by circulating ketones, 2) the simplicity of the 
diet, besides the restriction of variety of the food choices and possibly a greater satiating 
effect of protein (111). 
- Protein:  the recommended dietary protein in Canada is 46 g/day for women and 56 
g/day for men or 0.86 g/kg/day (106). These recommended dietary proteins are to 
prevent protein deficiency as a result of body nitrogen loss due to natural cell death or 
through normal metabolic processes such as ammonia detoxification and urea 
production (106). Weight loss intervention studies and randomized control trial support 
that weight loss and weight maintenance are more effective with an energy restricted 
diet high in protein than a diet with a lower protein composition (106, 118-121). Several 
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mechanisms may explain the relationship between high protein and intake weight loss: 
1) increasing in lean body mass at the expense of fat mass (106, 122, 123), 2) high 
protein may exert a greater thermogenic effect compared to carbohydrate and fat and 
therefore may contribute to greater energy expenditure during rest (106, 124, 125). For 
the first time, a previous study in our lab showed that dietary protein is negatively 
associated with all obesity indexes (body composition measured by DXA, weight, BMI, 
waist circumference, and waist-to-hip ratio) in a free-living, non-dieting population. 
This association was independent of age, sex, physical activity level, total calorie 
intake, carbohydrate intake, smoking status, medication use and menopausal status at 
the population level. Furthermore, weight and BMI was significantly different between 
low and high protein consuming groups (106). 
 Dietary intake assessment  
Several methods are available to assess individual’s food and energy intake. The commonly 
used methods include: a single 24-hour recall, multiple 24-hour recalls or multiple diet 
records, food frequency questionnaires (FFQ), brief dietary screening tools (126, 127). 
Among them, FFQs are more popular and has been widely used for epidemiological 
purposes (128). Since Compared to other dietary assessment methods, the FFQs are easy 
to administer, has relatively low cost, and provides a rapid estimate of usual food intake 
(129, 130). In FFQs, selected food items are listed, and the intake frequencies and a usual 
portion or serving sizes (average quantity of foods per intake) are noted (128). The 
consumption of a food item is estimated by intake in grams per day by multiplying the 
standard serving size of each food by its intake frequency (128, 131). The number of food 
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items listed in a FFQs tends to vary widely due to the differences in the food supply and 
dietary habits from one population to another, (129, 130, 132). Therefore, there is no 
universally accepted FFQ that can be used for all populations (129). Many FFQs are 
modeled like Block, National Cancer Institute (NCI), Health Habits and History 
Questionnaire (HHHQ), and Willett (133-136). These formats differ most notably in their 
approach to ascertaining consumption frequency and quantity of listed foods (136). For 
dietary assessment in the target population, FFQs should be developed specifically for each 
study group and research purposes because diet may be influenced by ethnicity, culture, an 
individual's preference, economic status, etc. and must be validated in that specific 
population (136, 137). 
The applicability and accuracy of FFQs are controversial and some limitations have been 
addressed in many studies. Part of the controversy is due to the fact that food frequency 
questionnaires needs to be tailored for the target population. In addition, this debate is also 
related to the inevitable biases due to the characteristic of questionnaire such as respondent-
related reporting bias and recall bias (138, 139).  
 Overeating 
It has been well documented that chronic overconsumption of calories plays a fundamental 
role in the development of obesity (140).  However, evidence suggests that overeating alone 
is not sufficient to explain the obesity epidemic. Thus, eating disorders may be due to an 
altered function in different systems and overeating may be a symptom rather than the cause 
of the obese phenotype (141). Overeating can occur in different conditions, for example in 
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response to stress. This reflex might reflect an attempt to self-soothe or self-medicate with 
“comfort” foods (142). Another type of overeating is habitual overeating. Environmental 
food-associated stimuli (easy to access, cheap and over sized food) can robustly enhance 
the desire to eat even in absence of food per se or in absence of physiological needs. Habits 
are formed through repeated reinforced action until the stimulus-response association 
lapses the goal of the behavior (142). However, habits can be changed to a compulsive 
behaviour when they persist despite a reduction in reinforce efficacy (142). 
 Food Addiction  
Overeating in some degree may occur in many individuals; however, a proportion of them 
may develop an obsessive/compulsive relationship to certain foods (143). These 
individuals chronically consume more food than they need to maintain health and show 
compulsive intake behaviors associated with loss of control of eating (144, 145).  
Accumulating research evidence has documented neurobiological and behavioral 
similarities between compulsive overeating and psychoactive drug dependence, leading 
researchers to use the term of food addiction to describe this pattern of overeating (146-
150). In animal models, foods high in sugar and fat are particularly associated with 
addiction-like eating behavior (151-153). Findings from human studies have suggested that 
the pattern of food intake in food addiction may parallel substance dependence and this 
phenomenon might be understood with the same neurobiological, behavioral and clinical 
framework as conventional drug dependence (154-156) 
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 Clinical and behavioral similarities between food addiction and substance 
dependence  
- Tolerance and withdrawal: 
Generally, tolerance is characterized by a reduced responsiveness to a stimulus of a 
particular magnitude and is usually manifest by the need to use increasing doses to achieve 
the desired effect. Withdrawal symptoms are the groups of syndromes that occur upon the 
abrupt cessation of chronic stimulus. These phenomena are key characteristics of substance 
dependence (146, 157). The evidence supporting the probable tolerance effect in animal 
studies after intermittent sucrose that slowly increased sucrose consumption from 37 to 112 
ml per day in rats (from 13 to 20ml in the first hour of access; refs 158, 159). The evidence 
of tolerance in the human comes largely from anecdotal clinical reports of individuals 
consuming more food in each binge as the disorder becomes more chronic (146). Tolerance 
in the human can be explained by a series of biologic responses designed to ready the body 
for metabolic work. These reactions start when the anticipation of food intake, and the 
preabsorptive signals generated by the body’s first indication that food has been consumed. 
It helps the body to prepare for incoming nutrients, and food-related stimuli trigger a 
compensatory response of cephalic insulin secretion, which is similar to compensatory 
responses to drugs of abuse. The compensatory cephalic insulin secretion reduces the level 
of glucose in the blood stream which may result in the need for increased consumption of 
sugar to achieve desired effects (160). 
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Similar to substance dependence, a certain type of food, particularly high in sugar and fat 
can cause withdrawal symptoms when removed from the diet. These symptoms most 
clearly resemble the physical sign of distress seen in withdrawal (146, 151). Evidence from 
the animal research showed that removal of sugar from dependent animals results in a drop 
in body temperature and behavioral changes associated with withdrawal, such as 
aggression, anxiety, teeth chattering, forepaw tremor, and headshaking (146, 158). In 
human, evidence of sugar withdrawal mostly comes from clinical observation and self-
reports. This symptom has been described as headaches, irritability, and flu-like symptoms 
among heavy sugar consumers who become abstinent (146). 
- Loss of control: 
Loss of control is defined as continuing to use despite negative consequences, and an 
inability to cut down problematic use (161). For instance, some obese individuals continue 
to eat unhealthy food even in the face of severing negative consequences like diabetes and 
cardiovascular disease (162). In addition, food addiction and substance dependence share 
many of the same neural pathways, regarding both craving and loss of control (148). 
- A great deal of time spent in activities necessary to obtain, use, or recover: 
It has been debated that this criterion for substance dependence cannot be applied for food 
addiction, due to the easy and inexpensive accessibility of calorie-dense, nutrient poor 
foods (160, 161, 163). However, it is possible for addiction to occur with something that is 
legal, socially acceptable to obtain and readily available, like nicotine. In the case of food 
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addiction, a person might drive across the town to a fast food restaurant to fulfill a craving 
even though they have other food available (160). 
- A desire or repeated failed attempts to reduce or stop consumption: 
There is evidence that the repeated failure of such attempts is happened in approximately 
83% of participants regaining their lost weight within 5 years (160).  
- Continued use despite physical or psychologic problems: 
A study highlighted the difficulty of abstaining from a certain type of food even in the face 
of adverse consequences. In a large clinical trial, participants were asked to abstain from 
chocolate during the study. Surprisingly, of the 1200 participants, 139 persons were 
dropped from the study due to the difficulty of abstaining from chocolate (160, 164). 
- Giving up other important activities 
Habitually, being overweight and obese is associated with less important life activities. In 
one hand, the lack of physical activity leads to be obese and on the other hand, obese 
individuals are usually giving up their activities because of the difficulty to move fast. As 
a possible part of weight bias experience, overweight/obese people even may experience 
less engagement in social activities, such as dating or marriage due to excessive food 
consumption and obesity (160, 165).  A study on obese and non-obese young women has 
confirmed the hypothesis that eating food is more reinforcing than selected alternative 
activities (sedentary activities) to a greater extent for obese than for non-obese. In this 
study, subjects could choose to eat food or engage in sedentary activities (like playing 
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computer games) based on their responding in a computer-generated concurrent schedules 
task. However, further research is needed to explore the extent to which excess food 
consumption may begin to replace other important life activities (160, 166). 
 Neurobiological similarities between food addiction and substance dependence 
Reward- associated learning plays a fundamental role in both food addiction and substance 
dependence (167). It is well known that certain foods, particularly those rich in sugars and 
fat, are potently rewarding. High-calorie foods can promote over-eating (eating that is 
uncoupled from energetic needs) and trigger learned associations between the stimulus and 
the reward (conditioning; ref 168). Both in food addiction and substance dependence have 
an activating effect on the dopaminergic mesolimbic reinforcement system (‘reward 
system’) (167). Animal studies demonstrated that sugar bingeing, like substance 
dependence, consistently stimulates dopamine release in the nucleus accumbens (NAc). In 
addition, compared to normal-weight rats fed a standard chow diet rats that become obese 
due to cafeteria-style diet show lower baseline levels of mesolimbic dopamine activity 
(147). In human studies, similar to substance dependents, food addicts show hypoactivation 
in the lateral orbitofrontal cortex (OFC), suggesting less inhibitory control in response to 
reward cues. However, after seeing a photo of a chocolate milkshake (anticipatory reward), 
a notable activation was seen in the amygdala and anterior cingulate cortex after seeing 
there was hypoactivation in the lateral OFC. (148). In addition both food addiction and 
substance dependence tolerance and/or a loss of control is related to hypoactivation of the 
lateral OFC (148). 
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 Assessment of food addiction 
Some researchers have argued that food addiction should be included as a substance use 
disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM; refs 140, 
169), although others have been critical of the clinical validity or utility of the food 
addiction concept (144, 170). Yale Food Addiction Scale (YFAS) has been developed, and 
validated, as a tool for the diagnosis of food addiction (158, 171, 172). This questionnaire 
consists of 27 items that assess eating patterns over the past 12 months. The YFAS 
translates the Diagnostic and Statistical Manual IV, Text Revision (DSM-IV TR) substance 
dependence criteria in relation to eating behavior (including symptoms, such as tolerance 
and withdrawal symptoms, a vulnerability in social activities, difficulties cutting down or 
controlling substance use, etc.). The scale uses a combination of Likert scale and 
dichotomous scoring options. The criteria for food addiction are met when three or more 
symptoms are present within the past 12 months and clinically significant impairment or 
distress is present. The Likert scoring option is used for food addiction symptom counts 
(for instance, tolerance and withdrawal), ranging from 0 to 7 symptoms (158). Very few 
studies also have used the modified YFAS (m-YFAS) which consisted of nine core 
questions including one item for each symptom plus two items for clinical impairment and 
distress (173). 
The YFAS criteria have been used to explore the prevalence of food addiction in eating 
disorder patients (174), obese subjects (175) and junior college students (176). In a previous 
study assessing obese patients with binge eating disorder (BED), the prevalence of food 
addiction was reported to be as high as 56.8% (174), suggesting an overlap between binge 
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eating and food addiction. The prevalence of food addiction in obese individuals seeking 
weight loss treatment was 15.2%, while in another study obese subjects not seeking weight 
loss, the prevalence of food addiction was 25% (175, 177). In a cohort of junior college 
students with a normal BMI range, 8.8% met the YFAS criteria of food addiction; however, 
the correlation between food addiction clinical symptom counts and BMI was negligible 
(176).  
1.4 Approaches to Understanding the Etiology of Food Addiction  
 Appetite-Regulating Hormones 
In humans, the regulation of food intake is based on an intricate feedback system controlled 
by hunger and satiety signals (178, 179). These signals are generated in the brain, peripheral 
tissue and/or organs through two complementary drives, including both homeostatic and 
hedonic pathways (179-181). The hedonic or reward-based regulation pathway is related 
to the mesolimbic dopamine pathway, which is stimulated in both drug abuse and the 
consumption of highly palatable foods (179). Evidence has shown that the release of 
dopamine coordinates food reward, which is impaired in food addicts (179, 182). In another 
word, hedonic appetite may be considered as a continuum, extending from the normal 
situation of individuals enjoying some foods more than others, through comfort eating 
which may occur when the mood is low, to the final extreme situation in which an 
individual appears to be addicted to food as to a drug of addiction (183). Contrastingly, the 
homeostatic pathway primarily regulates the energy balance between the brain and 
peripheries (for instance, digestive tract and adipose tissue; refs 178, 181, 184, 185). This 
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means that based on energy reservation and the psychological want for food, the brain 
increases or decreases food intake by interpreting the neuronal and hormonal signals 
received from peripheries (179, 185, 186). Therefore, in both pathways, a large number of 
neurotransmitters (dopamine, cannabinoids, opioids, gamma-aminobutyric acid (GABA) 
and serotonin), neuropeptides (α-MSH, β-endorphin, cortisol, melatonin, neurotensin, 
orexin A, oxytocin and substance P, etc.) and hormones (gut hormones, anterior pituitary 
hormones and adipokines) are involved, many of which can also be detectable in serum 
(181, 182, 185-195). Interestingly, many studies have linked these hormones and 
neuropeptides with the current obesity epidemic (186, 187, 189, 196, 197). 
 Hedonic Aspects of Food intake  
Evidence in animals and humans support the theory that both consumption of highly 
palatable food and substance dependence share the same pathway within the limbic system 
to mediate motivated behavior (179, 198, 199). The majority of the studies have focused 
on mesolimbic dopamine pathways since most of the common drug of abuse increase 
dopamine signaling from nerve terminals originating in the ventral tegmental area (VTA) 
onto neurons in the nucleus accumbens (also called the ventral striatum). Dopaminergic 
transmission increased by both direct action on a dopaminergic neuron or indirectly through 
inhibition of GABAergic interneurons in the VTA (179, 198, 199). Furthermore, the 
neurotransmitter orexin is the peptide that is expressed by a population of lateral 
hypothalamic neurons and involve in mediating drug-induced activation of VTA dopamine 
neurons (179, 200, 201). Natural rewards such as food stimulate similar responses within 
the mesolimbic dopamine pathway. This release of dopamine is believed to coordinate 
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many aspects of an animal’s attempts to obtain food rewards, including increased arousal, 
psychomotor activation, and conditioned learning (remembering food-associated stimuli). 
However, the mechanism by which food stimulates dopamine signaling is unclear (179). 
One possible mechanism is that orexin directly stimulating VTA dopamine neurons since 
orexin neurons may be activated during feeding (179). 
 Homeostatic aspects of food intake 
Homeostatic control of feeding, unlike hedonic aspect, is primarily associated with 
regulation of energy balance. Therefore, it is focused on circulating hormones that rely on 
information about peripheral energy levels to the brain. 
- Neuropeptides 
There is a strong evidence that hypothalamus plays an important role in feeding control 
(189, 202, 203). Orexigenic neuropeptides secreted by hypothalamus are neuropeptide Y 
(NPY), melanin-concentrating hormone (MCH), orexins, agouti-related peptide (AGRP), 
galanin, β-endorphin, and anorectic neuropeptides are cocaine and amphetamine regulated 
transcript (CART), Melanocortins (POMC), alpha-melanocyte-stimulating hormone (α-
MSH), corticotropin releasing factor (CRF), serotonin and neurotensin (189). The main 
regions of hypothalamus involved in feeding and satiety are: 1) Arcuate (ARC): ARC acts 
as a feeding control center and integrates hormonal signals for energy homeostasis (189, 
204). The ARC-median eminence area is one of the ‘circumventricular’ organs where the 
blood–brain barrier is specially modified to allow entry of peripheral peptides and proteins 
including insulin and leptin, both of which are considered to be signals of fat mass (189, 
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205). The ARC also contains a number of neurons that express NPY, AGRP, and POMC 
(189). 2) Paraventricular nucleus (PVN): the PVN is the main site of corticotropin releasing 
hormone (CRH) and thyrotropin releasing hormone (TRH) secretion (189). Furthermore, 
several neuronal pathways associated with energy balance converge in PVN such as 
orexins, α-MSH, major projections from NPY neurons of the ARC and the appetite 
stimulating peptide galanin. Therefore, PVN mostly plays a role in the integration of 
nutritional signals with the thyroid and hypothalamic-pituitary axis (189, 206). 4) 
Ventromedial nucleus of hypothalamus (VMH): VMH is mostly acting as a satiety center. 
Theses nucleus are a key target for leptin that acts as a feeding inhibitor on the 
hypothalamus and a stimulate for increasing energy expenditure.  Lesions of either VMH 
or PVN produce syndromes of hyperphagia and obesity (189, 207). 5) Dorsomedial 
hypothalamic nucleus (DMH): DMH has extensive connections with the lateral 
hypothalamus besides other medial hypothalamic nuclei. Therefore this nucleus serves the 
function of integration and processing of information from these nuclei (189, 208). 6) 
Lateral hypothalamic area (LHA): LHA is the classical ‘feeding center’. This area also 
contains glucose-sensitive neurons that are stimulated by hypoglycemia and consequently 
the marked hyperphagia which is normally induced by hypoglycemia (189, 209). 
- Gut Hormones and Polypeptides  
The gastrointestinal tract is one of the largest endocrine organs in the human body that 
secrets more than 20 appetite-regulating hormones (210). Food intake and  energy 
homeostasis are regulated by the brainstem and hypothalamus through a gut-brain 
communication pathway for neural and hormonal signals (211).  Since gut hormones 
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influence appetite and play an integral role in glucose/lipid metabolism and insulin 
sensitivity through gut-brain communication (212, 213) investigating appetite-regulating 
hormones and food addiction may provide valuable insight into the underlying mechanisms 
responsible for the development of obesity. Most of the gut hormones are sensitive to gut 
nutrient content, and short-term feelings of hunger and satiety are believed to be mediated, 
in part, by coordinated changes in circulating gut hormone levels (210). Among these 
hormones amylin, also named islet amyloid polypeptide (IAPP), is a 37 AA peptide that is 
synthesized along with insulin in the β-cells of the endocrine pancreas (214, 215). Amylin 
is an important player in the control of energy balance. Amylin inhibits food intake by 
promoting meal-ending satiation, possibly through stimulation of its receptor in the area 
postrema (215-217). Amylin has multiple actions beside controlling food intake such as 
inhibiting secretion of glucagon and insulin, as well as that of lipase and amylase (196). 
Normally amylin and the hormone insulin are co-secreted from the β-cells in a molar ratio 
that remains constant, but this ratio can vary in different diseases such as obesity (214). 
Amylin residence time in the plasma is longer than insulin and similar to C-peptide, 
although amylin has a faster clearance rate than insulin by the kidneys (196). Evidence has 
shown that plasma concentration of amylin is significantly higher in both overweight/ obese 
adults and children than normal-weight individuals (189, 215, 218-220). Based on the 
recent studies in both animals and humans, there is a clear evidence that amylin is, at least, 
partly effective in obesity, however, the process is not clear yet (216).  
The rest of anorexigenic gut hormones are pancreatic peptide YY (PYY), cholecystokinin 
(CCK), leptin, glucagon-like peptide-1(GLP-1), gastric inhibitory polypeptide (GIP), 
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pancreatic polypeptide (PP), C-peptide, and an only orexigenic gut hormone is ghrelin (189, 
221). Ghrelin is a 28-amino acid peptide secreted from the stomach lining which binds to 
the growth hormone secretagogue receptor (GHS-R; ref 222). This hormone acts directly 
on the CNS via the arcuate nucleus of the hypothalamus (223). Ghrelin increases food 
intake and consequently body weight by stimulating the production of NPY and AGRP in 
the arcuate nucleus and antagonizes the leptin-induced inhibition of food intake (189, 224). 
In human, the ghrelin level increases during fasting and peaks just before consumption of 
a meal. The concentration decreases the following feeding and drops to a minimum value 
roughly one-hour post meal (189, 225-227). The results of the studies on the association 
between circulating ghrelin level and adiposity are controversy. In most of the cross-
sectional studies, lean individuals have a higher level of circulating ghrelin with a negative 
association between adiposity and ghrelin (210, 228-231). However, other studies reported 
a positive or lack of association between ghrelin and increased adiposity (232, 233). 
Nevertheless, to the best of our knowledge, there is no study available regarding the 
differences in appetite-regulating gut hormonal level between being obese with and without 
food addiction. 
- Pituitary polypeptide hormones 
Among pituitary polypeptide hormones, it has been well established that the hypothalamic-
pituitary thyroid axis regulates body weight. Furthermore, evidence suggests that thyroid 
hormones may access the ARC and other regions of the hypothalamus to regulate appetite. 
It is well known that thyroid dysfunction has a significant impact on appetite and body 
weight. For instance, hypothyroidism causes a reduction in basal energy expenditure and 
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weight gain (234-238). In animal studies, an injection of TSH centrally shows a food intake 
reduction  (234, 239). Several mechanisms have been postulated to mediate the orexigenic 
effect of thyroid hormones. Evidence has shown an increased hypothalamic NPY mRNA 
after peripheral administration of T3, suggesting that T3 may increase appetite via NPY. 
Furthermore, reduced hypothalamic POMC expression was reported after T3 
administration (234, 240). In addition, evidence in recent human and animal studies also 
support that adipocytes and preadipocytes possess thyrotropin receptors (241, 242). In vitro 
and in vivo studies have demonstrated that thyrotropin via its receptors in fat tissues leads 
differentiation of preadipocytes into adipocytes, and expansion of adipose tissue 
(adipogenesis) (241, 243, 244). Several population-based studies also have shown a 
significant association of BMI with TSH levels (236, 244-246).  
Another appetite-regulating hormone from the anterior pituitary gland is prolactin which is 
a peptide hormone produced by lactotropes of the anterior pituitary (247). Lactotrope 
function is primarily regulated by thyrotropin-releasing hormone (TRH). Furthermore, 
dopamine inhibits the synthesis and secretion of prolactin. There is also preliminary 
evidence that ghrelin stimulates prolactin secretion in healthy women, but the effect is less 
than TRH and is not additive to TRH (247). Prolactin is a multifunctional hormone and 
may have more functions than all other pituitary hormones combined (248). Animal studies 
provide the consistent results on the positive effect of increased food intake and body 
weight (248-250). Studies in rats have shown that injections of prolactin induced 
hyperplasia through PVN, VMH and paraventricular nucleus in the hypothalamus. The 
PVN was the most sensitive of these sites (251). In humans also long-term 
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hyperprolactinemia is often accompanied by weight gain (248). Data from a number of 
studies have suggested that the serum TSH and prolactin level may be a marker of alcohol, 
opium and cocaine dependence and craving (247, 252-255). However, to the best of our 
knowledge, there is no study available regarding the differences in TSH and prolactin level 
between being obese with and without food addiction.  
There is also evidence that other anterior pituitary hormones like growth hormone (256, 
257), luteinizing hormone (LH) and follicle-stimulating hormone (FSH; (258, 259), brain-
derived neurotrophic factor (BDNF; refs 260-262), and adrenocorticotropic hormone 
(ACTH; refs 263, 264) control appetite, however, no study has been done on food 
addiction.   
- Adipokines 
Adipose tissue is no longer considered an inert energy store, but is deemed an endocrine 
organ capable of synthesizing a plethora of adipokines (265). Adipokines play an important 
role in the regulation of appetite and eating behavior (266). Adipokines act centrally to 
regulate appetite and energy expenditure (267). The most famous adipokine secreted by 
adipose tissue is leptin. However, leptin also is produced in several cell types in other 
organs such as gastric cells, osteoblasts, and placenta. Despite the wide range of cells that 
leptin is synthesized, white adipose tissue is the most important source of the hormone and 
the leptin production correlates positively with adipose tissue mass (189, 268). The 
principal biologic effect of leptin on appetite is via the hypothalamus. VMH in the 
hypothalamus is mainly identified as a key target for leptin and acting as a satiety center 
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(189). Production of leptin from adipose tissue and consequently circulating leptin 
concentration is decreased when the energy stores are low. Therefore, the hypothalamic 
neurotransmitters that increase food intake like NPY and AGRP increases and the level of 
α-MSH and CART declines (189).  
Another adipokine is tumor necrosis factor alpha (TNFα), as a cytokine with an 
anorexigenic effect. TNFα administered either centrally or systemically reduces food 
intake, and in the early stages of obesity, inflammation also occurs in the mediobasal 
hypothalamus (269). Furthermore, evidence has suggested that elevated leptin levels may 
contribute to the effect of TNFα to decrease food intake (270). However, a study on rats 
has suggested that, under high-fat feeding, increased hypothalamic levels of TNFα coincide 
with increased feeding and obesity (197). Despite the role of TNFα in food intake, there is 
a general agreement that TNFα level is elevated in obese adults (271, 272). However, other 
factors related to obesity may cause higher TNFα level as an inflammatory factor, 
including, cardiovascular disease, and diabetes mellitus (273). In adults also TNFα is 
positively correlated to adipocyte size (272). In addition, it was reported that the levels of 
circulating TNF-α have been altered in alcoholics, cocaine abusers, and opiate addicts. In 
addition, it has been suggested that TNF-α can be a potential diagnostic biomarker for drugs 
of abuse (274-278). In an animal model, TNF-α has been investigated as a potential 
therapeutic target to prevent drug abuse and to increase the chance of cessation (275). 
Despite the different roles of the discussed adipokines in appetite, obesity, and addiction, 
there is no study available on TNFα and leptin nor is there one on other adipokines like 
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adipsin, adiponectin, and resistin regarding the differences between being obese with and 
without food addiction. 
In chapter 3 as a first of its kind, we explore the potential biomarkers that may differentiate 
being obese with and without food addiction by measuring and comparing various 
hormones and neuropeptides regulating appetite and metabolism. This information will 
help us to unravel how food addiction develops. 
 Dietary Intake 
As discussed before, evidence in animals has supported that foods with high fat are partially 
associated with addiction like behavior such as withdrawal syndrome like teeth chattering, 
tremor, head shaking and anxiety (152, 153, 279). Furthermore, in animals, there is 
evidence that high-fat diet either to reduce the expression of NPY in ARC or to stimulate 
NPY.   The reason for this contradictory effect is not clear, but the type of fat ingested (poly 
saturated, monosaturated…etc.) might be important. For instance, saturated fat producing 
an upregulation of neuropeptide Y expression in contrast to polyunsaturated fat (280). In 
human studies, the abuse potential of carbohydrate beverage has been tested in a double 
blind, placebo-controlled trial study. The samples were 61 overweight carbohydrate craver 
Women. After being induced into sad mood participants were exposed double blind to taste 
matched carbohydrate and protein beverage and they were asked to choose the drink that 
made them feel better, interestingly they significantly preferred the carbohydrate beverage. 
They had a greater liking and greater reduction in dysphoria after administration of 
carbohydrate beverage (281). Overall, there appears to be significant support for the notion 
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that high intake of fats and sugars is closely linked to the diagnosis of food addiction. As 
discussed in the section 1.3.3, there is evidence on the role of diet macronutrients (protein, 
carbohydrate and fat) in the development of obesity. However, there is no study available 
on the potential differences of macro- and micro-nutrients between being obese with and 
without food addiction, which will be critical to unravel how food addiction develops. 
Therefore, in chapter 2 and 3, as a first of its kind, we explore the potential differences in 
dietary nutrient intakes among obese with and without food addiction. 
 Genetics 
Evidence from family, twin, and adoption studies across several drug classes (opioids, 
cocaine, cannabis, nicotine, alcohol) strongly implicates the role of a genetic factor in each 
step of addiction including vulnerability to initiation, continued use, and propensity to 
become dependent (282-284). There also exists a genetic overlap between drug and 
behavioral addictions like gambling (284). Many studies have discovered genes that 
increase the vulnerability in the development of substance dependence (285-291). For 
instance, twin studies have shown that the heritability of addictions ranges from 39% 
(hallucinogens) to 72% (cocaine) (292). Importantly, however, the predisposition to 
addiction may be due to genetic variants that are common to all addictions and/or to those 
specific to a particular addiction (285). However, to the best of our knowledge, there is 
very little information regarding genes associated with YFAS food addiction. A few studies 
like the genome-wide investigation (GWAS) of food addiction (293), evaluation of 
potential involvements in dopaminergic reward pathways in the brain (294) or mu-opioid 
receptor gene were reported (295). The GWAS of food addiction defined by modified 
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YFAS was done on 9,314 women of European ancestry. They did not find a candidate SNP 
or the gene for drug addiction to be significantly associated with food addiction after 
correction for multiple testing (293).  In the relationship of the genes related to 
dopaminergic reward pathways with food addiction, a multilocus genetic profile score 
[MLGP] as an index of elevated dopamine signaling based on six known dopamine-related 
polymorphisms (located in or close to ANKK, DRD2, SLC6A3 and COMT genes) was 
used to study food addiction by investigating whether this score distinguished those with 
YFAS-diagnosed food addiction from controls. The investigators reported that the MLGP 
score was significantly higher in the food-addiction group than in the controls, suggesting 
the involvement of dopamine signaling pathway (294). In the study of the relationship of 
mu-opioid receptor gene (OPRM1) with food addiction, a functional A118G single 
nucleotide polymorphism was tested. Results confirmed that the food-addiction group had 
significantly higher levels of hedonic responsiveness to food suggests that this bio-
behavioral trait may foster a proneness to overeating, to episodes of binge eating and 
ultimately to a compulsive and addictive pattern of food intake (295). However, a 
comprehensive understanding of the genomic landscape of food addiction is lacking. In 
chapter 4 for the fist time, we performed a two-stage study using an exome sequencing 
technology as a screening stage followed by a verification study using the most 
significantly associated genes discovered to validate candidate genes related to food 
addiction. 
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1.5 Rationale 
Given the complexity of obesity and the evidence on the role of food addiction in the 
increasing prevalence of human obesity, this thesis attempted to answer many fundamental 
questions to explore whether and to what degree, food addiction contributes to the common 
form of human obesity. Furthermore, this thesis sought to further understand how food 
addiction is involved in the development of human obesity from the aspects of physiology, 
endocrinology, nutrition and genetics.  
Study on food addiction is on the early stage. The prevalence of food addiction in the 
general population was not available and this was an essential first step towards evaluating 
the potential contribution of food addiction to human obesity; therefore, as a first step, in 
Chapter 2  we asnwered this question using a large number of subjects from the CODING 
(Complex Diseases in the Newfoundland Population: Environment and Genetics) study that 
could represent the general population in the province of Newfoundland and Labrador. 
CODING study as a population based study also provided us a legitimate number of 
females and males to examine the difference of the prevalence of food addiction in the two 
sex groups. Because there is an evidence of gender difference in the other types of eating 
disorders, however no study is available in food addiction. 
Furthermore, to find a strong evidence that food addiction contributes to the rising 
prevalence of obesity in the general population we performed our study based on both BMI 
and body fat percentage determined by DXA, the latter is an accurate measurement of body 
fat and body composition. The available variety of  obesity-related measurements (weight, 
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height, BMI, waist and hip circumference, body and trunk fat percentage) in the CODING 
study also provided us an opportunity to strongly prove the association of food addiction 
with common form of human obesity by assessing the correlation of clinical symptom 
counts of food addiction with these measurements. In addition, the study in Chapter 2 was 
our first step in understanding the dietary patterns particularly macronutrients consumption 
in food addicted individual recruited from the general population. Therefore, the objectives 
of my thesis in Chapter 2 was to assess: 1) the prevalence of food addiction in the 
Newfoundland population; 2) if the clinical symptom counts of food addiction are 
significantly correlated with the severity of obesity in the general population; 3) if 
individuals diagnosed as food addicted are significantly more obese than their non-food 
addicted counterparts; and 4) if food addicted subjects consumed more or less of any of the 
three macronutrients (i.e., fat, protein and carbohydrates). 
The study in Chapter 3 and 4, as a first in this field, was to unerstand the probable etiology 
of food addiction from the aspects of hormonal levels, nutritional intakes, and genetics. 
Therefore, we employed a unique study design with two equally obese groups (matched 
with age, sex, and physical activity) but different in only one aspect which was a phenotype 
of food addition (diagnosed as food addicts or with high food addiction symptom count). 
This unique study design enabled us to distinguish the factors which are related to only 
food addiction from other confounding factors. As mentioned previously, evidence from 
both humans and animals support the similarities between food addiction and substance 
dependence. To find out whether the diffrences between the two groups of euqally obese 
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patients are related to food adiction, we sought for any clue that was common with other 
types of addictions.  
As mentioned in the section 1.4.1, numerous hormones are likely involved in regulating 
appetite and food intake, however there is no study available regarding what hormones are 
related to food addiction. In addition, in section 1.4.2, a few evidence was mentioned in 
both animals and human that demonstrates which types of food can triger addiction. In 
Chapter 2, we started to reveal the nutritional charactersitics (macro-nutients intake) of food 
addcits in the general population, but still no reported evidence on the potential differences 
of macro- and micro-nutrients between being obese with and without food addiction, which 
will be critical to unravel how food addiction develops. Therefore, in Chapter 3 we 
attempted to explore potential biomarkers that may differentiate being obese with and 
without food addiction by measuring and comparing various hormones and neuropeptides 
that are regulating appetite and metabolism and dietary nutrient intakes between the groups. 
As I mentioned previously in section 1.4.3, many studies have discovered genes related to 
other types of addiction, however, there is little information available regarding genes 
associated with an addictive tendency toward food. Therefore, our final goal in this thesis 
(Chapter 4) was to discover genes related to food addiction. To achieve this goal, we 
designed a two-stage study, a combination of exome sequencing method to screen the entire 
exome and a candidate gene association approach to verify food addiction candidate genes. 
Exome sequencing was employed as the first step because this technique enables the 
unbiased discovery of coding variations for subsequent association testing for complex 
traits. More importantly, exome sequencing is providing a well-defined and interpretable 
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target for mutations in the locus. These mutations create variants at these loci that can be 
identified as being associated with the trait which in our study was food addiction. Since 
this technique is very expensive, therefore, we designed our unique population as I 
mentioned previously to achieve our goal in a most effective way. Therefore, we proposed 
three sets of equally number of subjects (8 in each group) matched with age, sex, physical 
activity and to be non-smoker. Since one of the major challenges in finding food addiction 
genes in obese patients is to separate the genes causing obesity by food addiction from 
genes that cause obesity by other mechanisms, therefore both groups were obese and the 
key difference was food addiction clinical symptom counts. The third group was a healthy 
control group. The reason we chose food addiction clinical symptom counts unlike Chapter 
3 was firstly based on the findings in Chapter 2 that provided us the evidence that the 
clinical symptom count of food addiction was highly associated with the severity of obesity. 
In addition, in Chapter 4 we aimed to investigate a quantitative relationship between 
addiction genes and addictive tendencies towards food; the food addiction diagnosis is a 
binary and “Yes” or “No” qualitative method would not meet this objective. Therefore, we 
decided to use the YFAS clinical symptom counts as a semi-quantitative genetic marker in 
the analysis. The large number of subjects in CODING study gave us this chance to verify 
our results in a candidate gene association approach.  
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Chapter 2. Food Addiction: Its Prevalence and Significant 
Association with Obesity in the General Population 
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2.1 Introduction 
Overweight and obesity are the abnormal or excessive accumulation of adipose tissue 
generally resulting from a chronic positive energy imbalance (1, 2). Recently it has been 
shown that globally approximately 1.0 billion adults are overweight, and a further 475 
million are obese (3). In the United States, the prevalence of obesity among adults increased 
by 1.1% between 2007 and 2009. If this trend continues, by 2050 close to 100% of 
Americans will be overweight or obese (4). Obesity and overweight are the fifth leading 
cause of global death (2) and the second most preventable cause of death in the United 
States (5). Obesity is a complex multifactorial disease but the causes are not yet completely 
known (6). Weight gain is usually the result of a complex interaction between an 
individual’s biology and environmental factors which lead to energy surplus (7). In 
westernized society, one of the main causes of a chronic energy surplus is a reduced 
physical activity level owing to a sedentary lifestyle.  Another equally important cause of 
energy surplus is overeating (8, 9). Overeating in some degree may occur in  many 
individuals; however, a proportion may develop an obsessive/compulsive relationship to 
certain foods (10). These individuals chronically consume more food than they need to 
maintain health and show compulsive intake behaviors associated with loss of control of 
eating (9, 11).  
Accumulating research evidence has documented neurobiological and behavioral 
similarities between compulsive overeating and  psychoactive drug dependence, leading 
researchers to use the term of food addiction to describe this pattern of overeating (12-16). 
In animal models, foods high in sugar and fat are particularly associated with addiction-
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like eating behavior (17-19). In human studies, it has also been suggested that the pattern 
of food intake in food addiction may parallel substance dependence and that this 
phenomenon might be understood with the same neurobiological, behavioral and clinical 
framework as conventional drug dependence (20-22). Some researchers have argued that 
food addiction should be included as a substance use disorder in the Diagnostic and 
Statistical Manual of mental Disorders (DSM; ref 23, 24), although others have been critical 
of the clinical validity or utility of the food addiction concept (9, 25).  Recently, the Yale 
Food Addiction Scale (YFAS) has been developed, and validated, as a tool for the diagnosis 
of food addiction (26-28). The YFAS criteria have been used to explore the prevalence of 
food addiction in eating disorder patients (29), obese subjects (30) and junior college 
students (21). There is a growing interest in the role of food addiction in the increasing 
prevalence of human obesity which has reached an epidemic degree globally (14). 
However, the exploration of food addiction in humans is at an early stage and many 
fundamental questions are yet to be answered (25, 26).  
First, the prevalence of food addiction in the general population has not yet been assessed 
and this is an essential first step towards evaluating the potential contribution of food 
addiction to human obesity. Only a few human studies are currently available and they were 
performed on specific cohorts like eating disorder patients (29), small stratified groups such 
as obese adults seeking weight loss (31) or junior college students (21). However, no data 
are currently available regarding the role of food addiction in the general population and 
there seems to be a high proportion of food addiction in obese with binge eating and obese 
seeking weight loss. However, the association of food addiction with BMI in junior college 
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students was negligibly weak. Therefore, a second equally important question to be 
answered is whether food addiction is significantly correlated with the severity of obesity 
in the general population. A third question concerns the intake of macronutrient in food 
addiction, because data suggest that each macronutrient may play a different role (32).  
Hence the current study was designed to assess: 1) the prevalence of food addiction in the 
Newfoundland population; 2) if the clinical symptom counts of food addiction are 
significantly correlated with the severity of obesity in the general population; 3) if 
individuals classified as food addicted are significantly more obese than their non-food 
addicted counterparts; and 4) if food addicted subjects consumed more or less of any of the 
three macronutrients (i.e., fat, protein and carbohydrates). 
2.2 Materials and Methods 
Ethics Statement 
This study was approved by the Health Research Ethics Authority (HREA), Memorial 
University of Newfoundland, Canada. All participants provided written informed consent. 
Study Sample 
A total of 652 participants (415 females, 237 males) were recruited from the Canadian 
province of Newfoundland and Labrador (NL) via advertisements, posted flyers, and word 
of mouth. The inclusion criteria were: 1) age >19 years, 2) born in NL with a family who 
lived in NL for at least three generations, 3) healthy without serious metabolic, 
cardiovascular or endocrine diseases, 4) not pregnant at the time of the study. 
78 
 
Anthropometric Measurements 
Body weight, height, waist and hip circumference were measured after a 12 hours fasting 
period.  Subjects were weighed to the nearest 0.1 (kg) in a standard hospital gown on a 
platform manual scale balance (Health O Meter, Bridgeview, IL). A fixed stadiometer was 
used to measure height to the nearest 0.1 (cm). Hip circumference was measured with the 
flexible measuring tape to the nearest 0.1 (cm) at the level of largest circumference between 
the waist and thighs while the participant was in a standing position. The same procedure 
was used to measure waist circumference at the level of the umbilicus, midway between 
the lowest rib and iliac crest. BMI was calculated by dividing participants’ weight in 
kilograms by the square of his/her height in meter (kg/m2). The subjects were classified as 
underweight/normal (BMI ≤ 24.99) and overweight/obese (BMI ≥ 25.00) based on BMI 
according to World Health Organization criteria (33). 
Body Composition Assessment 
Whole body composition measurements including fat mass and lean body mass were 
measured using Dual-energy X-ray absorptiometry (DXA; Lunar Prodigy; GE Medical 
Systems, Madison, WI, USA). The measurements were performed in a supine position after 
12 hours fasting. Total percent body fat (BF%) and percent trunk fat (TF%) were 
determined (34). The subjects were also classified as under/normal weight and 
overweight/obese based on BF% according to the criteria recommended by Bray (35). 
Food Addiction Assessment   
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The diagnosis of food addiction was based on the Yale Food Addiction Scale (YFAS, ref 
26).  This questionnaire consists of 27 items that assess eating patterns over the past 12 
months. The YFAS translates the Diagnostic and Statistical Manual IV TR (DSM-IV TR) 
substance dependence criteria in relation to eating behavior (including symptoms such as 
tolerance and withdrawal symptoms, vulnerability in social activities, difficulties cutting 
down or controlling substance use, etc.) by applying the DSM-IV TR. The scale uses a 
combination of Likert scale and dichotomous scoring options. The criteria for food 
addiction are met when three or more symptoms are present within the past 12 months and 
clinically significant impairment or distress is present. The Likert scoring option is used for 
food addiction symptom counts (e.g. tolerance and withdrawal) ranging from 0 to 7 
symptoms (26, 29). 
Macronutrient intake and Physical Activity Assessment 
Macronutrient intake (protein, fat and carbohydrate) during the past 12 months was 
assessed using the Willett Food Frequency Questionnaire (FFQ; ref 36).  Participants 
indicated their average use of a list of common food items, over the last 12 months. The 
amount of each selected food was converted to a mean daily intake value. The average daily 
intake for each food item consumed was entered into NutriBase Clinical Nutrition Manager 
(software version 9.0; CyberSoft Inc, Arizona). The total intake for each macronutrient per 
day was computed by the software for each subject (37).  This questionnaire has been 
validated numerous times in different populations and has been validated in Newfoundland 
population (38-40). 
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The Baecke physical activity questionnaire was used to assess physical activity. This 
questionnaire assesses physical activity using three indices including work, sport and 
leisure (41). 
Statistical Analysis 
Statistical analyses were performed using the R project for statistical computing version 
2.15.2 (R Development Core Team). Data are presented as mean ± standard deviations 
(SD), maximum and minimum.  Student t-test analyses were used to investigate the 
differences in measured variables between females and males. The prevalence of food 
addiction was assessed in both the total cohort and different adiposity subgroups according 
to BMI and BF% by sexes.  Relative risk ratios defined as the prevalence ratio were 
calculated to assess differences in the risk of food addiction between sexes and between 
participants of different obesity status. 
Student t-tests and Mann-Whitney-U tests (a non-parametric test) were employed to 
compare the anthropometric data related to obesity measures and macronutrients intake 
between food addiction and non-food addiction groups. Furthermore, to take possible 
confounding factors into consideration, an ANCOVA was conducted to compare 
differences between food addicted and non-food addicted groups on obesity measurements 
with age, sex, smoking status, medication use, and physical activity entered as covariates. 
Spearman partial correlation coefficients controlling for age, sex, smoking, medication use 
and physical activity were calculated to investigate the association between food addiction 
and the severity of obesity. For all analyses, the alpha level was set at 0.05. 
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2.3 Results 
Physical Parameters and Prevalence of Food Addiction  
Demographic and physical characteristics of the participants are presented in Table 2.1. 
The prevalence of food addiction according to the YFAS criteria was 5.4% in the entire 
population (in women and men it was 6.7% and 3.0%, respectively; Table 2-2). When 
participants were classified as under/normal weight or overweight/obese based on BMI, the 
prevalence of food addiction was 1.6% and 7.7% in these two groups respectively. When 
subjects were classified as under/normal weight or overweight/ obese based on BF% the 
prevalence of food addiction was 2.9% and 6.8%, respectively. The percentage of food 
addiction significantly increased with increasing obesity status regardless of how adiposity 
was defined (RR = 0.21, p < 0.001 and RR = 0.42, p = 0.03, respectively). When the sample 
was split based on gender, this trend remained significant only in females whose adiposity 
was classified using BMI (RR = 0.13, p < 0.001). The prevalence of food addiction was 
higher in women than in men (RR = 2.28, p = 0.046). Additionally, when using BMI 
adiposity classifications, but not the BF% adiposity classifications, overweight/ obese 
women had higher prevalence of food addiction as compared to overweight/ obese men 
(RR = 3.50, p = 0.002). 
When food addicted subjects were classified by weight status based on BMI, 11.4% were 
under/normal weight, 88.6% were overweight/obese. When food addicted subjects were 
classified into adiposity group based on BF%, 20% were under/normal weight, 80% were 
overweight/obese (Table 2-3). 
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Correlations between clinical symptom counts of food addiction and obesity  
Spearman partial correlation coefficients controlling for sex and age were used to assess 
the relationship between the symptom counts of food addiction and obesity measurements 
in the entire sample and in the non-food addicted subjects. All obesity related 
measurements (specifically markers related to central obesity) had strong positive 
correlations with YFAS symptom counts in both groups (Table 2-4).  Furthermore, when 
we controlled for potential confounding factors including smoking, medication use and 
physical activity, the correlations remained significant.  
83 
 
Table 2-1 Characteristics of Study Participants* 
 Entire cohort 
Mean ± SD 
(Min - Max) 
Female 
Mean ± SD 
(Min - Max) 
Male 
Mean  ± SD 
(Min - Max) 
Number 652 415 237 
Age (year) † 44.3 ± 12.9 
(20 - 90) 
45.1 ± 12.9 
(20 - 90) 
42.9 ± 12.8 
(20 - 75) 
Height (cm) † 168.4 ± 9.1 
(147.7 - 196.6) 
163.3 ± 5.9 
(147.7 - 187.6) 
177.3 ± 6.6 
(156.8 - 196.6) 
Weight (kg) † 78.1 ± 18.3 
(46.6 - 149.8) 
71.5 ± 15.7 
(46.6 - 149.8) 
89.8 ± 16.6 
(57.1 - 149.5) 
BMI (kg/m2) † 27.4 ± 5.4 
(17.05 - 54.2) 
26.8 ± 5.7 
(17.05 - 54.2) 
28.5 ± 4.6 
(19.10 - 42.5) 
BF% † 33.3 ± 10.2 
(5.3 - 60.2) 
37.3 ± 8.8 
(16.2 - 60.2) 
26.1 ± 8.2 
(5.3 - 42.6) 
TF%† 36.3 ± 10.6 
(5.3 - 61.8) 
38.9 ± 10.1 
(15.5 - 61.8) 
31.7 ± 9.9 
(5.3 - 50.7) 
Waist (cm) † 94.9 ± 14.9 
(52 - 168) 
91.7 ± 15.02 
(52 - 168) 
100.6 ± 12.8 
(65 - 131) 
Hip (cm) 100.5 ± 12.1 
(74 - 155) 
100.2 ± 13.2 
(74 - 155) 
100.9 ± 9.9 
(79 - 134) 
Waist / Hip † 0.9 ± 0.08 
(0.68 - 1.62) 
0.9 ± 0.07 
(0.68 - 1.62) 
1.0 ± 0.05 
(0.75 - 1.14) 
* Mean ± standard deviation (SD), (Maximum – Minimum), BMI – Body mass index, BF% – percent body fat, TF% – 
percent  trunk fat.  
† Significant difference between women and men (Independent t-test, p < 0.05). 
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Table 2-2 Prevalence of food addiction according to sex and obesity status* 
 
 Entire population (%) 
 
Female (%) 
 
Male (%) 
 
Relative Risk 
 
Entire Cohort 
 
5.4 6.7 3.0 2.28† 
Obesity status (BMI) Under/Normal weight 1.6  1.5  1.9  0.81 
 Overweight/Obese 7.7  11.4  3.3  3.50† 
 Relative Risk 0.21‡  0.13‡ 0.58  
Obesity status (%BF) Under/Normal weight 2.9  3.7  1.3 2.96  
 Overweight/Obese 6.8  8.7  3.8  2.28  
 Relative Risk  0.42‡  0.43 0.33  
* Prevalence of food addiction (%), BMI – Body mass index and BF% – percent body fat.  
Obesity status (Under/Normal weight and Overweight/Obese) was defined by BMI (33)and %BF according to the 
Bray (35) and world health organization (WHO) criteria, respectively.  
† Relative risk between females and males (Fisher’s exact test, p < 0.05). 
‡ Relative risk between under/normal and overweight/obese groups (Fisher’s exact test, p < 0.05). 
Table 2-3 The proportion of food addiction according to obesity status* 
  
  Under/Normal weight% (n) Overweight/Obese% (n) 
Food addition BMI 11.4% (4) 88.6% (31) 
 BF% 20.0% (7) 80.0% (28) 
Entire Cohort BMI 38.2% (249) 61.8% (403) 
 BF% 37.1% (242) 62.9% (410) 
* Proportion of food addiction (%), number of food addicts (n), BMI – Body mass index and BF% – percent body fat. 
Obesity status (Under/Normal weight and Overweight/Obese) was defined by BMI (33)and %BF according to the Bray 
(35) and world health organization (WHO) criteria, respectively.   
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Table 2-4 Correlation between food addiction clinical symptom counts with obesity 
measurements* 
  
BMI 
(kg/m2) 
Weight 
(Kg) 
Hip 
(cm) 
Waist 
(cm) 
Waist/ 
hip 
Height 
(cm) 
BF% TF% 
Entire 
Cohort 
 
r 0.36 0.35 0.36 0.35 0.15 0.0091 0.31 0.32 
 p <0.001 <0.001 <0.001 <0.001 <0.001 0.82 <0.001 <0.001 
NFA 
r 0.32 0.30 0.31 0.30 0.12 0.007 0.27 0.28 
 p <0.001 <0.001 <0.001 <0.001 0.003 0.86 <0.001 <0.001 
 
* NFA – non-food addiction, BMI – body mass index, BF% – percent body fat and TF% – percent trunk 
  fat.  Significance level for Spearman partial correlation (r), controlling for age and sex, were set to p < 0.05. 
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Comparison of obesity measurements and macronutrient intake between food addiction 
and non- food addiction groups  
Both student t-test and Mann- Whiney U test showed significant differences in all obesity 
measurements between food addiction and non-food addiction groups (p < 0.001) (Table 
2-5).  To consider the other confounding factors, we conducted an ANCOVA controlling 
for sex, age, medication use, physical activity and smoking.  All the differences remained 
significant. Food addicted subjects on average weighed 11.72 kg more and carried 4.61 
more BMI than non- food addicted subjects.  Additionally, food addicted subjects had 8.2% 
greater body fat and 8.5% more trunk fat. 
Macronutrient intake was compared for the food addiction and non-food addiction group 
(Table 2-5).  Overall, the amount of macronutrients consumed, expressed as gram per 
kilogram of body weight, was not significantly different between the food addicted and 
non-food addicted participants.  However, the percent calorie intake from protein (p = 0.04 
from Mann-Whitney-U test and p = 0.03 from ANCOVA) and the percent calorie intake 
from fat (p = 0.04 from Mann-Whitney-U test, p = 0.11 from ANCOVA) was significantly 
higher in food addicted as compared to non-food addiction participants. 
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Table 2-5 Obesity measurements and macronutrient intake characteristics of food addiction and 
non-food addiction* 
 FA 
(Mean ± SD) 
NFA 
(Mean ± SD) 
Mean difference P 
t test 
P 
Mann-Whitney-U test 
BMI (kg/m2) 31.8 ± 6.6 27.2 ± 5.2 4.6 <0.001 <0.001 
Weight (kg) 89.2 ± 21.5 77.5 ± 17.9 11.7 0.003 <0.001 
Waist (cm) 105.5 ± 15.3 94.4 ± 14.6 11.2 <0.001 <0.001 
Height (cm) 167.2 ± 9.4 168.5 ± 9.1 -1.3 0.42 0.25 
Hip (cm) 110.7 ± 14.7 99.9 ± 11.7 10.8 <0.001 <0.001 
BF% 41.04 ± 9.3 32.8 ± 10.05 8.2 <0.001 <0.001 
TF% 44.3 ± 9.4 35.8 ± 10.5 8.5 <0.001 <0.001 
Fat (g/kg) † 0.8 ± 0.4 0.8 ± 0.7 0.005 0.95 0.59 
Carbohydrates (g/kg) † 3.5 ± 1.8 3.9 ± 2.7 0.4 0.25 0.23 
Protein (g/kg) † 1.2 ± 0.5 1.2 ± 0.9 -0.06 0.47 0.89 
Fat (%) ‡ 26.6 ± 7.5 24.3 ± 7.2 2.3 0.08 0.04 
Carbohydrate (%) ‡ 52.2 ± 7.4 54.3 ± 8.5 2.1 0.11 0.07 
Protein (%) ‡ 19.0 ± 3.8 17.9 ± 3.9 1.1 0.10 0.04 
* Mean ± standard deviation (SD), FA – food addiction, NFA – non-food addiction, BMI – body mass index, BF% – 
percent, body fat and TF% – percent trunk fat.  
 Independent t-test and Mann-Whitney-U test significance level was set to p < 0.05.  
† Macronutrient intake (g) per unit body weight (kg). 
‡ Macronutrient intake (% total calorie intake).  
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2.4 Discussion 
In general, regardless of the various genetic predispositions and environmental influences, 
overeating is the primary factor responsible for the increasing prevalence of human obesity 
(14, 24).  To the best of our knowledge this is the first study reporting the contribution of 
food addiction to the prevalence of human obesity in the general population (21, 29, 30).  
One important finding is an estimation of the prevalence of food addiction in the general 
Newfoundland population was at 5.4% (6.7% in women and 3.0% in men). In a previous 
study assessing obese patients with BED, the prevalence of food addiction was reported to 
be as high as 56.8% (29), suggesting an overlap between binge eating and food addiction.  
The prevalence of food addiction in obese individuals seeking weight loss treatment was 
25%, while in another study obese subjects not seeking weight loss, the prevalence of food 
addiction was 15.2% (30, 31).  In a cohort of junior college students with a normal BMI 
range, 8.8% met the YFAS criteria of food addiction; however the correlation between food 
addiction clinical symptom counts and BMI was negligible (21, 42). Our results indicated 
that 80-88.6% of food addicted individuals were overweight/obese based on Bray or BMI 
criteria providing strong evidence that food addiction has contributed to the rising 
prevalence of obesity in the general population. Of note, food addicted individuals were 
also observed in the underweight and normal weight cohort, however in a lower number.  
The current findings suggest that obesity featured with food addiction may represent an 
important subgroup of the obese with a distinctive aetiology. The identification of this 
subgroup will open a novel avenue to assess the aetiology of obesity and thus aid in finding 
new effective methods to treat and prevent obesity. 
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The subjects in the present study were recruited from the general Newfoundland 
population. The prevalence of overweight/obesity in the current study is similar to data 
reported from Health Canada on the province of Newfoundland (62.1%; ref 43).  The 
prevalence of food addiction revealed in our study on the Newfoundland population may, 
to some degree, represent the prevalence in other Canadian provinces. Moreover, our 
findings also suggest a potential difference between men and women in regards to food 
addiction, as overweight/obese women classified using BMI had a significantly higher rate 
of food addiction as compared to men.  This is similar to the case with eating disorders in 
which women also are significantly more likely to suffer from an eating disorder than men 
(44, 45). Nevertheless, larger studies in other populations are warranted to confirm the 
findings from our investigation. 
The third major finding from the current study is the significant correlation between food 
addiction and the severity of obesity in the general Newfoundland population. This finding 
appears to be robust as we were able to demonstrate this significant correlation throughout 
a number of analyses controlling for many confounding factors. Firstly, the clinical 
symptom counts of food addiction was significantly correlated not only with BMI, but also 
with virtually all obesity related measurements including body weight, waist and hip 
circumferences, body fat and trunk fat percentage determined by DXA, an accurate 
measurement of body composition. This close correlation was seen in the non-food 
addicted group as well. We suggest that these robust and multiple correlations demonstrated 
a true association of food addiction with human obesity. Additionally, it was shown that 
obesity related variables were significantly different between food addicted and non-food 
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addicted subjects.  Participants who met criteria for food addiction on average weighed 
11.7 kg (25.79 lbs) more, had 4.6 higher BMI and possessed a 8.2% and 8.5% greater total 
body fat and trunk fat, respectively, as compared to non-food addicted subjects. These data 
provide the first direct evidence that food addiction is strongly associated with obesity in 
the general population. Importantly, the individuals who met the criteria for food addiction 
only represent between one fifth to one sixth of the total proportion of obese individuals in 
Newfoundland (25-30%; ref 43).  This suggests that food addiction is likely an important 
factor in the development of human obesity but not the sole contributor.  
Another important goal of our study was to examine differences in dietary patterns 
particularly macronutrients consumption between food addicted and non-food addicted 
subjects. Interestingly, the food-addicted subjects’ diet consisted of a higher percentage of 
calories from fat and protein, possibly suggesting that these types of foods are more likely 
to be associated with compulsive overeating. Given the significance of these findings will 
be important to verify these findings in other populations. 
In the present study the YFAS was used as a diagnostic tool to classify participants with 
food addiction, as this set of measure and the criteria on which it is based have been 
validated (26-28). Rather than directly asking if the subjects were addicted to food, the 
questionnaire assessed food addiction based on DSM-IV-TR criteria (42).  Furthermore, 
using this set of criteria helped to distinguish subjects who regularly indulged in hyper 
palatable foods from those who have lost control over their eating behaviour (26).   
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One limitation of the present study was that the number of female participants was larger 
than the number of males. Given the sex difference in the prevalence of food addiction 
found in the present study, it is possible that the actual prevalence in the general population 
may be lower than 5.4% if the study had consisted of equal numbers of women and men.  
Future studies using cohorts with an equal number of females and males in the population 
are warranted.  
In summary, our study has revealed for the first time that: 1) the prevalence of food 
addiction in the general Newfoundland population was 5.4%; 2) women are at high risk of 
food addiction than men; 3) food addiction contributes to human obesity and is significantly 
associated with the severity of obesity/amount of body fat from normal to obese individuals 
in the general population. Our findings provide strong evidence that food addiction may 
represent a distinct aetiology of human obesity in the general population. 
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Chapter 3.  Hormonal and Dietary Characteristics in Obese 
Human Subjects with and without Food Addiction 
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3.1 Introduction 
Obesity is a multifaceted condition (1) and represents a pandemic that needs urgent 
attention (2). In Canada, over one in four adults are obese (3), and the province of 
Newfoundland has one of the highest rates of obesity in the country (after the Northwest 
Territories and Nunavut; ref 3, 4). Obesity is caused by multiple factors, including genetics, 
endocrine function, behavioral patterns and environmental determinants (5). It has been 
well documented that chronic overconsumption of calories plays a fundamental role in the 
development of obesity (6). In a previous study on the general Newfoundland population, 
our laboratory discovered that chronic compulsive overeating, defined as “food addiction” 
by the Yale Food Addiction Scale (YFAS; refs 7, 8), significantly contributes to human 
obesity (9). Additionally, the clinical symptom counts of food addiction defined by the 
YFAS is highly associated with the severity of obesity (9). Addiction is considered a 
psychological disorder with a definite neuro-endocrine basis; however, food addiction is 
still not defined as an independent disorder in Diagnostic and Statistical Manual (DSM) V 
(10, 11). Similar to drug addiction, food addicts lose control over food consumption despite 
the negative consequences relevant to obesity (12, 13). This suggests that they suffer from 
repeated failed attempts to reduce their food intake, and they are unable to abstain from 
certain types of food or to reduce consumption (12). 
In humans, the regulation of food intake is based on an intricate feedback system controlled 
by hunger and satiety signals (5, 14, 15). These signals are generated in the brain, peripheral 
tissue and/or organs through two complementary drives, including both homeostatic and 
hedonic pathways (5, 15-17). The hedonic or reward-based regulation pathway is related 
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to the mesolimbic dopamine pathway, which is stimulated in both drug abuse and the 
consumption of highly palatable foods (15). Evidence has shown that the release of 
dopamine coordinates food reward, which is impaired in food addicts (15, 18). 
Contrastingly, the homeostatic pathway primarily regulates the energy balance between the 
brain and peripheries (for instance, digestive tract and adipose tissue; refs 14, 17, 19, 20). 
This means that based on energy reservation and the psychological want for food, the brain 
increases or decreases food intake by interpreting the neuronal and hormonal signals 
received form peripheries (15, 20, 21). Therefore, in both pathways, a large number of 
neurotransmitters (dopamine, cannabinoids, opioids, gamma-aminobutyric acid (GABA) 
and serotonin), neuropeptides (α-MSH, β-endorphin, cortisol, melatonin, neurotensin, 
orexin A, oxytocin and substance P, etc.) and hormones (gut hormones, anterior pituitary 
hormones and adipokines) are involved, many of which can also be detectable in serum 
(18, 20, 22-31). Interestingly, many studies have linked these hormones and neuropeptides 
with the current obesity epidemic (22, 23, 25, 32, 33). Moreover, in our previous 
aforementioned study on the general Newfoundland population, we have reported that food 
addicts consumed a higher percentage of calories from fat and protein (9). However, to the 
best of our knowledge, there is no study available regarding the differences in appetite 
regulating hormonal level between being obese with and without food addiction. 
Furthermore, macronutrients have been reported to play an imperative role in obesity, 
addiction-like behaviour and metabolic consequences (34-36). However, there is no study 
available on the hormonal characteristics and potential differences of macro- and micro-
nutrients between being obese with and without food addiction, which will be critical to 
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unravel how food addiction develops. Hence, the aim of the current study is to explore 
potential biomarkers that may differentiate being obese with and without food addiction by 
measuring and comparing various hormones and neuropeptides regulating appetite and 
metabolism and dietary nutrient intakes in both groups. 
3.2 Experimental Section 
Ethics Statement 
This study was approved by the Health Research Ethics Authority (HREA), Memorial 
University of Newfoundland, St. John’s, Canada, with Project Identification Code #10.33, 
(latest date of approval: 21 January 2014). All participants provided written and informed 
consent. 
Study Sample 
The food addiction study consists of 737 subjects recruited from the general Newfoundland 
and Labrador (NL) population. Among them, 36 subjects met the criteria of food addiction 
by the Yale Food Addiction Scale. Subjects with a body mass index (BMI) of 25 kg/m2 or 
less were excluded [WHO criteria: greater than 25 is classified as overweight; over 30 is 
classified as obese (37)]. After exclusion, 29 subjects were left for analysis. 
Correspondingly, 29 non-food-addicted overweight/obese (NFO) subjects were selected 
and matched for age, sex, BMI and physical activity. All of the subjects were part of the 
population CODING (Complex Diseases in the Newfoundland population: Environment 
and Genetics) study (38, 39) and were recruited from the Canadian province of 
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Newfoundland and Labrador using advertisements, posted flyers and word of mouth. The 
inclusion criteria were: (1) age >19 years; (2) born in NL with family who lived in NL for 
at least three generations; (3) healthy without serious metabolic, cardiovascular or 
endocrine diseases; and (4) not pregnant at the time of the study. 
Anthropometric Measurements 
Body weight and height were measured after a 12-h fasting period. Subjects were weighed 
to the nearest 0.1 (kg) in a standard hospital gown on a platform manual scale balance 
(Health O Meter, Bridgeview, IL, USA). A fixed stadiometer was used to measure height to 
the nearest 0.1 (cm). BMI was calculated by dividing participants’ weight in kilograms by 
the square of his/her height in meter (kg/m2). The subjects were classified as 
overweight/obese (BMI ≥ 25.00) based on BMI according to the World Health 
Organization criteria (37). 
Body Composition Assessment 
Whole body composition measurements including fat mass and lean body mass were 
measured using dual-energy X-ray absorptiometry (DXA; Lunar Prodigy; GE Medical 
Systems, Madison, WI, USA). The measurements were performed in a supine position after 
12 h fasting, and the total percent body fat (BF%) and percent trunk fat (TF%) were 
determined (40). 
Food Addiction Assessment 
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The diagnosis of food addiction was based on the Yale Food Addiction Scale (YFAS; refs 
7, 41). This questionnaire consists of 27 items that assess eating patterns over the past 12 
months. The YFAS translates the Diagnostic and Statistical Manual IV, Text Revision 
(DSM-IV TR) substance dependence criteria in relation to eating behavior (including 
symptoms, such as tolerance and withdrawal symptoms, vulnerability in social activities, 
difficulties cutting down or controlling substance use, etc.) by applying the DSM-IV TR. 
The scale uses a combination of Likert scale and dichotomous scoring options. The criteria 
for food addiction are met when three or more symptoms are present within the past 12 
months and clinically significant impairment or distress is present. The Likert scoring 
option is used for food addiction symptom counts (for instance, tolerance and withdrawal), 
ranging from 0 to 7 symptoms (13, 42). 
Dietary Intakes Assessment 
Macronutrients (protein, fat and carbohydrate) and 71 micronutrients intake during the past 
12 months were assessed using the Willett Food Frequency Questionnaire (FFQ; ref 43). 
Participants indicated their average use of a list of common food items, over the last 12 
months. The amount of each selected food was converted to a mean daily intake value. The 
average daily intake for each food item consumed was entered into NutriBase Clinical 
Nutrition Manager (software version 9.0; CyberSoftInc, Phoenix , AZ, USA), and daily 
intake of macro- and micro-nutrient intakes were computed (41, 44, 45). 
Serum Metabolism Regulating Hormones and Neuropeptides Measurement 
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The concentration of a total of 34 hormones and neuropeptides were measured by magnetic 
bead-based quantitative immunoassay using the MAGPIX system (Millipore, Austin, TX, 
USA) or using enzyme-linked immunosorbent assays (ELISA; ALISEI QS, Radim, Italy) 
(using morning fasting serum). Gut hormones [amylin (total), ghrelin (active), leptin, total 
glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP), pancreatic 
polypeptide (PP), pancreatic peptide YY (PYY), connecting peptide (C-peptide) and 
glucagon), pituitary polypeptide hormones (prolactin, brain-derived neurotrophic factor 
(BDNF), adrenocorticotropic hormone (ACTH), ciliary neurotrophic factor (CNTF), 
follicle-stimulating hormone (FSH), luteinizing hormone (LH), growth hormone (GH) and 
thyroid-stimulating hormone (TSH)), adipokines (adiponectin, lipocalin 2, resistin, adipsin, 
plasminogen activator inhibitor-1 (PAI-1) and TNF-α) and neuropeptides (alpha-
melanocyte-stimulating hormone (α-MSH), β-endorphin, cortisol, melatonin, neurotensin, 
orexin A, oxytocin, substance P, monocyte chemotactic protein-1 (MCP-1) and Agouti-
related peptide (AgRP)] were measured in duplicate using the magnetic bead-based 
quantitative immunoassay with the MAGPIX system. The system was calibrated prior to 
each assay with the MAGPIX calibration kit, and performance was verified with the 
MAGPIX performance verification kit. Milliplex Analyst software was used for the 
analyses of data. Moreover, the concentration of fasting neuropeptide Y (NPY) was 
measured with the ELISA method (Millipore Corporation Pharmaceuticals, Billerica, MA, 
USA). All measured hormonal and neuropeptide levels were above the manufactural 
sensitivity. Moreover, there was no/negligible cross-reactivity between the antibodies for 
an analyte and any of the other analytes in these panels. 
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Serum Lipids, Glucose and Insulin Measurement 
Concentrations of serum total cholesterol, high-density lipoprotein (HDL) cholesterol, 
triacylglycerols (TG) and glucose were analyzed using Synchron reagents with an Lx20 
analyzer (Beckman Coulter Inc., Fremont , CA, USA). Low-density lipoprotein (LDL) 
cholesterol was calculated by the following: total cholesterol-HDL-TG/2.2. Serum insulin 
was evaluated using an immunoassay analyzer (Immulite; DPC, Los Angeles, CA, USA). 
Additionally, the serum insulin level was measured using an immunoassay analyzer 
(Immulite; DPC, Los Angeles, CA, USA; ref 46, 47). 
Physical Activity Assessment and Other Covariates 
The Baecke physical activity questionnaire was used to assess physical activity. This 
questionnaire assesses physical activity using three indices, including work, sport and leisure. 
All participants completed forms to screen medical history, demographics (gender, age and 
family origin), disease status, cigarette usage and medication use (48, 49). 
Statistical Analysis 
All statistical analyses were completed using SPSS, version 19.0 (SPSS Inc., Chicago, IL, 
USA). Data are presented as the mean ± standard deviations (SD). Student’s t-test analyses 
were employed to investigate the differences in measured variables between food addicted 
and non-food-addicted obesity. For all analyses, statistical tests were two-sided and the 
alpha level was set at 0.05.  
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3.3  Results 
Physical Characteristics and Fasting Serum Lipids, Glucose and Insulin Level 
Demographic, fasting serum lipids, glucose and insulin level and physical characteristics 
of the participants are presented in Table 3-1 (adiposity is based on BMI). There were no 
significant differences for the aforementioned variables between the food-addicted 
overweight/obese (FAO) and non-food addicted-overweight/obese (NFO) groups. 
The Comparison of Metabolism Regulating Hormones and Neuropeptides in Food-
Addicted and Non-Food-Addicted Overweight/Obese 
Serum hormonal levels were compared between the food addiction overweight/obese and 
non-food addiction overweight/obese groups (Table 3-2). The FAO group had a 
significantly lower level of amylin, TNF-α and TSH and a higher level of prolactin, as 
compared to the NFO group (p < 0.05). 
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Table 3-1 Characteristics of the study participants *. 
Variables NFO (Mean ± SD) FAO (Mean ± SD) 
Number 29 29 
Age (year) 42 ± 8.9 42.5 ± 9.4 
Sex F 24 24 
M 5 5 
BMI (kg/m2) 32 ± 4.42 32.5 ± 6 
BF% 42.32 ± 6.4 42.7 ± 7.8 
TF% 45.1 ± 5.3 46.2 ± 7.1 
Physical activity 7.1 ± 1.3 7.3 ± 1.1 
Glucose (mmol/L) 5.2 ± 1 5.3 ± 0.8 
Cholesterol (mmol/L) 5.3 ± 1 4.9 ± 1.3 
TG (mmol/L) 1.4 ± 0.9 1.3 ± 0.7 
HDL (mmol/L) 1.3 ± 0.3 1.4 ± 0.3 
LDL (mmol/L) 2.9 ± 1.1 3.3 ± 1.0 
Albumin (g/L) 39.5 ± 3.3 39.1 ± 2.9 
Insulin (pmol/L) 90.4 ± 101.9 95.9 ± 139.9 
* Mean ± standard deviation (SD); BMI, body mass index; BF%, percent 
body fat; TF%, percent trunk fat; TG, triglycerides; HDL, high-density 
lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; FAO, 
food-addicted overweight/obese; NFO, non-food-addicted 
overweight/obese was defined by BMI according to World Health 
Organization (WHO) criteria (37) .  
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Table 3-2 Hormonal and neuropeptide characteristics in food-addicted and non-food-
addicted overweight/obese *. 
Hormones 
FAO NFO 
p ** Mean ± SD  
(14–29) 
Mean ± SD 
(14–29) 
Neuropeptides 
NPY (pg/mL) 8.81 ± 3.74 5.71 ± 3.82 0.65 
α-MSH (pg/mL) 148.06±84.16 147.2±89.12 0.88 
β-Endorphin (pg/mL) 377.86±90.82 396.54±108.3 0.48 
Cortisol (pg/mL) 230,056±100,323 232,807.9±138,900 0.09 
Melatonin (pg/mL) 3,320.9±1,377.7 3,652.75±1,652.43 0.65 
MCP1 (pg/mL) 294.43±88.2 282.56±90.11 0.83 
Neurotensin (pg/mL) 379.6±103.05 379.32±100.7 0.84 
Oxytocin (pg/mL) 119.5±49.13 120.22±57.86 0.78 
Orexin A (pg/mL) 969.6±438.2 974.5±347.5 0.28 
AGRP (pg/mL) 16.11±6.94 16.18±8.26 0.88 
Substance P (pg/mL) 39.16±12.51 39.7±15.06 0.53 
Gut hormones 
Amylin (pg/mL) 24.9±11.3 32.05±18.75 0.04 
GLP-1 (pg/mL) 19.91±22.54 21.4±22.1 0.10 
Ghrelin (pg/mL) 25.4±15.8 25.91±17 0.9 
Leptin (pg/mL) 20,795.4±12,173.3 18,206.72±10,765.9 0.50 
GIP (pg/mL) 17±16.31 17.05±12 0.90 
Glucagon (pg/mL) 22.61±10.5 45.1±52.02 0.77 
PP (pg/mL) 49.3±79.4 46.85±53.4 0.50 
PYY (pg/mL) 68.33±122.3 93±109.3 0.45 
C-peptide (pg/mL) 1,373.7±740.15 1269±506.74 0.50 
Pituitary 
polypeptide 
hormones 
Prolactin (pg/mL) 2,335.1±1,197.8 1,938.3±745.5 0.02 
ACTH (pg/mL) 3.05±2.56 5.55±6.93 0.12 
BDNF (pg/mL) 2,219.3±658.73 2,138.38±931.52 0.17 
LH (mlU/mL) 6.2±7.3 6.21±8.6 0.93 
FSH (mlU/mL) 13.27±18.75 9.58±14.12 0.35 
GH (pg/mL) 505.76±635.84 810.83±1,019.56 0.07 
TSH (μlU/mL) 0.23±0.32 1.1±2.14 0.01 
CNTF (pg/mL) 148.1±324.22 1,647.4±6,280.6 0.06 
Adipokines 
TNF-α (pg/mL) 4.21±1.23 4.5±2.2 0.02 
Adiponectin (pg/mL) 65,700.8±68,327.1 71,437.3±56,215.3 0.71 
Lipocalin (pg/mL) 357±151.7 462.2±153 0.71 
Adipsin (pg/mL) 7,167.66±2,888.25 8,009.9±2,733 0.86 
PAL1 (pg/mL) 261.3±88.8 261.31±88.84 0.80 
Resistin (pg/mL) 82±43.4 109±55.8 0.33 
* Mean ± standard deviation (SD); FAO, food-addicted overweight/obese; NFO, non-food-addicted 
overweight/obese; NPY, neuropeptide Y; α-MSH, alpha-melanocyte-stimulating hormone; MCP1, monocyte 
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chemotactic protein-1; AGRP, agouti-related peptide; GLP-1, glucagon-like peptide-1; GIP, gastric inhibitory 
polypeptide; PP, pancreatic polypeptide; PYY, pancreatic peptide YY; ACTH, adrenocorticotropic hormone; 
BDNF, brain-derived neurotrophic factor; LH, luteinizing hormone; FSH, follicle-stimulating hormone; GH, 
growth hormone; TSH, thyroid-stimulating hormone; CNTF, ciliary neurotrophic factor; PAL1, plasminogen 
activator inhibitor-1.  
** The independent t-test was set to p < 0.05. Some significant results would be no longer significant 
if multiple corrections were performed. 
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 Comparison of Macronutrients and Micronutrients Intake between Food Addiction and 
Non-Food Addiction Overweight/Obese Groups 
Total calorie intake and macronutrients consumed expressed in absolute grams and in gram 
per kg of body weight, BMI, %BF and %TF are shown in Table 3-3. Total calorie intake 
per kg of body weight was significantly higher in the FAO group. The amount of 
carbohydrate intake per kg of body weight, fat consumed (per kg body weight, per BMI, 
per percentage of trunk fat) and the percent calorie intake from fat were significantly higher 
in food-addicted obesity as compared to non-food-addicted obese subjects (p < 0.05). 
In addition, micronutrient intakes expressed as gram per kg body weight were compared 
between the two groups (Table 3-4). In general, FAO consumed significantly higher 
amounts of dietary sugar, mineral substances, including sodium, potassium, calcium and 
selenium, fat, saturated fat, trans fat, monounsaturated fat, omega 3, omega 6, vitamin D 
and gamma-tocopherol than the NFO group. 
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Table 3-3 Macronutrient intake characteristics in food addiction and non-food addiction 
overweight/obese groups *. 
Macronutrients 
FAO (n = 29) NFO (n = 29) 
p 
Mean±SD Mean±SD 
Calorie 
intake 
Per person 
2,077.4±687.
6 
1,714.0±612 0.7 
per kg body 
weight 
24.4±10.9 19.5±6.6 0.02 
per BMI 66.2±26.5 54.1±19.5 0.3 
per BF% 50±16.4 42.0±19.4 0.7 
per TF% 45.6±14.8 38.6±15.5 0.8 
Fat (g) 
Per person 63.6±26.3 45±15.6 0.054 
per kg body 
weight 
0.7±0.4 0.5±0.2 0.004 
per BMI 2±0.9 1.4±0.5 0.01 
per BF% 1.5±0.7 1.1±0.5 0.1 
per TF% 1.4±0.6 1±0.4 0.04 
percent calorie 27.1±7.5 23.4±4 0.005 
Carbohydrate 
(g) 
Per person 273±103 246.3±93 0.6 
per kg body 
weight 
3.2±1.6 2.8±1 0.03 
per BMI 8.7±3.9 7.8±3 0.2 
per BF% 6.5±2.4 6.01±2.8 0.6 
per TF% 6±2.2 5.5±2.3 1 
percent calorie 51.2±7.1 56.3±5.2 0.3 
Protein (g) 
Per person 99±29 79.2±30.8 0.8 
per kg body 
weight 
1.1±0.4 0.9±0.3 0.2 
per BMI 3.1±1.1 2.5±1 0.3 
per BF% 2.4±0.7 1.9±0.9 0.8 
per TF% 2.2±0.6 1.8±0.7 0.9 
percent calorie  19.3±3.9 18.2±2.6 0.2 
* Mean ± standard deviation (SD); FAO, food-addicted overweight/obese; NFO, non-food-
addicted overweight/obese; BMI, body mass index; BF%, percent body fat; TF%, percent trunk 
fat.  
The independent t-test was set to p < 0.05.  
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Table 3-4 Significant differences of selected micronutrient intakes between food addicts 
(FAO) and non-food addicts (NFA) of overweight/obese groups *. 
Micronutrient Intake 
FAO (n = 29) NFO (n = 29) 
p 
Mean±SD Mean±SD 
Sugar (g/kg) 1.4±0.8 0.2±0.5 0.03 
Saturated fat (g/kg) 0.3±0.1 0.2±0.1 0.01 
Trans fat (mg/kg) 1.0±0.0 0.1±0.0 0.01 
Monounsaturated fat 
(g/kg) 
0.3±0.1 0.2±0.1 0.01 
Poly-saturated fat 
(g/kg) 
0.1±0.1 0.1±0.0 0.0 
Omega 3 (mg/kg) 7.0±0.0 5.0±0.0 0.01 
Omega 6 (g/kg) 0.1±0.0 0.03±0.0 0.0 
Vitamin B1 (mg/kg) 0.02±0.01 0.02±0.0 0.04 
Vitamin D (IU/kg) 2.5±2.1 1.9±1.0 0.04 
Dihydrophylloquinone 
(mcg/kg) 
0.3±0.0 0.2±0.0 0.03 
Gamma tocopherol 
(mg/kg) 
0.3±0.0 0.0±0.0 0.04 
Sodium (mg/kg) 26.1±12.0 19.4±6.3 0.01 
Calcium (mg/kg) 13.0±7.1 10.0±4.0 0.02 
Potassium (mg/kg) 50.8±21.3 41.2±16.8 0.04 
Selenium (mg/kg) 1.4±0.6 1.1±0.3 0.02 
* Mean ± standard deviation (SD); FAO, food-addicted overweight/obese; NFO, non-food-
addicted overweight/obese. The independent t-test was set to p < 0.05.  
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3.4 Discussion 
In general, endocrine factors have an important role as appetite regulating signals. A large 
number of hormones play a role in feeding regulation (15-17, 25). The abnormality in the 
aforementioned hormonal secretions can lead to overeating and, consequently, obesity (16, 
25). Interestingly, similarities in hormonal changes have been found between obesity and 
substance abuse addiction (10, 18). According to the etiology, obesity is a complex disease 
and can be caused by many genetic and environmental factors. As we previously reported, 
food addiction may be an important factor leading to obesity as a unique etiology (41). To 
the best of our knowledge, this study is the first to attempt to prove the idea that obesity 
with a definite food addiction may manifest distinguished dietary intake and hormonal 
characteristics. 
The first finding in the current study was the significantly lower serum level of TSH and 
the higher level of prolactin in obese food addicts as compared to obese non-food addicts. 
Several population-based studies have shown a significant association of BMI with TSH 
and prolactin levels (50-54) but it is not clear why and which sub-group of obese is 
associated with the abnormality of these hormones. Findings from our current study 
indicate that the combined abnormality of TSH and prolactin might be one of the hormonal 
characteristics in obesity with food addiction rather than in the general common form of 
obesity. Data from a number of studies have suggested that the serum TSH level may be a 
marker of alcohol, opium and cocaine dependence and craving (55-57). A significant 
negative correlation between TSH level and alcohol craving has been reported in alcohol-
dependent subjects (55), and a significantly lower level of TSH has been found in opium 
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users as compared to healthy controls (58). However, we are the first lab that discovered 
low TSH is associated with obese food addicts. Taken together with our present findings, 
a lower level of circulating TSH is not only associated with alcohol, opium and cocaine 
dependence, but also with food addiction. The significant association of prolactin in obese 
food addicts and the data from other studies on alcoholics, heroin and cocaine addicts with 
elevated basal prolactin (55, 59-62) strongly suggests the involvement of circulating 
prolactin with food addiction, as well. 
Another significant finding in the current study is the significant lower level of serum TNF-
α in the obese food addiction group as compared to the obese non-food addiction group. 
TNF-α level is usually higher in the obese people compared to healthy controls (63). TNF-
α is known as an anorexigenic cytokine, which reduces food intake. It is thought that the 
impaired actions of TNF-α may lead to obesity (33). It was reported that the levels of 
circulating TNF-α have been altered in alcoholics, cocaine abusers and opiate addicts. In 
addition, it has been suggested that TNF-α can be a potential diagnostic biomarker for drugs 
of abuse (64-69). In an animal model, TNF-α has been investigated as a potential 
therapeutic target to prevent drug abuse and to increase the chance of cessation. (65). The 
current findings of the association of low TNF-α with food addiction is very interesting and 
unique. There is more likely a specific manifestation in obese food addicts contrary to the 
increased level of TNF-α in obese people. 
In the current study, we also measured serum neuropeptides regulating appetite. 
Neuropeptides are predominately synthesized and secreted in the central nervous system; 
however, levels of some neuropeptides can be detected in the peripheral circulation system 
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(23, 24, 27-31, 70). Abnormalities of neuropeptide levels have also been found in 
individuals with other addictions and obesity (71-75); however, in this study, no significant 
differences in the level of any of the measured neuropeptides were found between food 
addicted and non-food addicted obese subjects. 
The third important finding in the current study was the significantly lower level of serum 
amylin in obese food addicts compared to the obese non-food addicts. This seems to be the 
first report regarding the link of amylin with food addiction or any other types of addictions. 
It is not clear at this stage if this low level of circulating amylin is a reflection of food 
addiction status or simply is just a secondary change owing to other factors. In a randomized 
crossover study on 10 healthy males consuming one meal high in carbohydrate or fat, it has 
been shown that amylin is affected by the macronutrient compositions of a meal, as the 
amylin level was greater after a high carbohydrate meal compared to a high fat meal (76). 
In this study, dietary fat intake was higher in obese food addicts, which may be at least 
partially responsible for the low level of serum amylin. 
In our previous study, we found that all food addicts, regardless of obesity status, consumed 
a higher percentage of calories from fat (41); the same result was also found in an obese 
food addicts cohort. The high intake of dietary fat was further supported by the finding 
showing that obese food addicts consumed higher total calories per kilogram of body 
weight, higher carbohydrates per kilogram of body weight and dietary fat per kilogram of 
body weight (and per BMI and per percentage of trunk fat). For the first time, we also 
explored the potential differences of 71 micronutrients intake between food-addicted and 
non-food-addicted obese subjects. Corresponding to our previous discovery, we found that 
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obese food addicts consumed a significantly higher amount of fat subcomponents: 
saturated, monosaturated, poly-saturated and trans fat, omega 3 and 6, vitamin D, gamma 
tocopherol and dihydrophylloquinone [the main source in commercially-baked snacks and 
fried food (77)] compared with obese non-food addicts. In addition, obese food addicts 
consumed higher amounts of sodium and sugar. Therefore, taken together, the data suggest 
that obese food addicts may consume more hyper-palatable foods that are known to have 
high amounts of fat, sugar and salt (sodium). 
In the present study, the Yale Food Addiction Scale (YFAS) and Willett Food Frequency 
Questionnaire (FFQ) were used as tools for the diagnosis of food addiction and measuring 
nutrient intake over the past 12 months. These sets of measures and the criteria on which 
they are based have been validated in different populations (7, 43, 78-81). The YFAS is the 
only tool available for the diagnosis of food addiction. Using this set of criteria can help to 
distinguish subjects who regularly indulge in hyper-palatable foods from those who have 
lost control over their eating behaviour (7, 41). However, since the aforementioned 
questionnaires are self-reported, there tends to be self-reporting bias. 
It needs to indicate that food addiction is a complex disease, and numerous factors are 
involved in the etiology. Psychological conditions, like anxiety and depression, which may 
cause the fluctuation of TSH, prolactin and TNF-α, were not assessed in the current study 
(82-89). A related study showed that in alcohol-dependent patients, it has been shown that 
the hypothalamic-pituitary thyroid axis may have the ability to lead to anxious or depressed 
mood, which may further affect the TSH level (55). 
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In the current study, the active form of ghrelin was measured. However, the specific 
inhibitor was not added during sample collection, and therefore, it cannot be excluded that 
part of the ghrelin may have been degraded. Since all of the samples after blood drawing 
were placed immediately on ice during the entire process of all experiment, we believe that 
any degradation would be little, because enzymes that degrade ghrelin would have little 
activity at this ice-cold temperature. 
The correction for multiple comparisons has not been made, since this study is a pioneering 
study and numerous markers were measured. Moreover, the sample size is relatively small 
in both groups. However, each of the individuals were well matched in both groups for 
gender, age, BMI and physical activity level, which would reduce the heterogeneity of 
subjects and increase the statistical power to detect possible difference in most variables 
between the two groups. Nonetheless, larger cohorts in different populations are warranted 
to replicate our findings. 
3.5  Conclusions 
To the best of our knowledge, this is the first study that has discovered significant 
differences in multiple aspects, including hormonal levels and nutritional intakes, between 
obese food addicts and obese non-food addicts. The findings provide valuable evidence to 
promote further understanding of the mechanism of food addiction and its role in the 
development of human obesity. 
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4.1 Introduction 
Over the past 3 decades, the global prevalence of obesity, defined by a body mass index 
(BMI) of 30 or higher, has increased substantially. By 2019, it is estimated that 55.4% of 
the Canadian adult population will be categorized as overweight or obese (1). Obesity is a 
multifactorial disease and the etiology is not completely understood (2). It has been well 
documented, however, that genetics (3, 4), endocrine function (5, 6), behavioral patterns 
(7, 8) and environmental determinants (9) play fundamental roles in the development of 
obesity. Genetic predisposition might be a key factor responsible for the large individual 
difference in body weight, body fat and other obesity-related aspects (10, 11). Estimates of 
the heritable variation contributing to obesity range from 30–60% in family studies to 60–
80% in twin studies (12, 13). In a previous study, we discovered that chronic compulsive 
overeating, defined as food addiction by the Yale Food Addiction Scale (YFAS), 
significantly contributes to the common form of human obesity (14). Additionally, the 
clinical symptom count of food addiction defined by the YFAS is highly associated with 
the severity of obesity (14). Furthermore, one study has reported that the prevalence of food 
addiction in obese individuals seeking weight loss treatment was 15.2%, while in another 
study, the prevalence of food addiction in obese subjects not seeking weight loss was 25% 
(15, 16). These studies suggest that food addiction with co-morbid obesity may represent 
an important subgroup of the obese population with a distinctive etiology.  
Accumulating evidence has demonstrated the neurobiological and behavioral similarities 
between food addiction and substance dependence in both human and animal studies (17-
21). In animal models, foods high in sugar and fat are particularly associated with 
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addiction-like behavior (22-24). In human studies, it has also been suggested that the 
pattern of food intake in food addiction may parallel substance dependence and this 
phenomenon might share the same neurobiological, behavioral and clinical framework as 
conventional drug dependence (25-27). Data from family, twin, and adoption studies across 
several drug classes (opioids, cocaine, cannabis, nicotine, alcohol) strongly implicates the 
role of genetic factor involved in each aspect of addiction development including 
vulnerability to initiation, continued use, and propensity to become dependent (28-30). 
There also exists a genetic overlap between drug and behavioral addictions like gambling 
(30). Studies have discovered many genes that increase the vulnerability in the development 
of substance dependence (31-37). For instance, twin studies have shown that the heritability 
of addictions ranges from 39% (hallucinogens) to 72% (cocaine; ref 38). Importantly, 
however, the predisposition to addiction may be caused by genetic variants that are 
common to all addictions and by those specific to a particular addiction (31). However, to 
the best of our knowledge, there is little information available regarding genes associated 
with an addictive tendency toward food measured by YFAS. A few studies were reported 
including a genome-wide investigation of food addiction (39), an evaluation of potential 
involvements in dopaminergic reward pathways in the brain (40) or mu-opioid receptor 
gene (41). Exome sequencing is a powerful genome-wide screening method and is an 
effective way to discover disease causing mutations and genes. (42). Candidate gene-based 
association study is the most common method for discovering the link between complex 
disease and genes that are suspected to be associated with phenotypes of interest (43).   
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In the current study, which was the first of its kind in the field, we employed a two-stage 
approach: an exome sequencing technology as a screening stage followed by a genetic 
association study to discover and verify genes related to food addiction. 
Ethics Statement 
This study was approved by the Health Research Ethics Authority (HREA), Memorial 
University of Newfoundland, St. John’s, Canada, with project identification code: #10.33, 
(latest date of approval: February 10, 2016). All participants provided written and informed 
consent. 
4.2 Method 
Study Sample 
The current study was designed and performed in two stages. Stage I, included a genome-
wide screening study using a whole-exome sequencing method on selected samples, and 
stage II was a verification study using a candidate gene association method on the genes 
related to addiction found in stage I, in the entire study population.  
Stage I: A total of 752 subjects in the food addiction study were used for the selection of 
patients for the exome sequencing study. All the subjects were part of the CODING 
(Complex Diseases in the Newfoundland population: Environment and Genetics) study and 
were recruited from the Canadian province of Newfoundland and Labrador (NL) via 
advertisements, posted flyers, and word of mouth. The inclusion criteria were: 1) age >19 
years, 2) born in NL with a family who lived in NL for at least three generations, 3) healthy 
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without serious metabolic, cardiovascular or endocrine diseases, 4) not pregnant at the time 
of the study (14, 44). Among the 752 subjects thirty-four subjects (25 females and 9 males) 
had a very high symptom counts (> or = 5) calculated by the Yale Food Addiction Scale. 
Subjects with a BMI of 25 kg/m2 or less were excluded [WHO criteria: greater than 25 is 
classified as overweight; over 30 is classified as obese (45)]. After exclusion, 8 
overweight/obese females with high symptom counts (FAO), 8 overweight/obese females 
and 8 healthy normal weight females with low/zero symptom counts (NFO and control 
respectively) were selected. All subjects in the three groups were matched for age and 
physical activity. None of the subjects was smokers or alcoholics, nor substance addicted 
(or taking any medication).  
Stage II: This stage contained the entire 752 subjects.  
Anthropometric Measurements 
Body weight and height were measured after a 12-hour fasting period. Subjects were 
weighed to the nearest 0.1 (kg) in a standard hospital gown on a platform manual scale 
balance (Health O Meter, Bridgeview, IL). A fixed stadiometer was used to measure height 
to the nearest 0.1 (cm). BMI was calculated by dividing participants’ weight in kilograms 
by the square of his/her height in meter (kg/m²). Subjects were classified as 
overweight/obese (BMI ≥25.00) and normal weight (BMI=18.5-24.99) based on BMI 
according to World Health Organization criteria (45).  
Food Addiction Assessment  
126 
 
Food addiction diagnosis and food addiction symptom counts were calculated according to 
the YFAS (14, 46). This questionnaire consists of 25 items that assess eating patterns over 
the past 12 months. The YFAS translates the Diagnostic and Statistical Manual IV-TR 
(DSM-IV-TR) substance dependence criteria in relation to eating behavior (including 
symptoms such as tolerance and withdrawal symptoms, a vulnerability in social activities, 
difficulties cutting down or controlling substance use, etc.). The scale uses a combination 
of Likert scale and dichotomous scoring options. The Likert scoring option is used for food 
addiction symptom counts (for instance tolerance and withdrawal) ranging from 0 to 7 
symptoms. The criteria for food addiction were met when three or more symptoms were 
present within the past 12 months and clinically significant impairment or distress was 
present. (46, 47). 
Genomic DNA Isolation, Whole Exome Sequencing and Genotyping 
Genomic DNA was isolated from ∼5 ml of whole blood using the Wizard Genomic DNA 
Purification kit (Promega, Madison, WI) according to the manufacturer's protocol (48). In 
stage I, the samples were kept on the ice and they were sent to BGI Americas, for exomes 
sequencing. The sequencing was done using Latest Illumina HiSeq 4000 system with 100bp 
and 150bp paired-end sequencing with mapping rate above 98% (49). The coverage of 
target region and flanking region in our samples were above 99.6% overall. 
In stage II, genotyping of the listed SNPs in Table 6 were completed in Génome Québec 
Innovation Centre using Sequenom iPLEX Gold genotyping technology. The genotyping 
reaction is based on a multiplex PCR followed by a template-directed single base extension 
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(SBE) using a probe. The products were then separated and detected by mass spectrometry 
(MALDI-TOF MS). The assay conversion rate was between 85% depending on the 
projects. The call rate was about 92% and the error rate was less than 0.1 % (50).  
Physical Activity Assessment  
The Baecke physical activity questionnaire was used to assess physical activity. This 
questionnaire assesses physical activity using three indices including work, sport, and 
leisure. (51). This questionnaire has been validated numerous times in different populations 
and has well applied in our studies in the Newfoundland population (44, 52-54).  Physical 
activity level was used as a confounding factor in subjects’ selection among the three 
groups in stage I study. 
Statistical Analysis 
In both stages the subjects were categorized by BMI and food addiction symptom counts 
into three groups: obese subjects with high food addiction symptom counts ≥5 (FAO), 
obese subjects with low/zero food addiction symptom counts (NFO) and normal weight 
subjects with low/zero food addiction symptom counts which was the healthy control group 
(Ctrl). In the exome sequencing study, we had limited subjects (8 in each group), the aim 
was to investigate a quantitative relationship between addiction genes and addictive 
tendencies towards food; the YFAS food addiction diagnosis is a binary and “Yes” or “No” 
qualitative method would not meet this objective. Therefore, we decided to use the YFAS 
clinical symptom counts as a semi-quantitative genetic marker in the analysis. Physical 
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characteristics are reported as mean±SD, maximum and minimum values using SPSS, 
version 20.0 (SPSS Inc, Chicago).  
Stage I: The primary exome sequencing data included 270263 Single Nucleotide 
Polymorphisms (SNPs). The quality of data was checked using PLINK 1.9 (55, 56). The 
inclusion criteria were: 1) SNPs with call rates above 95%; 2) SNPs with minor allele 
frequencies 5% or greater; and 3) SNPs deviating from Hardy-Weinberg Equilibrium 
(HWE) at p-values <0.01 obtained from Pearson’s chi-squared test. Following the 
aforementioned steps, linkage disequilibrium based SNPs pruning was performed. After all 
quality control steps, 12288 subsets of the tagging SNPs remained available for the 
analysis. To compare the differences between the three groups of FAO, NFO and Ctrl, 
genetic association analysis and odds ratio calculation were performed using a chi-squared 
test. For all analyses, the alpha level was set at 0.05. The correction for multiple 
comparisons was not performed, because the exome sequencing study was a pilot study 
and the sample size was relatively small in the three groups. However, each of the 
individuals was well matched between three groups for gender, age, and physical activity 
level that would reduce the heterogeneity of subjects and increase the chance to detect a 
potential difference among the three groups. The 100 SNPs with the most significant 
differences among the 3 groups were evaluated in the vast literature review to find out their 
relevant functions, the genes that each SNP falls in and furthermore the gene functions. All 
the discovered genes were categorized into 5 subgroups based on gene functions i.e. 
addiction, psychological disorders, energy metabolism and obesity or obesity-related 
diseases, cancer and the genes with unknown function or with other diseases out of the 
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previously listed diseases. The addiction-related genes were selected. These genes are 
associated with alcohol, nicotine, substance dependence or behavioral addictions, like 
gambling. Psychological disorder related genes were all associated with major depression 
(57, 58), bipolar disorder (59, 60), Alzheimer disease (61), Parkinson disease (62), 
schizophrenia (63), seizure (64), anorexia nervosa (65), Attention Deficit Hyperactivity 
Disorder (ADHD; refs 66, 67), and autism (68, 69). The reason these psychological 
disorders were selected was the positive association of these diseases with addiction, 
addiction mechanisms or addiction-like behavior (these data are presented in 
supplementary).  
Stage II: A chi-square test was applied to compare the allele frequencies between the three 
groups of FAO, NFO, and Ctrl. Logistic regression under an additive model of inheritance 
adjusting for potential confounders (age, gender, and smoking) was used to find the 
association of the SNPs with high symptom counts within the three groups. We also divided 
the entire population to the subjects with high (HSC) and low symptom counts (LSC). The 
cut-off point for the high symptom counts was set based on 3 and above. In addition, the 
cut-off point for the high symptom count was raised to 4 and above to increase the chance 
of vulnerability of the subject to food addiction and we repeated all the analysis. 
As there were three genotypic groups for each SNP, indicator coding as the reference group 
was tested in two ways of dominant and recessive, since a genetic marker consists of a 
single biallelic locus with alleles a and A (i.e., a SNP). Unordered possible genotypes are 
then a/a, a/A and A/A. A common recessive model indicates that two copies of allele A are 
required for a γ-fold increase in disease risk, and a common dominant model indicates that 
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either one or two copies of allele A are required for a γ-fold increase in disease risk (70). 
The significance level was set at alpha level =0.05. All the analyses were done using SPSS, 
version 20.0 (SPSS Inc, Chicago). 
4.3 Results 
Physical characteristics of subjects in stages I and II 
Demographic and physical characteristics of the participants in the three groups based on 
adiposity and food addiction symptom counts are presented in Table 1 (adiposity was based 
on BMI).  
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Table 4-1 Characteristics of study participants in the two stages* 
Groups  Number Gender Age(Y/O) 
(Min-Max) 
Weight (kg) 
(Min-Max) 
BMI(kg/m2) 
(Min-Max) 
symptom count 
(Min-Max) 
Stage I FAO 8 F 37.4±4.3 
(31-44) 
90.8±9.1 
(78-81) 
33.6±3.1 
(28.8-40) 
5-7 
NFO 8 F 40.5±6.6 
(30-49) 
92.6±3.3 
(88-97) 
34.2±1.2 
(32.4-36.2) 
0-1 
Ctrl 8 F 44.5±11.1 
(30-61) 
59.1±4.9 
(50-65) 
21.6±1.8 
(18.7-24) 
0-1 
Stage II FAO 103 F:69 
M:34 
43.5±10.8 
(19.8-73.8) 
93.4±19.3 
(63-149.8) 
32.6±5.2 
(25-54.2) 
3-7 
NFO 359 F:170 
M:189 
45.5±12.2 
(19-77.4) 
87.3±15.8 
(57-139.8) 
29.7±4.1 
(22.7-53.6) 
0-2 
Ctrl 264 F:208 
M:56 
44±14.8 
(19-90) 
62.8±8.1 
(38.6-95.8) 
22.4±1.6 
(16.8-25) 
0-2 
 
* Y/O– years old, Min– minimum, Max– Maximum, BMI – Body mass index, FAO –overweight/obese 
subjects with high Food addiction symptom, NFO –overweight/obese subjects with low/zero food addiction 
symptoms, Ctrl– Normal weight subjects with low/zero food addiction symptoms were  defined by BMI 
according to world health organization (WHO) criteria (45) 
**Mean±Standard deviation 
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Stage I: Exome Sequencing Study 
I. SNPs with significant difference of allele frequencies in genes associated with 
addiction among the three groups  
I.1. Comparison between FAO and NFO 
Among the 100 SNPs with the most significant allele frequency differences between two 
groups of FAO and NFO, 7 SNPs located in 7 different genes were discovered that are 
associated with addiction (Table 2). All the SNPs had significantly higher minor allele 
frequencies in FAO than NFO. In the case of minor allele frequency equal to zero in any 
group, all the SNPs except rs2167068 were functional based on the information obtained 
from F-SNP database (http://compbio.cs.queensu.ca/F-SNP/). Among these addiction-
related genes, TIRAP (71), ITPR2 (72) and MYPN (73) are positively associated with 
smoking. MMADHC (74), ERAP1 (75, 76), GRID1 (77, 78) and ITPR2 (79) are related to 
alcohol dependence.  ITPR2 is also associated with gambling (80). NTM is closely linked 
to a related gene family member, opioid binding protein/cell adhesion molecule-like 
(OPCML), on chromosome 11 (81). 
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Table 4-2 SNPs with significantly different frequencies that are associated with addiction-
related genes between FAO and NFO * 
CHR SNPs Alleles Minor 
Allele 
Freq 
FAO 
Freq 
NFO 
P OR Gene 
11 rs625413 T/C T 0.4 0.1 0.01 11.7 TIRAP 
2 rs10932467 G/T G 0.3 0 0.02 0 MMADHC 
5 rs26653 C/G C 0.3 0 0.02 NA ERAP1 
11 rs2739287 T/C T 0.5 0.1 0.02 7 NTM 
10 rs3814183 A/G A 0.4 0.06 0.03 9 MYPN 
10 rs2607863 T/C T 0.3 0 0.03 NA GRID1 
12 rs2167068 T/C T 0.3 0 0.03 NA ITPR2 
* CHR- chromosome, SNPs- Single Nucleotide Polymorphisms, Freq_FAO- minor allele frequencies in 
obese subjects with high symptom counts, Freq_NFO- minor allele frequencies in obese subjects with 
low/zero symptom counts, OR-odds ratio.  
**Independent t-test, p<0.05 
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I.2. Comparison between FAO and Ctrl 
Among the 100 SNPs with the most significant allele frequency differences between FAO 
and control, nine SNPs on 8 different genes were found and these genes had previously 
been associated with addiction (ndence or nicotine dependence.  
Table 4-3). All the SNPs mentioned above had significantly higher minor allele 
frequencies in FAO than NFO. In the case of minor allele frequency equal to zero in any 
group, all the SNPs except rs28429551 were functional based on the information obtained 
from F-SNP database (http://compbio.cs.queensu.ca/F-SNP/). The addiction-related 
genes, including GPSM1 (82, 83), ZCCHC14 (84), TNN (85) , PPARD (86), CAV1 (87), 
CACNA1C (88) and SIM1 (89) were associated with alcohol dependence, drug 
dependence or nicotine dependence.  
Table 4-3 SNPs with significantly different frequencies associated with addiction-related 
genes between FAO and Ctrl 
CHR SNP Alleles Minor 
Allele 
Freq 
FAO 
Freq 
Ctrl 
P OR Gene 
9 rs28429551 T/A T 0.5 0 0.002 NA GPSM1 
16 
rs1050847 C/T C 0.5 0.06 0.007 15 ZCCHC14 
rs2042395 G/A G 0.5 0.06 0.007 15 
11 rs2739287 T/C T 0.5 0.07 0.01 13 NTM 
1 rs4651335 C/G C 0 0.3 0.01 0 TNN 
6 rs2016520 C/T C 0.3 0 0.01 NA PPARD 
7 rs1997623 A/C A 0.3 0 0.01 NA CAV1 
12 rs7136355 T/C T 0.3 0 0.02 NA CACNA1C 
6 rs397662 C/T C 0.3 0 0.02 NA SIM1 
* CHR- chromosome, SNPs- Single Nucleotide Polymorphisms, Freq_FAO- minor allele frequencies in 
obese subject with high symptom counts, Freq_Ctrl- minor allele frequencies in normal weight subject with 
low/zero symptom counts, OR-odds ratio 
** Independent t-test, p<0.05 
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I.3. Comparison between NFO and Ctrl 
In comparison between the two groups of obese and normal weight subjects both with 
low/zero symptom counts, only 35 SNPs had significant differences in allele frequencies. 
Among them, minor allele G of rs2511521 located in DRD2 (90, 91) had higher frequencies 
in the control group (Table 4). 
 
Table 4-4 SNP with significantly different frequencies associated with addiction-related 
genes between NFO and healthy Ctrl* 
CHR SNP Alleles Minor 
allele 
Freq_NFO Freq_Ctrl P 
 
OR 
 
Gene 
 
11 rs2511521 G/A G 0.1 0.5 0.02 0.1 DRD2 
*CHR- chromosome, SNPs- Single Nucleotide Polymorphisms, Freq_NFO minor allele 
frequencies in obese subject with low/zero symptom counts, Freq_Ctrl- minor allele frequencies 
in normal weight subject with low/zero symptom counts, OR-odds ratio 
**Independent t-test, p<0.05 
 
I.4. Comparison between FAO and NFO+Ctrl 
When the subjects with low/zero symptom counts from NFO and Ctrl groups were 
combined (NFO+Ctrl), the allele frequencies were compared within FAO. Eight SNPs 
located in 8 addiction-related genes has been found (Table 5). All the SNPs had 
significantly higher minor allele frequencies in FAO. Among them, the frequency of minor 
allele T in rs2739287 located in NTM was significantly higher in FAO compared to NFO 
and Ctrl, remained strongly significant when the subjects in FAO were compared to the 
subjects in the combined NFO plus Ctrl group. In addition, 3 SNPs including rs2042395 
(G), rs397662 (C) and rs7136355 (T) located in 3 addiction-related genes including 
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ZCCHC14, SIM1, and CACNA1C respectively, that had significant differences in allele 
frequencies between FAO and NFO, remained significant when FAO was compared to 
NFO plus Ctrl. In addition to the SNPs discussed above, rs2272409 (C), rs4728329 (A), 
rs4833463(A), and rs3934648 (T) located in ALK (92, 93), AKR1B10 (94), UGT8 (95, 96) 
and PTPN7 (78) respectively, showed higher allele frequencies in FAO. Based on the 
information obtained from F-SNP, both rs4728329 and rs4833463 with the minor allele 
frequency equal to zero in subjects with low/zero symptom counts were functional.  
Table 4-5 SNPs with significantly different frequencies associated with addiction-
related genes between NFO and NFO+Ctrl* 
CHR SNP Alleles Minor 
alleles 
Freq_FAO Freq_NC P OR Gene 
11 rs2739287 T/C T 0.5 0.1 0.003 9 NTM 
16 rs2042395 G/A G 0.5 0.1 0.01 7 ZCCHC14 
2 rs2272409 C/T C 0.4 0.1 0.01 7 ALK 
6 rs397662 C/T C 0.3 0.04 0.01 12.3 SIM1 
7 rs4728329 A/G A 0.2 0 0.01 NA AKR1B10 
12 rs7136355 T/C T 0.3 0.03 0.01 11.6 CACNA1C 
4 rs4833463 A/G A 0.2 0 0.01 NA UGT8 
1 rs3934648 T/C T 0.4 0.1 0.02 5.8 PTPN7 
CHR- chromosome, SNPs- Single Nucleotide Polymorphisms, Freq_FAO- minor allele frequencies in obese 
subject with high symptom counts, Freq_NC- minor allele frequencies in obese and normal weight subject with 
low/zero symptom counts, OR-odds ratio 
** Independent t-test, p<0.05 
  
137 
 
Stage II: The genetic association study 
Genotype frequencies of SNPs located in addiction-related genes 
Table 4-6 presents the comparison of genotypic frequencies of the 19 SNPs located in 
addiction-related genes among FAO, NFO, and healthy Ctrl groups.  
Table 4-6 Comparisons of allelic and the genotypic 
frequencies of the SNPs located in addiction genes 
SNPs CHR Groups Genotype  
TT TC CC 
rs1050847 16 
Ctrl 85(%32.2) 124(%47) 53(%20.1) 
NFO 106(%29.5) 189(%52.6) 64(%17.8) 
FAO 35(%34) 50(%48.5) 17(%16.5) 
rs10932467 2 
 
TT TG GG 
Ctrl 165(%62.5) 79(%29.9) 9(%3.4) 
NFO 225(%62.7) 116(%32.3) 12(%3.3) 
FAO 69(%67) 29(%28.2) 2(%1.9) 
rs1997623 7 
 
CC AC AA 
Ctrl 195(%73.9) 55(%20.8) 12(%4.5) 
NFO 248(%69.1) 101(%28.1) 8(%2.2) 
FAO 70(%68) 29(%28.2) 3(%2.9) 
rs2016520 6 
 
TT TC CC 
Ctrl 163(%61.7) 87(%33) 11(%4.2) 
NFO 225(%62.7) 119(%33.1) 15(%4.2) 
FAO 61(%59.2) 37(%35.9) 4(%3.9) 
rs2042395 16 
 
AA AG GG 
Ctrl 148(%56.1) 94(%35.6) 20(%7.6) 
NFO 217(%60.4) 125(%34.8) 17(%4.7) 
FAO 62(%60.2) 32(%31.1) 8(%7.8) 
rs2167068 12 
 
CC CT TT 
Ctrl 185(%70.1) 69(%26.1) 8(%3) 
NFO 276(%76.9) 74(%20.6) 9(%2.5) 
FAO 77(%74.8) 23(%22.3) 2(%1.9) 
rs2511521 11 
 
AA AG GG 
Ctrl 146(%55.3) 102(%38.6) 14(%5.3) 
NFO 223(%62.1) 123(%34.3) 13(%3.6) 
FAO 69(%67) 25(%24.3) 8(%7.8) 
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SNPs CHR Groups Genotype  
TT TC CC 
rs2607863 10 
 
CC CT TT 
Ctrl 229(%86.7) 31(%11.7) 2(%0.8) 
NFO 308(%85.8) 47(%13.1) 4(%1.1) 
FAO 85(%82.5) 17(%16.5) 0 
rs26653 5 
 
CC CG GG 
Ctrl 143(%54.2) 96(%36.4) 22(%8.3) 
NFO 195(%54.3) 129(%35.9) 35(%9.7) 
FAO 58(%56.3) 36(%35) 8(%7.8) 
rs2739287 
 
11 
 
TT TC CC 
Ctrl 7(%2.7) 68(%25.8) 187(%70.8) 
NFO 2(%0.6) 93(%25.9) 264(%73.5) 
FAO 2(%1.9) 32(%31.1) 68(%66) 
rs28429551 9 
 
AA AT TT 
Ctrl 18(%6.8) 88(%33.3) 155(%58.7) 
NFO 17(%4.7) 138(%38.4) 200(%55.7) 
FAO 9(%8.7) 38(%36.9) 55(%53.4) 
rs3814183 10 
 
GG AG AA 
Ctrl 190(%72) 65(%24.6) 6(%2.3) 
NFO 245(%68.2) 106(%29.5) 8 (%2.2) 
FAO 76(%73.8) 24(%23.3) 2(%1.9) 
rs3934648 1 
 
CC CT TT 
Ctrl 152(%57.6) 98(%37.1) 12(%4.5) 
NFO 206(%57.4) 135(%37.6) 16(%4.5) 
FAO 63(%61.2) 35(%34) 4(%3.9) 
rs397662 6 
 
TT TC CC 
Ctrl 176 (%66.7) 70(%26.5) 4(%1.5) 
NFO 251(%69.9) 86(%24) 4(%1.1) 
FAO 75(%72.8) 22(%21.4) 1(%1) 
rs4651335 1 
 
CC CG GG 
Ctrl 181(%68.6) 77(%29.2) 4(%1.5) 
NFO 267(%74.4) 85(%23.7) 7(%1.9) 
FAO 70(%68.8) 29(%28.2) 3(%2.9) 
rs4728329 7 
 
GG AG AA 
Ctrl 221(%83.7) 39(%14.8) 2(%0.8) 
NFO 282(%78.6) 72(%20.1) 5(%1.4) 
FAO 85(%82.5) 17(%16.5) 0 
rs4833463 4 
 
AG GG 
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SNPs CHR Groups Genotype  
TT TC CC 
Ctrl 14(%5.3) 248(%93.9) 
NFO 19(%5.3) 340(%94.7) 
FAO 6(%5.8) 96(%93.2) 
rs625413 11 
 
CC CT TT 
Ctrl 153(%58) 90(%34.1) 19(%7.2) 
NFO 231(%64.3) 110(%30.6) 18(%5.0) 
FAO 50(%48.5) 42(%40.8) 10(%9.7) 
rs7136355 12 
 
CC CT TT 
Ctrl 185(%70.1) 71(%26.9) 6(%2.3) 
NFO 237(%66) 109(%30.4) 12(%3.3) 
FAO 70(%67.8) 31(%30.1) 1(%1.0) 
* CHR- chromosome, SNPs- Single Nucleotide Polymorphisms, 
FAO–overweight/obese subjects with high food addiction symptom, 
NFO–overweight/obese subjects with low/zero food addiction 
symptoms, Ctrl– Normal weight subjects with low/zero food 
addiction symptoms was defined by BMI according to world health 
organization (WHO) criteria (45). 
The association between SNPs in addiction-related gene and food addiction 
Table 7 shows the significant results. rs2511521 located in DRD2 gene and rs625413 
located in TIRAP gene were significantly associated with increased risk of food addiction. 
In model 1, the indicator coding as genotype reference was carrying the minor allele using 
a recessive model. The major allele A of rs2511521 in NFO subjects is associated with an 
increased risk of food addiction [OR=3.1(95% CI 1.1-8.2)]. In addition, minor allele T of 
rs625413 in NFO subjects is associated with an increased risk of food addiction 
[OR=2.5(95% CI 1.1-5.8)]. In model 2 the indicator coding as genotype reference was 
carrying the minor allele using a dominant model. The results remained significant for 
rs625413 [OR=1.8(95% CI 1.2-2.9)] in NFO. 
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All subjects were classified based solely on symptom counts to the subjects with high 
(HSC) and low symptom counts (LSC). The cut-off point for the high symptom counts was 
set based on 3 and above. Logistic regression under an additive model of inheritance 
adjusting for sex and age was performed based on the new classification as well (Table 8). 
All analyses were repeated after the cut-off point for the high symptom count was raised to 
4 and above. In both classifications, minor allele T of rs625413 in subjects with LSC had 
increased the risk to food addiction. 
In addition, all the analyses were completed between food addicts and non-food addicts, 
and female food addicts and all female non-food addicts (adjusting for major confounding 
factors of age and sex). No significant differences were found in the two models (1 and 2) 
of analysis. 
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Table 4-7 Significant association between SNPs and food addiction 
Model of 
analysis  
SNPs Groups Minor allele Alleles p OR (95% CI) 
Model 1 
rs2511521 FAO 
NFO GG 
AG 0.2 1.8(0.7-4.6) 
AA 0.03 3.1(1.1-8.2) 
Ctrl GG 
AG 0.7 1.2(0.5-3.0) 
AA 0.1 2.3(0.9-6.0) 
rs625413 FAO 
NFO TT 
CT 0.04 2.5(1.1-5.8) 
CC 0.4 1.4(0.6-3.4) 
Ctrl TT 
CT 0.2 1.6(0.7-3.8) 
CC 0.8 1.1(0.5-2.6) 
Model 2 
rs2511521 FAO 
NFO GG+AG AA 0.2 0.7(0.5-1.2) 
Ctrl GG+AG AA 0.048 0.6(0.4-1.0) 
rs625413 FAO 
NFO TT+CT CC 0.007 1.8(1.2-2.9) 
Ctrl TT+CT CC 0.09 1.5(0.9-2.4) 
* SNPs- Single Nucleotide Polymorphisms, OR- Odds Ratio, CI- Confidence Interval, FAO –
overweight/obese subjects with high Food addiction symptom, NFO –overweight/obese subjects 
with low/zero food addiction symptoms, Ctrl– Normal weight subjects with low/zero food addiction 
symptoms was defined by BMI according to world health organization (WHO) criteria (45).  
** Independent t-test, p<0.05 
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Table 4-8 SNPs with significant association to food addiction in the subjects categorized 
solely based on symptom counts  
Symptom counts SNPs Groups 
(N) 
Minor 
allele 
p OR (95% CI) 
3 and above rs625413 
HSC(131) 
TT+CT 0.045 0.7(0.5-1.0) 
LSC(617) 
4 and above 
rs625413 
HSC(69) 
TT+CT 0.01 1.9(1.2-3.2) 
LSC(679) 
rs625413 
HSC(69) 
TT 0.03 1.5(1.0-2.2) 
LSC(679) 
* SNPs- Single Nucleotide Polymorphisms, OR- Odds Ratio, CI- Confidence Interval, HSC-
High Symptom Count, LSC-Low Symptom Count. 
**The reference category was HSC 
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4.4 Discussion: 
As the first exome study on food addiction, the unique study design with two equally obese 
groups but different in food addiction symptom counts, plus a healthy control group was 
likely the key for us to identify food addiction-related genes in a relatively small study. 
Several hundreds of genes have been linked to the development of the common form of 
human obesity (13) . It has been well documented that human obesity is a complex disease 
with multiple routes of etiology. One of the major challenges in finding food addiction 
genes in obese patients is to separate the genes causing obesity by food addiction from 
genes that cause obesity by other mechanisms. The two sets of equally obese patients were 
carefully selected. The key difference between the two groups was the food addiction 
clinical symptom counts. There are significant differences in different age groups and the 
prevalence is higher in women than men in food addiction (14, 97). Moreover, physical 
activity level is likely the most prominent factor in the development of human obesity (98, 
99). Physical activity level affects energy expenditure, appetite, food intake (100, 101). It 
is one of the key confounding factors and should have strictly been controlled. Age, gender 
and physical activity level were matched among selected three subject groups in the present 
study. Furthermore, what makes the finding of our study reliable is the combination of the 
screening study using exome sequencing followed by a validation study using a genetic 
association approach. The exome sequencing study enables the unbiased discovery of 
coding variations for subsequent association testing for complex traits. One of the important 
advantages of exome sequencing is providing a well-defined and interpretable target for 
mutations in the locus. These mutations create variants at these loci that can be identified 
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as being associated with the trait (42). However, it is likely that many addiction-related 
genes were potentially missed because of the limitation of the technology and low power 
of the study owing to the small sample size. 
Accumulating evidence from both animal studies as well as our own data on obesity in the 
general population strongly support the concept that food addiction is one of the distinctive 
etiologies of obesity (14). The most compelling evidence that an addiction to food exists is 
the similarities and overlaps in the neurobiological systems activated in both substance 
abuse and over consumption of hyper-palatable food (17-19). There are strong genetic 
components in the development of both obesity and addiction that have been well 
demonstrated by evidence from animal models and humans. Many studies have 
documented genes responsible for addiction in general and especially in substance abuse 
(31-37). However, the knowledge regarding the genetic background of food addition is still 
in the early stage and corresponding data are very scarce. Our present study is the first that 
employed two groups of equally obese patients with distinguished food-addiction symptom 
scores of clinical symptom counts of food addiction, to identify the candidate genes that 
are more likely responsible for food addiction.  
The first gene identified in the present study as a candidate gene for food addiction is the 
DRD2 gene on chromosome 11.  The DRD2 or dopamine receptor D2 gene encodes the 
D2 subtype of the dopamine receptor (102). It is well known that the dopaminergic 
pathways regulate neuronal systems associated with reward sensitivity in both food and 
substance consumption (103, 104). DRD2 is coupled to inhibitory G proteins and its 
activation results in a decrease in intracellular cyclic adenosine monophosphate (105). In 
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the current study, the major allele A of rs2511521 in the DRD2 gene in NFO subjects is 
associated with an increased risk of food addiction [OR=3.1(95% CI 1.1-8.2)]. Because 
both groups of FAO and NFO were obese and the only difference between them was the 
high symptom counts, therefore, the major allele A could represent a risk allele in the DRD2 
gene for food addiction only in obese subjects. This is the first study that has directly 
demonstrated that the DRD2 is a candidate gene responsible for food addiction in obese 
subjects. Previously, a multi-loci genetic profile score [MLGP] as an index of elevated 
dopamine signaling based on six known dopamine-related polymorphisms (located in or 
close to ANKK, DRD2, SLC6A3 and COMT genes) was used to study of food addiction 
by investigating whether this score distinguished those with YFAS-diagnosed food 
addiction from controls (40). The investigators reported that the MLGP score was 
significantly higher in the food-addiction group than in the controls, suggesting the 
involvement of the dopamine-signaling pathway. In addition, in a GWAS of food addiction, 
using a modified Yale Food Addiction Scale (mYFAS) on 9314 women of European 
ancestry, it was reported that DRD2 was nominally significant for food addiction symptom 
counts (p<0.05; ref 106). However, it did not meet their pre-specified significant threshold 
for GWAS (p <2.1×10-4). In addition, one of the main weaknesses of this study was the 
older age of the population and therefore the lower prevalence of food addiction. The 
majority of the population was aged between 62-87 where the prevalence of food addiction 
was only 2.6% and as a result, this may not have been the ideal population in which to study 
food addiction. 
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DRD2 is also the gene that has been reported in several studies to be associated with 
substance dependence (90, 91). For instance, DRD2 (rs1076560) was associated with 
opioid dependence and was significantly associated with increased risk for drug 
dependence (105). Interestingly this reported SNP is on the same LD block as rs2511521 
in the DRD2 gene identified in our food addiction study. The significant associations found 
in drug dependency and food addiction with the DRD2 gene suggest an overlap in the 
neurological pathway between food addiction and substance dependence. 
The second gene identified in the present study is the TIRAP gene (toll-interleukin 1 
receptor (TIR) domain containing adaptor protein) on chromosome 11. TIRAP is an adapter 
involved in Toll-like receptors (TLRs) signaling pathways in the innate immune response 
that results in activation of NF-kappa-B. The innate immune system recognizes pathogens 
through TLRs, which identify pathogen-associated molecular patterns. TLRs recognize 
different pathogen-associated molecular patterns and all TLRs have a Toll-interleukin 1 
receptor (TIR) domain, which is responsible for signal transduction. The protein encoded 
by this gene is a TIRAP involved in the TLR4 signaling pathway of the immune system. It 
activates NF-kappa-B, MAPK1, MAPK3 and JNK, which then results in cytokine secretion 
and the inflammatory response. In addition, TIRAP positively regulates the production of 
TNF-alpha and interleukin-6 (107-109). Over-expression of the TIRAP gene in the brain 
was found after exposure to alcohol and nicotine in mice. Analysis of brain gene expression 
in mice that are genetically predisposed to alcohol consumption indicates a key role of 
TIRAP in regulating alcohol intake (109). In addition evidence in mice with dopaminergic 
neurodegeneration in the nigrostriatal pathway showed that nicotine and caffeine exposure 
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upregulates the gene expression of TIRAP (71). Our previous study on 58 food-addicted 
and non-food-addicted overweight/obese individuals (FAO, NFO) matched for age, sex, 
BMI and physical activity showed FAO group had lower levels of TNF-α as compared to 
NFO group. It indicates there is more likely a specific manifestation in obese food addicts 
contrary to the increased level of TNF-α in obese people (44). Since TIRAP positively 
regulates the production of TNF-alpha, therefore, this gene is also more likely to be 
responsible for increasing the likelihood of food addiction in obese subjects.  
In addition to the two genes, we identified in stage I, the frequency of minor allele T for 
rs2739287 located in NTM in FAO remained significantly different compared to the other 
three groups (NFO, Ctrl, and NFO+Ctrl). However, these significant differences were not 
seen in the verification study. It has to be emphasized that although the total number of 
subjects in our second stage was 752, the statistical power is still relatively small for a 
genetic association study. It is likely many potential candidate genes may have been missed 
including the NTM because of the low statistical power of the present study. NTM or 
neurotrimin is closely linked to a related gene family member, opioid binding protein/cell 
adhesion molecule-like (OPCML), on chromosome 11 (81). In a GWAS for food addiction, 
NTM were significantly associated with clinical symptom counts. As well, the SNP 
rs75038630 located in NTM was significantly associated with a positive diagnosis of food 
addiction (106). Therefore, a verification study on a larger sample is warranted. 
Despite the significant and novel findings, there were limitations in our study. The 
correction for multiple comparisons was not made in the stage I of screening study. 
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Furthermore, in the present study, the information on psychiatric comorbidities and family 
history of eating disorder were not available.   
Another is related to the limitation of exome sequencing technology. In stage I of the 
current study, the sequencing platform had sufficient depth of coverage (≥50X) with high-
quality sequencing data (Q20>90%，Q30>85%). However, exome sequencing has the 
disadvantage that this technology is unable to find non-protein coding genes. In addition, 
in stage I (the exome sequencing study) the medication use has been controlled for the 
selection of the subjects. However, in stage II because so many types of medications were 
used in 752 subjects, it was not possible to categorize the subjects based on medication use 
in a genetic association study. 
The YFAS has been validated in different populations and is used as a tool for the 
calculation of symptom counts over the previous 12 months. The YFAS is the only tool 
available for the diagnosis of food addiction. Using this set of criteria can help to distinguish 
subjects who regularly indulge in hyper-palatable foods from those who have lost control 
over their eating behavior. However, since the questionnaire is self-reported, there may be 
a self-reporting bias (44). 
4.5 Conclusion  
In the current study we employed a strategy of combining the exome sequencing 
technology with a genetic association study to find food addiction related genes. Two genes 
related to addictive tendencies towards food were identified and validated: the DRD2 and 
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TIRAP genes in the Newfoundland population. This is the first time that TIRAP has been 
reported as to be associated with addictive tendencies towards food. 
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Supplementary  
Stage I 
I.S1. SNPs with significant difference of allele frequencies in genes associated with 
psychological disorders among the three groups 
I.S1.1. Comparison between FAO and NFO 
Among the 100 SNPs with the most significant allele frequency differences between two 
groups of FAO and NFO, 19 SNPs located in 15 different genes related to psychological 
disorders has been discovered (Table S1). All the SNPs had significantly higher minor 
allele frequencies in FAO except for rs2991363 (A) located in SVEP1 in which the 
differences between allele frequencies were significantly lower in FAO. In the case of 
minor allele frequency equal to zero in any group, all the SNPs except rs1890100 were 
functional (based on the information obtained from F-SNP database 
(http://compbio.cs.queensu.ca/F-SNP/)).  
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Table S1. SNPs with significantly different frequencies associated with psychological 
disorders related genes between FAO and NFO* 
  
CHR SNP Alleles Minor 
allele  
FreqF
AO 
FreqN
FO 
P OR Gene Disease 
  
8 
rs11203929 T/C T 0.5 0.1 0.01 15 
PCM1 
Schizophrenia 
(110, 111) 
rs28655174 G/A G 0.4 0.1 0.01 11.7 
rs208060 G/A A 0.4 0.1 0.01 11.7 
rs3780103 T/C C 0.5 0.1 0.02 7 
6 rs1890100 G/A A 0.3 0 0.01 NA SYNE1 Bipolar Disorder 
and depression 
(112) (113) 
2 rs10193313 C/A C 0.3 0 0.02 NA EPC2 Alzheimer 
Disease (114) 
2 rs1980844 G/A G 0.3 0 0.02 NA ABCA12 Alzheimer's 
Disease (115) 
13 rs4628819 T/C T 0.3 0 0.02 NA CARS2 Epilepsy (116) 
19 rs1864113 G/C G 0.3 0 0.02 NA BABAM1 Schizophrenia 
(117) 
23 rs5926304 T/C T 0.5 0.1 0.02 7 PTCHD1 Autism (118, 
119) 
11 rs1837971 G/A G 0.4 0.1 0.02 10.1 NAV2 Alzheimer (120), 
ADHD (121), 
schizophrenia 
(122) 
2 
rs2303606 C/A C 0.5 0.1 0.02 7 
DYSF 
Alzheimer 
disease (123) rs2288355 A/T A 0.2 0 0.03 NA 
3 rs4894810   0.2 0 0.03 NA FNDC3B 
(intron) 
Parkinson's 
Disease (124) 
4 rs7694129 T/C C 0.4 0.1 0.03 9 PPP2R2C 
(intron) 
Bipolar disorder 
(125, 126) 
6 rs195860 T/G T 0.3 0 0.03 NA POU3F2 Schizophrenia 
(127), bipolar 
disorder (128)  
6 rs486881 T/G T 0.4 0.1 0.03 9 CCNC Alzheimer's 
disease (129) 
9 rs2991363 A/T A 0 0.3 0.03 0 SVEP1 Bipolar Disorder 
(130)  
11 rs2445290 G/A A 0.4 0.1 0.03 9 OR51L1 Anorexia 
nervosa (131) 
* CHR- chromosome, SNPs- Single Nucleotide Polymorphisms, Freq_FAO- minor allele frequencies in 
obese subject with high symptom counts, Freq_NFO- minor allele frequencies in obese subject with low/zero 
symptom counts, OR-odds ratio 
** Independent t-test, p<0.05  
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I.S1.2. Comparison between FAO and Ctrl 
Among the 100 SNPs with the most significant allele frequency differences between two 
groups of FAO and control, 14 SNPs located in 14 psychological disorders related genes 
has been found (Table S2). All the SNPs had significantly higher minor allele frequencies 
in FOA except for rs1042044 (A), rs2050831 (C), and rs2070179 (T) respectively located 
in GLP1R, VPS13A, and HCLS1. These SNPs had lower frequencies in FAO. Among the 
SNPs with minor allele frequency equal to zero in any group, based on the information 
obtained from F-SNP, no function has been reported for rs13135591, rs534286, rs2861575, 
and rs2272219.  
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Table S2. SNPs with significantly different frequencies associated with 
psychological disorders related genes between FAO and Ctrl* 
C
H
R 
SNP Alleles Minor 
Allele 
Freq 
FAO 
Freq 
Ctrl 
P OR Gene Disease 
13 rs812808 T/C T 0.4 0 0.007 NA DOCK9 Bipolar disorder 
(132) 
19 rs880090 C/G C 0.4 0 0.01 NA GMIP Major 
depressive 
disorder (133) 
22 rs2239766 T/G T 0.5 0.1 0.01 13 SYN3 Schizophrenia 
(134) 
5 rs306573 A/G A 0.4 0.1 0.01 11.
7 
MCTP1 Bipolar 
Disorder (135) 
6 rs1042044 A/C A 0.1 0.4 0.01 0.0
9 
GLP1R Depression 
(136) 
2 rs3770016 A/G A 0.3 0 0.01 NA PDE11A Major 
depressive 
disorder (137) 
4 rs13135591 C/T C 0.3 0 0.01 NA COL25A1 Alzheimer's 
disease (138) 
9 rs534286 A/G G 0.3 0 0.01 NA TMEM24
5 
Schizophrenia 
(139) 
10 rs2861575 T/C C 0.3 0 0.01 NA OPALIN Epilepsy (140) 
9 rs2050831 T/C C 0 0.3 0.02 0 VPS13A Mood disorder 
and 
Schizophrenia 
(141) 
15 rs2272219 T/C C 0.3 0 0.02 NA MTMR10 Seizure (142) 
19 rs3746321 A/G A 0.3 0 0.02 NA ZNF224 Alzheimer 
disease (143) 
21 rs13052645 T/C T 0.3 0 0.02 NA PRDM15 Parkinson 
disease (144) 
3 rs2070179 T/C T 0 0.3 0.02 0 HCLS1 Parkinson 
disease (145) 
*CHR- chromosome, SNPs- Single Nucleotide Polymorphisms, Freq_FAO- minor allele frequencies in 
obese subject with high symptom counts, Freq_Ctrl- minor allele frequencies in normal weight subject with 
low/zero symptom counts, OR-odds ratio 
** Independent t-test, p<0.05 
 
I.S1.3. Comparison between NFO and Ctrl 
Among the 35 SNPs with the most significant allele frequency differences between two 
groups with low/zero symptom counts, 4 SNPs located in 4 psychological disorders 
related genes have been discovered (Table S3). All the SNPs had significantly higher 
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minor allele frequencies in Ctrl except for rs3800842 located in TMEM106B. Minor allele 
C in rs2303606 located in DYSF that was significantly lower in NFO compared to FAO 
(Table S2), remained significantly lower when it was compared to Ctrl. 
Table S3. SNPs with significantly different frequencies associated with psychological disorders 
related genes between NFO and Ctrl* 
CHR SNP Alleles Minor 
allele 
Freq 
NFO  
Freq 
Ctrl  
P 
 
OR 
 
Gene 
 
Disease 
7 rs3800842 A/G A 0.5 0.1 0.04 6 TMEM106B Alzheimer's 
disease (146) 
1 rs3753527 T/C T 0.1 0.4 0.05 0.2 SOAT1 Alzheimer's 
disease (147) 
2 rs2303606 C/A C 0.1 0.4 0.05 0.2 DYSF Alzheimer's 
disease (123) 
1 rs3753527 T/C T 0.1 0.4 0.05 0.2 SOAT1 Alzheimer's 
disease (148) 
*CHR- chromosome, SNPs- Single Nucleotide Polymorphisms, Freq_NFO minor allele frequencies in obese subject 
with low/zero symptom counts, Freq_Ctrl- minor allele frequencies in normal weight subject with low/zero symptom 
counts, OR-odds ratio 
** Independent t-test, p<0.05 
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I.S1.4. Comparison between FAO and NFO+Ctrl 
When the subjects with low/zero symptom counts from NFO and Ctrl groups were 
combined (NFO+Ctrl), the allele frequencies were compared within FAO. Among the 100 
SNPs discovered with the most significant differences in allele frequencies between two 
groups, 13 SNPs located in 13 psychological disorders related genes has been found (Table 
S4). All the aforementioned SNPs had significantly higher minor allele frequencies in FAO. 
In the case of minor allelic frequency equal to zero in any group, based on the information 
obtained from F-SNP, all the SNPs has been functional. 
Among all the reported SNPs in Table S4, rs3746321 (A) and rs880090 (C) located in 
ZNF224 and GMIP, that the minor allele frequencies were significantly higher in FAO 
compared to healthy control (Table S2), the allele frequencies remained significantly higher 
in the subjects with high symptom counts when they were compared with NFO+Ctrl. In 
addition, rs28655174 (G) and rs7694129 (C) located in PCM1 and PPP2R2C that had 
significantly higher minor allele frequencies in FAO compared to NFO (Table S1) 
remained significantly higher when FAO was compared with all the subjects with low/zero 
symptom counts. Furthermore, the frequency of minor allele A in rs28477638 located in 
PRDM15 was significantly higher in FAO compared to all the subjects with low/zero 
symptom counts. More interestingly, different tagging SNPs (rs13052645 and rs28477638) 
located on PRDM15 was significantly higher in FAO when it was compared to healthy 
control or NFO+Ctrl (Table S2).  
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Table S4. SNPs with significantly different frequencies associated with psychological disorders 
related genes between FAO and NFO+Ctrl* 
 
CH
R 
SNP Allele
s 
Mino
r 
allele 
Fre
q 
FA
O 
Freq 
NC 
P OR Gene Disease 
7 rs858506 T/C T 0.3 0.03 0.01 12.4 GATS Depression (149) 
19 rs3746321 A/G A 0.3 0.03 0.01 12.4 ZNF224 Alzheimer Disease 
(143) 
3 rs1480361 T/C T 0.2 0 0.01 NA DOCK3 ADHD-like 
phenotype (150, 
151) 
5 rs545358 C/A C 0.2 0 0.01 NA PLCXD3 Bipolar disorder 
(152) 
14 rs4906357 C/A A 0.2 0 0.01 NA KLC1 Alzheimer Disease 
(153) 
17 rs854625 A/G A 0.2 0 0.01 NA CCL15 Alzheimer Disease 
(154, 155) 
19 rs880090 C/G C 0.4 0.1 0.01 7.8 GMIP Major depressive 
disorder (133)   
17 rs4969350 A/G G 0.5 0.2 0.01 5.4 BAIAP2 ADHD (156) and 
Autism (157) 
8 rs2865517
4 
A/G G 0.4 0.1 0.01 5.4 PCM1  Schizophrenia 
(110, 111) 
21 rs2847763
8 
A/G A 0.2 0 0.01 NA PRDM15 Parkinson disease 
(144) 
4 rs7694129 C/T C 0.4 0.1 0.01 5.8 PPP2R2C 
(intron) 
Bipolar disorder 
(125, 126) 
1 rs2771122 A/G A 0.2 0 0.2 NA PGLYRP4 Parkinson's disease 
(158) 
3 rs310764 A/G A 0.2 0.03 0.2 10.33 SYN2 Epilepsy (159), 
Depression (160) 
* CHR- chromosome, SNPs- Single Nucleotide Polymorphisms, Freq_FAO- minor allele frequencies in 
obese subject with high symptom counts, Freq_NC- minor allele frequencies in obese and normal weight 
subject with low/zero symptom counts, OR-odds ratio 
** Independent t-test, p<0.05 
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I.S2. SNPs with significant difference of allele frequencies in genes associated with 
energy metabolism and obesity or obesity-related disease among the three groups 
I.S2.1. Comparison between FAO and NFO 
Among the 100 SNPs with the most significant allele frequency differences between two 
groups of FAO and NFO, 22 SNPs located in 19 genes related to energy metabolism and 
obesity or obesity-related disease have been found (Table S5). All of the above mentioned 
SNPs had significantly higher minor allele frequencies in FAO except for 3 SNPs including 
rs2733743 (A), rs445664 (G) and rs1004976 (G) located respectively in ATP4A, REG3G, 
and GALNT10. In the case of minor allele frequency equal to zero in any groups, all the 
SNPs except rs2181687 (G), rs10443987 (A), and rs4832106 (G) were functional based on 
the information obtained from F-SNP (http://compbio.cs.queensu.ca/F-SNP/).  
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Table S5. SNPs with significantly different frequencies associated with the genes related 
energy metabolism and obesity or obesity-related disease between FAO and NFO * 
C
H
R 
SNP Alleles Minor 
allele 
Freq 
FAO 
Freq 
NFO 
P OR Gene Disease 
6 
rs3823310 A/C A 0.4 0 0.003 NA 
AKAP12 
Abdominal Fat , 
Waist-Hip Ratio 
(161) 
rs6941075 T/A T 0.5 0.1 0.01 15 
1 rs1409986 A/G A 0.4 0 0.01 NA PTGER3 Obesity  (162) 
6 
rs2181687 A/G G 0.4 0 0.01 NA USP45 
Insulin (163) 
rs6934692 A/G G 0.4 0.1 0.03 9 
11 rs1466426 C/T T 0.4 0.1 0.01 11.7 AMPD3 Energy 
metabolism 
(164) 
2 rs4973588 A/G A 0.3 0 0.02 NA NGEF Obesity (165) 
10 rs1044398
7 
T/A A 0.3 0 0.02 NA ANKRD26 Extreme obesity 
(166), insulin 
resistance (167) 
16 rs9940089 G/C G 0.3 0 0.02 NA ABCC6 Cardiovascular 
disease (168) , 
Diabetes type 2 
(169) 
16 
rs699444 C/T T 0.3 0 0.02 NA 
ZFHX3 
Cardiovascular 
Diseases (170, 
171) rs740178 T/A T 0.3 0 0.02 NA 
14 rs2273394 C/G C 0.3 0 0.02 NA SLC7A8 Blood 
cholesterol 
(172) 
19 rs2733743 A/G A 0 0.3 0.02 0 ATP4A Type 1 diabetes 
(173) 
2 rs7561798 A/G A 0.4 0.1 0.03 9.8 SPHKAP Body Weight 
(161) 
1 rs3768436 G/T G 0.4 0.1 0.03 9 CDC42BP
A  
Cholesterol, 
HDL (172) 
2 rs445664 G/T G 0.1 0.4 0.03 0.1 REG3G Obesity (174) 
2 rs4832106 A/G G 0.3 0 0.03 NA DNAH6 BMI  (161) 
2 rs2579387 C/T C 0.3 0 0.03 NA ANKRD44 Hip circumflex 
(161)  
5 rs6453373 T/A A 0.3 0 0.03 NA AP3B1 Cardiovascular 
disease (175)  
5 rs1004976 A/G G 0.1 0.4 0.03 0.1 GALNT10 BMI (176) 
9 rs4837213 C/T T 0 0.3 0.03 0 FAM102A Obesity-related 
disease  (177) 
9 rs7867211 A/G G 0.3 0 0.03 NA FNBP1 LDL (178) 
11 rs2663168 A/G A 0.4 0.1 0.03 9 ANO3  BMI  (161)  
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C
H
R 
SNP Alleles Minor 
allele 
Freq 
FAO 
Freq 
NFO 
P OR Gene Disease 
11 rs293980 C/T T 0.4 0.1 0.03 9 MUC15 Obesity 
(extreme) (179) 
12 rs310791 A/G A 0 0.3 0.03 0 E2F7 Subcutaneous 
Fat (161) 
12 rs868158 A/G A 0.3 0 0.03 NA GPR133 Obesity (180) 
* CHR- chromosome, SNPs- Single Nucleotide Polymorphisms, Freq_FAO- minor allele 
frequencies in obese subject with high symptom counts, Freq_NFO- minor allele frequencies in 
obese subject with low/zero symptom counts, OR-odds ratio 
** Independent t-test, p<0.05 
 
I.S2.2. Comparison between FAO and Ctrl 
Among the 100 SNPs with the most significant allele frequency differences between two 
groups of FAO and control, 26 SNPs located in 24 genes related to energy metabolism and 
obesity or obesity-related disease have been found (Table S6). All the aforementioned 
SNPs had significantly higher minor allele frequencies in the group with higher symptom 
counts except for rs1560511 (T), rs2886232 (T), rs1883790 (G), rs6009 (T), rs7802841 
(C), rs605251 (G), and both rs6420479 (A) and rs6565491 (C) respectively located in 
PXDNL, ABCA10, JPH2, F5, KIAA1549, ME3, and RPTOR. Among the SNPs with 
minor allele frequency equal to zero in any groups, based on the information obtained from 
F-SNP, for rs734538 (G), rs1560511 (T), rs11243457 (A), rs2886232 (T), rs2235120 (G), 
rs605251 (G), rs6420479 (A), rs6565491 (C), and rs7163339 (T) no function has been 
reported. 
Table S6. SNPs with significantly different frequencies associated with the genes 
related energy metabolism and obesity or obesity-related disease in between FAO 
and Ctrl* 
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C
H
R 
SNP Alleles Minor 
allele 
Freq
FAO 
Freq 
Ctrl 
P OR Gene Disease 
4 rs2278576 C/G C 0.4 0 0.01 NA KIAA0922 Cardiovascular 
disease (181) 
5 rs37567 C/G C 0.4 0 0.01 NA MAST4 Body Weight (182) 
3 rs782427 A/G A 0.4 0 0.01 NA MCM2 Diabetes (183) 
1
1 
rs1044782 A/G A 0.5 0.07 0.01 13 PGM2L1 Diabetes (184)  
2 rs7426114 C/T C 0.4 0.06 0.01 11.7 NEB Waist 
Circumference (161) 
1
1 
rs1074269
9 
A/G A 0.4 0.06 0.01 11.7 ALX4 Diabetes (185) 
1
7 
rs1294016
1 
A/G G 0.4 0.06 0.01 11.7 MYH3 Cardiovascular 
disease (186) 
2 rs3749022 C/T C 0.3 0 0.01 NA HIBCH  BMI (161) 
5 rs1445804 C/T T 0.3 0 0.01 NA DNAH5  Blood Pressure 
(187) 
5 rs2115500 C/T C 0.3 0 0.01 NA POLR3G  Cardiovascular 
disease (188) 
6 rs734538 A/G G 0.3 0 0.01 NA SCUBE3 Cardiovascular 
disease (189) 
8 rs1560511 T/G T 0 0.3 0.01 0 PXDNL Cardiovascular 
disease (190) 
8 rs6991629 A/G A 0.3 0 0.01 NA FER1L6 Diabetes (169) 
9 rs1124345
7 
A/C A 0.3 0 0.01 NA RAPGEF1 Diabetes (191) 
1
1 
rs3802762 A/G A 0.3 0 0.01 NA  CHST1  Glucose metabolism 
(192) 
1
7 
rs2886232 C/T T 0 0.3 0.01 0 ABCA10 Cholesterol 
metabolism (193) 
2
0 
rs1883790 A/G G 0 0.3 0.01 0 JPH2 Cardiovascular 
disease (194) 
1 rs6009 C/T T 0 0.3 0.02 0 F5 Cardiovascular 
disease (195) 
7 rs7802841 C/A C 0 0.3 0.02 0 KIAA1549 Cardiovascular 
disease (196) 
8 rs2235120 C/G G 0.3 0 0.02 NA MYOM2 Cardiovascular 
disease (172) 
1
1 
rs1154907
6 
A/G A 0.3 0 0.02 NA 
ME3 
(intron) 
Diabetes (197) 
rs605251 A/G G 0 0.3 0.02 0 
1
7 
rs6420479 A/G A 0 0.3 0.02 0 
RPTOR Obesity (198, 199) 
rs6565491 C/T C 0 0.3 0.02 0 
5 rs379707 C/A C 0.3 0 0.02 NA FYB Diabetes(200) 
1
5 
rs7163339 C/T T 0.3 0 0.02 NA SPRED1  Obesity (201) 
*CHR- chromosome, SNPs- Single Nucleotide Polymorphisms, Freq_FAO- minor allele 
frequencies in obese subject with high symptom counts, Freq_Ctrl- minor allele frequencies in 
normal weight subject with low/zero symptom counts, OR-odds ratio 
** Independent t-test, p<0.05 
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I.S2.3. Comparison between NFO and Ctrl) 
Among the 35 SNPs with the most significant allele frequency differences between two 
groups with low/zero symptom counts, 5 SNPs located in 5 genes related to energy 
metabolism and obesity or obesity-related disease has been found (Table S7). Among 
these SNPs, rs1950501 (G), and rs10497553 (C), respectively located in RIPK3, and 
CWC22 had significantly higher minor allele frequencies in the group with higher BMI 
(NFO). 
Table S7. SNP with significantly different frequencies associated with the genes 
related energy metabolism and obesity or obesity-related disease between NFO and 
healthy Ctrl* 
 
CHR SNP Alleles Mino 
allele 
Freq 
NFO  
Freq 
Ctrl  
P 
 
OR 
 
Gene 
 
Disease  
12 rs2255301 T/C T 0.1 0.5 0.03 0.1 CD4 Diabetes type 1(202) 
14 rs1950501 G/C G 0.5 0.1 0.03 7 RIPK3 Obesity (203)  
2 rs10497553 T/C C 0.5 0.1 0.04 6 CWC22 Obesity (204) 
6 rs1874230 A/G A 0.1 0.5 0.04 0.2 EEF1A1 Hypertension (205) 
17 rs8531 T/G T 0.1 0.4 0.05 0.2 C17orf59 Cholesterol regulation 
(206) 
*CHR- chromosome, SNPs- Single Nucleotide Polymorphisms, Freq_NFO minor allele frequencies in 
obese subject with low/zero symptom counts, Freq_Ctrl- minor allele frequencies in normal weight 
subject with low/zero symptom counts, OR-odds ratio 
** Independent t-test, p<0.05 
I.S2.4. Comparison between FAO vs. NFO+Ctrl 
When the subjects with low/zero symptom counts from NFO and Ctrl groups were 
combined (NFO+Ctrl), the allele frequencies were compared within FAO. Among the 
100 SNPs discovered with the most significant allele frequency differences between two 
groups, 25 SNPs located in 20 genes related to energy metabolism and obesity or obesity-
related disease has been found (Table S8). All the SNPs had significantly higher minor 
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allele frequencies in the group with high symptom counts. In the case of minor allele 
frequency equal to zero in any groups, based on the information obtained from F-SNP, all 
the SNPs had been functional except for rs2854437 (T), rs228075 (A), rs4970433 (G), 
rs5909118 (T), rs556674 (G), and rs2482023 (A) respectively located in SORD, 
SLC37A1, GLTPD1, MAP3K15, COL12A1 and CAMK1D.  
Among all the reported SNPs, the frequency of minor allele C in rs2278576 located in 
KIAA0922 that was significantly higher in FAO compared to the control group (Table 
S6) remained significantly higher when they were compared to NFO+Ctrl. In addition, 
the minor allele frequency of rs6941075 (T), rs1409986 (A), rs2273394 (C), rs2579387 
(C), and rs2181687 (G) that was significantly higher in FAO compared to NFO (Table 
S5) remained significantly higher when FAO was compared with NFO+Ctrl (Table S8).  
Table S8. SNPs with significantly different frequencies associated with the genes 
related energy metabolism and obesity or obesity-related disease between FAO and 
NFO+Ctrl 
 
C
H
R 
SNP Alleles Mino 
allele 
Freq 
FAO 
Freq 
NC 
P OR Gene Disease 
4 rs2278576 C/G C 0.4 0.03 0.001 18.6 KIAA0922 Cardiovascular 
disease (181) 
8 rs10956163 C/G C 0.3 0 0.004 NA FER1L6 Diabetes (169) 
1
5 
rs2854437 T/G T 0.3 0 0.004 NA SORD Diabetes (207, 
208) 
2
1 
rs228075 A/G A 0.3 0 0.004 NA SLC37A1 Body Weight 
(161) 
6 rs6941075 T/A T 0.5 0.1 0.01 7 AKAP12 
(intron) 
Abdominal Fat , 
Waist-Hip Ratio 
(161) 
1 rs1409986 A/G A 0.4 0.1 0.01 9 PTGER3 Obesity (162) 
2 rs4665119 T/G T 0.4 0.1 0.01 9 RBM43 Diabetes (209) 
9 rs2767012 T/G G 0.2 0 0.01 NA MUSK  
(intron) 
Obesity (210) 
rs8011016 C/T C 0.2 0 0.01 NA SLC7A8 
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C
H
R 
SNP Alleles Mino 
allele 
Freq 
FAO 
Freq 
NC 
P OR Gene Disease 
1
4 
rs2273394 C/G C 0.3 0.03 0.01 12.4 Blood 
cholesterol (172) 
1 rs4970433 A/G G 0.2 0 0.01 NA GLTPD1 Obesity (211) 
2 
rs7565685 C/T T 0.2 0 0.01 NA 
ANKRD44 
Hip circumflex 
(161) rs2579387 C/T C 0.3 0.03 0.02 10.3 
2
3 
rs5909118 T/A T 0.2 0 0.01 NA MAP3K15 Hypertension 
(212, 213) 
1 rs2282366 A/G A 0.2 0 0.01 NA ACTN2 Cardiomyopathy
(214)  
4 rs10856978 C/T C 0.2 0 0.01 NA  NPNT Cardiovascular 
Diseases(215) 
6 rs9348724 C/G C 0.2 0 0.01 NA SYCP2L Cholesterol, 
LDL(172)  
6 rs556674 A/G G 0.2 0 0.01 NA COL12A1 Cardiovascular 
Diseases(216) 
1
0 
rs2482023 A/C A 0.2 0 0.01 NA CAMK1D Diabetes (217) 
1 
rs571026 C/T T 0.4 0.1 0.02 5.8 
RYR2 
Cardiovascular 
Diseases(218) rs1759123 A/G A 0.4 0.1 0.02 5.8 
2 rs2015983 A/C A 0.4 0.1 0.02 5.8 ASB18 Cholesterol, 
LDL(219)  
6 rs2181687 A/G G 0.4 0.01 0.02 5.8 USP45 Diabetes (163) 
* CHR- chromosome, SNPs- Single Nucleotide Polymorphisms, Freq_FAO- minor allele frequencies in 
obese subject with high symptom counts, Freq_NC- minor allele frequencies in obese and normal weight 
subject with low/zero symptom counts, OR-odds ratio 
** Independent t-test, p<0.05 
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I.S3. SNPs associated with the genes related to cancer and the genes with unknown 
function or with other diseases out of the aforementioned disease 
Among the 100 SNPs with the most significant differences in frequencies between 
different groups of FAO, NFO, Ctrl and NFO+Ctrl, the rest of the non-reported SNPs 
listed above were located in the genes associated with different types of cancers, 
congenital genetic diseases, immune system, reproductive system, some diseases like 
Crohn’s disease, dermal disease, malaria, etc. However, some of the SNPs were located 
on genes whose the function has not been cleared yet. 
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Chapter 5. Conclusions, Limitations, and Future Directions  
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5.1 Concluding remarks 
Over the past 3 decades, the global prevalence of obesity has increased substantially and 
this disease has been recognized as the fifth principal cause of death in the world. There is 
a growing interest in the role of food addiction in increasing prevalence of human obesity.  
However, the exploration of food addiction in humans is at an early stage and many 
fundamental questions are yet to be answered. This thesis by a multi-tired approach has 
added distinguished findings in the field of food addiction.  These findings open a novel 
avenue to assess the etiology of obesity and consequently may aid in finding new effective 
methods to treat and prevent obesity.  
In my thesis, the approach for the understanding of the contributing factors in food 
addiction was in three phases and to the best of our knowledge, all the three studies were 
the first study of its kind.  
 In the first phase, we revealed that the prevalence of food addiction in the general 
Newfoundland population was 5.4% with a higher risk in women than men. In addition, on 
average 84% of food addicts were overweight/obese suggesting that obesity featured with 
food addiction may represent an important subgroup of the obese with a distinctive 
etiology. Interestingly, food addiction was significantly associated with the severity of 
obesity/amount of body fat from normal to obese individuals in the general population. 
These data provided a direct evidence that food addiction is strongly associated with 
obesity in the general population. In this phase of the study, we also found that food-
addicted subjects’ diet consisted of a higher percentage of calories from fat and protein, 
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possibly suggesting that these types of foods are more likely to be associated with 
compulsive overeating.  Taken all these findings together, highlighted the necessity to 
understanding the probable etiology of food addiction.  Therefore, in the second and third 
phase of our study, we set two equally obese groups matched by age, gender and physical 
activity levels but with the different phenotype of food addiction (food addicts and non-
food addicts, or with high and low clinical symptom count). Thus, the key difference 
between the two groups was the food addiction phenotype. This study design provided us 
an excellent opportunity to discover the potential cause of obesity-related food addiction. 
In phase II, we discovered significant differences in multiple aspects, including hormonal 
levels and nutritional intakes, between obese food addicts and obese non-food addicts. 
Among 34 neuropeptides, gut hormones, pituitary polypeptide hormones and adipokines 
that regulate appetite and metabolism, obese food addicts had lower levels of TSH, TNF-
α, and amylin, but higher levels of prolactin, as compared to obese non-food addicts. 
Furthermore, in comparison between the two groups, obese food addicts consumed higher 
amount of total calorie intake (per kg body weight), the dietary fat intake (per g/kg body 
weight, per BMI and per percentage of trunk fat), the percent calorie intake from fat and 
carbohydrates (g/kg), sugar, minerals (including sodium, potassium, calcium and 
selenium), fat and its components (such as saturated, monounsaturated and trans fat), 
omega 3 and 6, vitamin D and gamma-tocopherol. Therefore, taken together, the data 
suggest that obese food addicts may consume more hyper-palatable foods that are known 
to have high amounts of fat, sugar, and salt (sodium). 
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The third phase of food addiction study was a two-stage study, a combination of exome 
sequencing method and a candidate gene association approach to find food addiction 
candidate genes. In this study, we used YFAS clinical symptom count as a phenotype of 
food addiction and we also added a healthy group as a control to the other two groups of 
obese with high and low/zero clinical symptom counts. In the first stage, which was the 
exome sequencing study, the 100 SNPs with the most significant allele frequency 
differences among 3 groups were categorized into 5 subgroups based on gene functions. 
The top 19 SNPs (TIRAP, MMADHC, ERAP1, NTM, MYPN, GRID1, ITPR2, GPSM1, 
ZCCHC14, TNN, PPARD, CACNA1C, SIM1, and DRD2) in the addiction subgroup were 
genotyped in the second stage on the entire food addiction population. In the stage II, we 
discovered that the major allele A of rs2511521 located in DRD2 (OR=3.1(95% CI 1.1-
8.2)) and the minor allele T of rs625413 located in TIRAP (OR=2.5(95% CI 1.1-5.8)) in 
obese subjects with low/zero clinical symptoms significantly associated with increased risk 
of food addiction. What made the finding of our study reliable was the combination of the 
screening study using exome sequencing followed by a validation study using different 
methodology, i.e. a genetic association approach. 
In conclusion, this thesis has provided an exclusive insight into the underlying causes of 
obesity and especially food addiction. The major strength of the current thesis was using 
different technologies that allowed us to explore the etiology of food addiction based on 
the fundamental factors responsible for obesity and addiction.  
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5.2 Limitations of the present work 
Despite the significant and novel findings in each study of this thesis, there were limitations 
in our study. Aside from the limitations that were discussed in each paper, there are few 
additional concerns on the studies. The first limitation was attributed to the fact that our 
established food addiction study, as a part of CODING study, was a cross-sectional study. 
Therefore, unlike the longitudinal study, through a cross-sectional study, it was not possible 
to characterize inter-relationships and roles of disease risk factors and to supply evidence 
to cause-effect relationships, especially between some of the associations discovered. 
Another limitation of our study is due to the greater number of females compared to males 
in the food addiction study. This could be justified by the notion that females are more 
likely to participate in population-based studies.  
5.3 Future direction 
The findings of the current thesis have opened up a number of avenues for the future work. 
As mentioned in above, a cross-sectional study has some limitations. Converting the 
existing cross-sectional CODING study to a new longitudinal design will greatly increase 
its value because a longitudinal study will provide valuable information to further 
characterize interrelationships and roles of appetite-regulating hormones and dietary intake 
in obesity and food addiction. Furthermore, this type of study will supply evidence to 
cause-effect relationships, especially between some of the associations discovered in the 
CODING study. At the current time, 10% of the subjects has participated from 2 to 8 times.  
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We have the plan to expand our CODING study to a longitudinal study in the near future 
and re-invite the subjects. 
We recently started to add a further questionnaire to evaluate binge eating disorder in our 
CODING study. One of the limitations of our study was the lack of information on other 
eating disorders comorbidities. Evidence supports that there are overlaps between food 
addiction and other eating disorders like binge eating disorder. However, there is no study 
available to show, to what degree and in which aspect this overlap exists. Therefore, this 
information will provide valuable information on differences of the genes and appetite 
regulating hormones in the subjects with food addiction and binge eating disorder. 
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A2.1 The role of food addiction and gut hormones in obese Newfoundland children 
Agency:  
Janeway Foundation Research Award 
Grant period  
2013-2014 
Budget:  
$5,000 
Summary 
Background: Background: Childhood obesity is one of the most serious public health 
challenges. In Canada, Newfoundland has the highest rate of overweight and obese. The 
causes of childhood obesity are not yet completely understood. Our findings in our 
previous study on adult general population provide strong evidence that food addiction 
may represent a distinct etiology of human obesity. However, to the best of our knowledge 
there is no data are currently available regarding the role of food addiction in childhood 
obesity. 
Objectives: To assess 1) the prevalence of food addiction in obese children, 2) the 
correlation of clinical symptom counts of food addiction with body composition 
measurements in obese children and 3) comparison of gut hormones level in food addicted 
and non-food addicted obese children to investigate if gut hormones are related to food 
addiction. 
Method: With a previously awarded CIHR operating grant, a total of 125 families from 
the Canadian province of Newfoundland and Labrador with at least one obese child plus a 
parent or two parents recruited. And anthropometric measurements, body composition 
measurements, physical activity level and calorie intake was measured and the data entered 
in our data base. With the help of participant’s parent or guardian the Yale Food Addiction 
Scale (the questionnaire for diagnosis of food addiction) will be filled. Gut hormones 
(Ghrelin, GLP-1, PYY, GIP, CCK, amylin, PP) will be measured using MAGPIX system 
and ELISA. 
Expected results: For the first time, we will: 1) find prevalence of food addiction in obese 
children, which is extremely important for dissecting the etiology of childhood obesity, 2) 
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obtain solid evidence that food addiction contributes to childhood obesity, and 3) explore 
if gut hormones are related to food addiction. 
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A2.2 The Association of Dietary Selenium Intake and Level of Serum Selenium with 
Childhood Obesity 
Agency:  
Janeway Foundation Research Award 
Grant period  
2015-2016 
Budget:  
$6,000 
Summary 
Background: The rapidly rising prevalence of childhood obesity in Newfoundland and 
Canada has become a severe public health problem. However, the etiology of childhood 
obesity is not completely clear. Studies from our lab and others suggested that certain 
micronutrients might be associated with increased body fat deposition in adults, however 
little research has been done on obese children. In one of our previous studies on adults in 
the Newfoundland population we have discovered that dietary selenium has a significant 
beneficial effect on body composition. There are few studies available regarding the 
beneficial effect of serum selenium in obese children, however, the results from these 
studies were inconsistent. To the best of our knowledge there is no study available 
regarding the effect of dietary selenium on obesity indexes in children. 
Objectives: In the current proposal, we will: 1) compare dietary selenium intake and serum 
selenium levels among obese/overweight, and normal weight children in Newfoundland, 
2) analyze the correlation between dietary selenium intake and serum selenium levels with 
obesity indexes, 3) find out the beneficial dose of dietary selenium on obesity indexes 
Method: The proposed study will be built on an existing CIHR previously funded 
childhood obesity cohort consisting of 125 obese children recruited from Newfoundland. 
In addition, 125 Normal weight children will be used from study funded by a 2013 Janeway 
Research Award. Serum selenium level will be measured in both groups using atomic 
absorption spectrometry. The Dietary selenium intake will be measured in both groups 
using Willet Food Frequency Questionnaire.  
Expected results: We are expecting to obtain:1) Beneficial association of dietary selenium 
with obesity measurements, 2) Significant difference of dietary selenium intake and serum 
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selenium level among obese/overweight and normal children. The findings will provide 
solid evidence for policy makers to create policy or program to reduce the prevalence of 
child obesity in Newfoundland by implanting new program to supplement selenium in diet 
(school lunch for example). 
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A2.3 The Association of Dietary Calcium Intake and Level of Serum Calcium with 
Obesity and Insulin Resistance in NL Children 
Agency:  
Janeway Foundation Research Award 
Grant period  
2016-2017 
Budget:  
$5,000 
Summary 
Background: Childhood obesity is one of the most serious public health challenges in 
Newfoundland and Labrador and Canada. Dietary Calcium (Ca) as an important 
micronutrient is well recognized as a critical nutrient, beyond its key role in the 
maintenance of skeletal integrity, in modulating chronic disease risk in both children and 
adults. There are numerous studies available in supporting the beneficial association of 
dietary calcium on body composition in adults and also children. However, it is not clear 
how and in which level the extra cellular calcium can affect the body composition and 
sensitivity to insulin in children. There have been few isolated reports with inconsistent 
results on the relationship between serum calcium and obesity in adults.  However, to the 
best of our knowledge there is no study available on the effect of serum calcium on obesity 
indexes in children. 
Objectives: in the current proposal, we will 1) compare the dietary calcium intake and 
serum calcium levels among obese/overweight, and normal weight children in 
Newfoundland, 2) analyze the correlation between serum calcium levels and dietary 
calcium intake with obesity indexes (BMI, waist and hip circumference, percentage of 
body fat, trunk fat, gynoid and android fat and visceral fat), 3) analyze the correlation 
between serum calcium levels and dietary calcium intake with insulin resistance 
Method: The proposed study will be built on an existing CIHR previously funded 
childhood obesity cohort consisting of 125 obese children recruited from Newfoundland. 
In addition, 125 Normal weight children will be used from study funded by a 2013 Janeway 
Research Award. Fasting serum calcium, insulin level, PTH and 25-OH vitamin D will be 
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measured in both groups. HOMA-β and HOMA-IR will be calculated. The Dietary calcium 
intake will be measured in both groups using Willet Food Frequency Questionnaire. 
Expected results: We are expecting to obtain the following research findings: 1) 
Beneficial association of dietary calcium with obesity indexes, 2) Beneficial association of 
serum calcium with obesity indexes and insulin resistance. 
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ORAL PERESENTAION 
 
1. Two new candidate genes of food addiction identified, 34th Annual Scientific 
Meeting of The Obesity Society; New Orleans, LA , November 2016. 
 
2. Food Addiction: Its Prevalence and Significant Association with Obesity in the 
General Population", 31st Annual Scientific Meeting of The Obesity Society, 
Atlanta, Georgia, November, 2013. 
 
3. Prevalence of food addiction and its association with obesity in the 
Newfoundland population, 3rd Canadian obesity summit, May.2013, Vancouver, 
Canada. 
 
4. The comparison between efficacy of Tamsulosin and Terazosin in alpha-
adrenergic blockers in spontaneous passage of ureter stones after ESWL: 10th 
International Students’ Conference on Biomedical and Interdisciplinary 
Researches (SICOBAIR) May,2009, Iran University of Health and Medical 
Sciences, Tehran, Iran. 
 
POSTER PERESNETATION  
 
1. P Pedram, Tracy Bridger, Yun Huang, Haicheng Zhou, Wayne Gulliver, 
Guangju Zhai, Sudesh Vasdev, Mike Whal, Guang Sun; The Associations of 
Dietary Selenium Intake and Level of Serum Selenium with Childhood Obesity; 
34th Annual Scientific Meeting of The Obesity Society; New Orleans, LA , 
November 2016 
 
2. P Pedram, Tracy Bridger, Yun Huang, Haicheng Zhou, Wayne Gulliver, Sudesh 
Vasdev, Guangju Zhai, Mike Whal, Guang Sun; Negative associations of dietary 
and serum selenium with insulin resistance in children;  34th Annual Scientific 
Meeting of The Obesity Society; New Orleans, LA , November 2016 
 
3. Matthew Nelder, Pardis Pedram, Farrell Cahill, Hongwei Zhang, Guangjo Zhai, 
Wayne Gulliver, Guang Sun; The Association between Food Addiction and Body 
Fat Distribution in Men and Women of the General Newfoundland Population;  
34th Annual Scientific Meeting of The Obesity Society; New Orleans, LA , 
November 2016 
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4. Haicheng Zhou, Pardis Pedram, Yun Huang, Hongwei Zhang, Guang Sun; 
Serum selenium level in response to short term overfeeding in young men;  34th 
Annual Scientific Meeting of The Obesity Society; New Orleans, LA , 
November 2016 
 
5. P. Pedram, P. Gregory, A. Card, T. Bridger, H. Zhang, G. Sun; Serum GLP-1, 
PYY, ghrelin, amylin and TNFα are significantly associated with the severity of 
Childhood Obesity; 33rd Annual Scientific Meeting of The Obesity Society; Los 
Angeles (CA), November 2015 (it has been selected as a top 10 abstract 
presentation in The Paediatric Obesity Section). 
 
6. P. Pedram, W. Gulliver, G. Zhai, E. Aref-Eshghi, H. Zhang, G.Sun; Identifying 
candidate genes of food addiction by exome sequencing; 33rd Annual Scientific 
Meeting of The Obesity Society; Los Angeles (CA), November 2015. 
 
7. Yongbo Wang, Xiang Gao, Pardis Pedram, Mariam shahidi, Jianling Du, 
Yanqing Yi, Wayne Gulliver, Guang Sun. Significantly beneficial association of 
dietary selenium intake with reduced body fat. 33rd Annual Scientific Meeting of 
The Obesity Society, 2015. Los Angeles, November 2-7, 2015 
 
8. P. Pedram, W. Gulliver, D. Wadden, F. Cahill, E. Randell and G. Sun; Hormonal 
and Dietary Characteristics in Obese Human Subjects with and without Food 
Addiction; 32nd Annual Scientific Meeting of The Obesity Society; Boston 
(MA), November 2014. 
 
9. P. Pedram, G. zhai, W. Zhang, Y Zhang, W Gulliver, F Cahill, G Sun; 
Metabolomics Characteristics in Obese Human Subjects with Food Addiction; 
32nd Annual Scientific Meeting of The Obesity Society; Boston (MA), 
November 2014. 
 
10. P. Pedram, P. Amini, D. Wadden, F. Cahill, W. Gulliver, G. Zhai, G. Sun, 
Hormonal, metabolic and dietary characteristics in food addicted obese. 31st 
Annual Scientific Meeting of The Obesity Society, Atlanta, Georgia, November 
2013. 
 
11. P. Amini, D. Wadden, F. Cahill, P. Pedram, S. Vidyasankar, W. Gulliver, E.W. 
Randell, H. Zhang, G. Sun. Serum Acylated Ghrelin Is Negatively Correlated 
with High Sensitivity C - Reactive Protein in the Newfoundland Population. 31st 
Annual Scientific Meeting of The Obesity Society, Atlanta, Georgia, November 
2013. 
 
196 
 
12. P. Amini, F. Cahill, D. Wadden, P. Pedram, S. Vidyasankar, W. Gulliver, E.W. 
Randell, G. Sun. High Dietary Selenium Intake Is Associated with a Low 
Percentage of Body Fat in the Newfoundland Population. 31st Annual Scientific 
Meeting of The Obesity Society, Atlanta, Georgia, November 2013. 
 
13. P. Amini, F. Cahill, D. Wadden, P. Pedram, W. Gulliver, E.W. Randell, T. 
Bridger, H. Zhang, G. Sun. Correlation of Gut Hormones with Body Composition 
Characteristics in Obese Children. 31st Annual Scientific Meeting of The 
Obesity Society, Atlanta, Georgia, November 2013. 
 
14. D. Wadden, P. Amini, F. Cahill, P. Pedram, T. Bridger, W. Gulliver, E.W. 
Randell, G. Sun. Gut Hormones and Childhood Obesity in the Newfoundland 
Population. 31st Annual Scientific Meeting of The Obesity Society, Atlanta, 
Georgia, November 2013. 
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A4.1 Hormonal and Dietary Characteristics in Obese Human Subjects with and 
without Food Addiction 
Presented in 32nd Annual Scientific Meeting of The Obesity Society; Boston (MA), 
November 2014. 
Background: The concept of food addiction (FA) is a potentially important contributing 
factor to the development of obesity in the general population; however, little is known 
about the hormonal and dietary differences between obesity with and without FA. 
Objectives: The aim of our study was to explore potential biomarkers, including various 
hormones and neuropeptides, which regulate appetite and metabolism, and dietary 
components that could potentially differentiate obesity with and without FA.  
Design: Of the 737 adults recruited from the general Newfoundland population, 58 food-
addicted and non-food-addicted overweight/obese individuals (FAO, NFO) matched for 
age, sex, BMI and physical activity were selected. A total of 34 neuropeptides, gut 
hormones, pituitary polypeptide hormones and adipokines were measured in fasting serum. 
Results: We found that the FAO group had lower levels of TSH, TNF-α and amylin, but 
higher levels of prolactin, as compared to NFO group. The total calorie intake (per kg body 
weight), the dietary intake of fat (per g/kg body weight, per BMI and per percentage of 
trunk fat) and the percent calorie intake from fat and carbohydrates (g/kg) was higher in 
the FAO group compared to the NFO group. The FAO subjects consumed more sugar, 
minerals (including sodium, potassium, calcium and selenium), fat and its components 
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(such as saturated, monounsaturated and trans fat), omega 3 and 6, vitamin D and gamma-
tocopherol compared to the NFO group.   
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Table 1: Hormonal and neuropeptide characteristics in food addicted (FAO) and non – food 
addicted (NFO) overweight/obese 
Hormones  
 (pg/ml) 
FAO  
mean± SD  
(14-29) 
NFO 
mean± SD 
 (14-29) 
P  
N
eu
ro
p
ep
tid
es 
NPY  8.81±3.74 5.71±3.82 ns 
α-MSH 148.06±84.16 147.2±89.12 ns 
β-Endrophin 377.86±90.82 396.54±108.3 ns 
Cortisol 230056±100323 232807.9±138900 ns 
Melatonin 3320.9±1377.7 3652.75±1652.43 ns 
MCP1 294.43±88.2 282.56±90.11 ns 
Neurotensin 379.6±103.05 379.32±100.7 ns 
Oxytocin 119.5±49.13 120.22±57.86 ns 
Orexin A 969.6±438.2 974.5±347.5 ns 
AGRP 16.11±6.94 16.18±8.26 ns 
Substance P 39.16±12.51 39.7±15.06 ns 
G
u
t h
o
rm
o
n
es  
Amylin 24.9±11.3 32.05±18.75 0.04 
GLP-1 19.91±22.54 21.4±22.1 ns 
Gherelin 25.4±15.8 25.91±17 ns 
Leptin 20795.4±12173.3 18206.72±10765.9 ns  
GIP 17±16.31 17.05±12 ns 
Glucagon  22.61±10.5 45.1±52.02 ns 
PP 49.3±79.4 46.85±53.4 ns 
PYY 68.33±122.3 93±109.3 ns 
C-peptide  1373.7±740.15 1269±506.74 ns 
P
itu
ita
ry
 p
o
ly
p
ep
tid
e 
h
o
rm
o
n
es 
Prolactin 2335.1±1197.8 1938.3±745.5 0.02 
ACTH 3.05±2.56 5.55±6.93 ns 
BDNF 2219.3±658.73 2138.38±931.52 ns 
LH 6.2±7.3 6.21±8.6 ns 
FSH 13.27±18.75 9.58±14.12 ns 
GH 505.76±635.84 810.83±1019.56 ns 
TSH 0.23±0.32 1.1±2.14 0.01 
CNTF 148.1±324.22 1647.4±6280.6 ns 
A
d
ip
o
k
in
es 
TNF-α 4.21±1.23 4.5±2.2 0.02 
Adiponecin  65700.8±68327.1 71437.3±56215.3 ns 
Lipocalin 357±151.7 462.2±153 ns 
Adipsin 7167.66±2888.25 8009.9±2733 ns 
PAL1 261.3±88.8 261.31±88.84 ns 
Resistin 82±43.4 109±55.8 ns 
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Mean ± standard deviation (SD), FAO– food addiction 
overweight/obese  NFO – non-food addiction overweight/obese, 
BMI – body mass index.  Independent t-test was set to p < 0.05. 
 
Table 2:The significant differences of micronutrient intakes per kg 
body weight between food addicts (FAO) and non-food addicts 
(NFO) overweight/obese. 
BMI 
Dietary intakes FAO (29) 
(mean ± SD) 
NFA (29) 
(mean ± SD) 
p* 
Sugar (g/kg) 1.4 ± 0.8 0.17 ± 0.54 0.03 
Saturated fat (g/kg) 0.25 ± 0.14 0.16 ± 0.06 0.01 
Trans fat (g/kg) 0.001 ± 0.00 0.0007 ± 0.0 0.01 
Monounsaturated fat (g/kg) 0.30 ± 0.13 0.20 ± 0.06 0.01 
Poly saturated fat (g/kg) 0.14 ± 0.07 0.10 ± 0.03 0.00 
Omega 3 (g/kg) 0.007 ± 0.0 0.005 ± 0.0 0.01 
Omega6 (g/kg) 0.05 ± 0.03 0.03 ± 0.02 0.00 
Vitamin B1 (mg/kg) 0.02 ± 0.01 0.017 ± 0.00 0.04 
Vitamin D (IU/kg) 2.5 ± 2.1 1.9 ± 1.0 0.04 
Dihydrophylloquinone (mcg/kg) 0.3 ± 0.03 0.2 ± 0.02 0.03 
Gamma tocopherol (mg/kg) 0.3 ± 0.02 0.02 ± 0.01 0.04 
Sodium (mg/kg) 26.1 ± 12.0 19.4 ± 6.3 0.01 
Calcium (mg/kg) 13.0 ± 7.1 10.0 ± 4.0 0.02 
Potassium (mg/kg) 50.8 ± 21.3 41.2 ± 16.8 0.04 
Selenium (mg/kg) 1.4 ± 0.6 1.1 ± 0.3 0.02 
* Independent t-test was set to p < 0.05. Bolded p indicates p < 0.05 between 
FAO and NFO based on percentage of the body fat as well. 
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Fig.1: Calorie intake characteristics in food addiction and non- food addiction overweight/obese 
groups 
 
Independent t-test test significance level was set to p < 0.05
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Fig. 2: Macronutrients intake characteristics in food addiction (FAO) and non- food addiction (NFO) overweight/obese group 
 
* Independent t-test test significance level was set to p < 0.05 
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A4.2 Metabolomics Characteristics in Obese Human Subjects with Food Addiction 
Presented in 32nd Annual Scientific Meeting of The Obesity Society; Boston (MA), November 
2014. 
Background: Food addiction (FA) is a clinical trait in 5% of the adult population.  
However, the metabolomics (chemical fingerprint of metabolism processes) methodology 
has not been applied to obese with FA.  
Objectives: This study explored the potential differentiation of metabolites among FA and 
non-FA obese. 
Methods: From a total of 737 adults recruited from the general Newfoundland (NL) 
population 25 FA overweight/obese (FAO) and 25 non-FA overweight/obese (NFO) 
matched for sex, age and physical activity were selected. Obesity was evaluated by BMI 
and FA was assessed using the Yale Food Addiction Scale. Serum metabolomics profile 
including 183 metabolites (Acylcarnitines (AC), sphingolipids (SP), amino acids (AA), 
biogenic amines (BA) and glycerophospholipids (GP)) were measured by high 
performance liquid chromatography (HPLC). 
Results: FAO had lower citrulline,SM(OH)C20:2,Ac-Orn and nitrotyrosine vs. NFO. 
Moreover, citrulline and histidine are positively and isoleucine negatively correlated to FA. 
AC (C16:1 and C16:2), SP [SM(OH)C20:2] and BA (Ac-Orn,dopamine,nitrotyrosine) are 
negatively associated with FA in obese. In FAO, C10 (r:0.43) was positively and C5-M-
DC (r:-0.44) negatively among AC,GP (lysoPC a C16:0(r:-0.43) and lysoPC a C20:4(r:-
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0.408) and AA (asparagine (r:-0.40) were negatively correlated to FA symptoms. However 
no metabolites was related to FA symptoms in NFO. 
Conclusions: We have discovered, for the first time, that a number of metabolites may be 
associated with overweight/obesity with food addiction. These metabolites are valuable 
candidates in the study of food addiction. 
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Fig. 1: Significant differences of metabolites level between food addicts and non-food addicts overweight/obese 
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Table 1. The significant association between food addiction 
and serum metabolites 
 
 
Table 2. the significant association between severity of food addiction and 
serum metabolites 
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A4.3 Serum GLP-1, PYY, ghrelin, amylin and TNFα are significantly associated with 
the severity of Childhood Obesity 
Presented in 33rd Annual Scientific Meeting of The Obesity Society; Los Angeles (CA), November 
2015 (it has been selected as a top 10 abstract presentation in The Paediatric Obesity Section). 
Background: The gastrointestinal tract and adipose tissue secrete many hormones that are 
actively involved the regulation of appetite and energy metabolism. The differences 
between obese and normal weight children are rarely reported.  
Objectives: In the current study, we investigated the levels of an adipokine (TNFα) and 9 
gut hormones: amylin, ghrelin, leptin, GLP-1, GIP, PP, PYY, C-peptide and insulin and 
the correlation to obesity measurements in obese and normal weight children.  
Method: 120 obese children from the on-going Childhood Obesity Study were compared 
with 38 normal weight children in the province of Newfoundland (matched with the same 
F:M). Obesity was evaluated using BMI based on the criteria recommended by The Center 
for Disease Control. Gut hormones and TNFα were measured using MAGPIX system on 
fasting serum samples. Body fat percentage (total, trunk, gynoid and android) were 
determined using Dual-energy X-ray absorptiometry.  
Results: ANCOVA analysis, controlling for age showed that obese children have 
significantly lower levels of GLP-1, PYY and TNFα than normal weight group, contrary 
to the report of PYY and TNFα in obese adults. In obese children TNFα and ghrelin were 
negatively while amylin was positively correlated with body composition measurements, 
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further suggesting the uniqueness of relationship between these hormones and obesity in 
children.  
Conclusion: Our results for the first time demonstrated that the severity of childhood 
obesity might be associated with the serum concentration of TNFα, PYY, ghrelin and 
amylin in a different way than adults.  
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Fig. 1:  Comparison between adipokine and gut hormones controlling for age in obese and 
normal weight children 
 
GLP-1, glucagon-like peptide 1, PYY, peptide tyrosine tyrosine, PP, pancreatic peptide, C-Peptide, 
connecting peptide, GIP, glucose-dependent insulinotropic peptide, TNF- α, tumor necrotic factor alpha, 
MCP-1, monocyte chemoattractant protein 1 
*Independent t-test test significance level was set to p < 0.05
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Table 1. Correlation between obesity indexes and adipokine and gut hormones in obese children   
 
 
  TNF-α GLP1 leptin PYY Amylin C-peptide Ghrelin GIP Insulin PP 
%Body fat 
R -0.2 0.1 0.7 -0.1 0.2 -0.1 -0.3 -0.4 0.1 -0.1 
P 0.02 n.s 0.0 n.s n.s n.s 0.02 n.s n.s n.s 
%Android fat 
R -0.2 0.2 0.6 -0.03 -0.0 -0.1 -0.3 -0.1 0.02 -0.03 
P n.s n.s 0.0 n.s n.s n.s 0.01 n.s n.s n.s 
% Trunk fat 
R -0.2 0.1 0.7 -0.1 0.2 0.02 -0.2 -0.0 0.2 -0.2 
P 0.02 n.s 0.0 n.s n.s n.s 0.04 n.s n.s n.s 
% Gynoid fat 
R -0.2 0.01 0.6 -0.1 0.04 -0.2 -0.2 -0.1 -0.1 -0.1 
P 0.03 n.s 0.0 n.s n.s n.s 0.04 n.s n.s n.s 
Weight 
R -0.1 0.1 0.4 -0.1 0.3 0.0 -0.2 0.2 0.5 -0.1 
P n.s n.s 0.0 n.s 0.003 0.03 n.s n.s 0.0 n.s 
BMI 
R -0.2 0.1 0.5 -0.2 0.2 0.1 -0.2 0.1 0.4 -0.1 
P 0.04 n.s 0.0 n.s 0.02 n.s 0.02 n.s 0.0 n.s 
GLP-1, glucagon-like peptide 1, PYY, peptide tyrosine tyrosine, PP, pancreatic peptide, C-Peptide, connecting peptide, GIP, glucose-dependent 
insulinotropic peptide, TNF- α, tumor necrotic factor alpha, MCP-1, monocyte chemoattractant protein 1 
*Independent t-test test significance level was set to p < 0.05
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A4.4 The Associations of Dietary Selenium Intake and Level of Serum Selenium with 
Childhood Obesity 
Presented in 34th Annual Scientific Meeting of The Obesity Society; New Orleans, LA , November 
2016 
Background: Selenium (Se) is a trace element that plays an important role in adipocyte 
hypertrophy and adipogenesis. Our previous study found that high dietary Se intake (SeD) 
is associated with a beneficial body composition profile in adult Newfoundland (NL) 
population. However, to the best of our knowledge there is no study available in children. 
Objectives: To investigate the association of dietary Se intake and Selenium serum level 
with major obesity indexes 
Method: 120 obese children (Ob) were compared with 38 normal weight children (NW) 
all recruited from NL (matched with gender ratio). Obesity was evaluated using BMI based 
on the CDC criteria for children. Body fat percentages (total and trunk) and visceral fat 
were determined using DXA. SeS (µg/L) was measured by atomic absorption 
spectrometry. SeD (µg/kg/day) was evaluated using the Willett FFQ. 
Results: t-test controlling for age and calorie intake showed that Ob consumed lower 
amount of Se and have lower SeS (p<0.05). In the entire population and Ob, negative 
correlations were found between SeD and all obesity indexes (r:-0.5_-0.2, p<0.03). 
However, SeS in both groups had a significant correlation to only hip and waist 
circumference (r:-0.02 p<0.04). When subjects were grouped into tertiles (low, medium, 
or high) according to SeD (µg /day) and SeS controlled for covariates, those in the highest 
SeD consuming group (top 33.3% or above 128µg /day) had significantly lower level of 
213 
 
all obesity indexes. This level is higher than recommended dietary allowances in children 
and even in adults. However only weight, body fat percentages and visceral fat was 
significantly different between different levels of SeS. 
Conclusion: Our results for the first time showed that in obese children lack of Se intake 
and low level of Se are associated with obesity, especially central obesity marked by higher 
trunk and visceral fat.
214 
 
 
 
Figure 1.Comparison of  A. serum selenium, B. dietary selenium intake per day and C. dietary selenium intake per body weight 
between obese and normal weight children 
*Independent t-test test significance level was set to p < 0.05 
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Table 1.Correlation of serum selenium, dietary selenium intake per day and dietary selenium intake per body weight  with 
major obesity indexes 
Variables    Selenium intake(µg/d) selenium intake 
(µg/kg/day) 
Serum selenium(µg/L) 
Age  
&  
Calorie 
Weight (kg) r -0.02 -0.5 -0.1 
p NS 0.001 NS 
BMI (kg/m2) r -0.1 -0.3 -0.2 
p NS NS NS 
Waist (cm) r -0.1 -0.3 -0.2 
p NS NS NS 
Hip (cm) r -0.09 -0.4 -0.2 
p NS 0.03 NS 
Waist/Hip r -0.04 0.01 -0.04 
p NS NS NS 
BF% r -0.2 0.02 0.03 
p NS NS NS 
TF% r -0.2 0.02 0.04 
p NS NS NS 
Visceral Fat Volume 
(cm3) 
r -0.2 -0.1 -0.3 
p NS NS 0.05 
Visceral Adipose Fat 
Mass (g) 
r -0.2 -0.1 -0.3 
p NS NS 0.05 
BF% – percent, body fat and TF% – percent trunk fat.  
*Independent t-test test significance level was set to p < 0.05
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A4.5 Negative associations of dietary and serum selenium with insulin resistance in 
children 
Presented in 34th Annual Scientific Meeting of The Obesity Society; New Orleans, LA , November 
2016 
Background: Selenium (Se) can mimic insulin function. Se has been shown to be 
protective against the development of diabetes. Recent studies in adults have shown that 
high Se exposure may increase the risk of type 2 diabetes and insulin resistant (IR). 
However, to the best of our knowledge, there is no study in children.  
Objectives: In the current study, we investigated the link between dietary Se (SeD) and 
serum Se (SeS) with IR. 
Method: 120 obese children (Ob) were compared with 38 normal weight children (NW) 
in Newfoundland (matched with gender ratio). Obesity was evaluated using BMI based on 
the CDC criteria for children. SeS (µg/L) was measured by atomic absorption 
spectrometry. SeD (µg/kg/day) was evaluated using the Willett FFQ. Fasting serum 
glucose (FSG) was measured by Immulite 2500 autoanalyzer.  Fasting insulin (FIN) was 
measured by MAGPIX. Homeostatic Model Assessment of β cell function (HOMA-β) and 
Insulin Resistance (HOMA-IR) were used for measurement of insulin resistance.  
Results: Partial correlation controlling calorie intake and age in the entire study showed a 
significant negative correlation between SeD and FIN, HOMA-β and HOMA-IR (r:-0.3, 
p<0.0001) but no correlation with SeS was found. In obese children no association was 
found between SeD and SeS and IR. However in the NW there was a negative correlation 
between SeS and FIN, HOMA-β and HOMA-IR (r:-0.5, p<0.01) but no association was 
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found between SeD and IR. When subjects were grouped into tertiles (low, medium, or 
high) according to SeD (µg /day) and SeS controlled for covariates, those in the lowest 
SeD consuming group (lowest 33.3% or below 87µg /day) had significantly lower FIN, 
HOMA-β and HOMA-IR. However SeS between 59-74 µg/L (medium level) had 
significantly lower level of HOMA-β and HOMA-IR. 
Conclusion: Our results showed the beneficial association of dietary Se on IR is consistent 
in both obese and normal weight groups. The beneficial association of serum Se was seen 
in NW children in low to medium level of serum Se. 
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Table 1. Correlation of Serum Selenium (µg/L), dietary Selenium intake (µg/day), dietary Selenium intake per body weight 
(µg/kg/day)  in entire population 
Variables   Serum Selenium 
(µg/L) 
Selenium Intake 
(µg/d) 
Selenium per weight 
(µg/kg/day) 
Age  
&  
Calorie 
Fasting Blood Glucose 
(mmol/L) 
r 0.02 -0.02 0.03 
p NS NS NS 
Insulin (pmol/L) r -0.08 -0.4 -0.4 
p NS 0.00 0.00 
HOMA-IR r -0.06 -0.3 -0.3 
p NS 0.001 0.00 
HOMA-β r -0.1 -0.3 -0.4 
p NS 0.00 0.00 
HOMA-β-Homeostatic Model Assessment of β cell function, HOMA-IR, Homeostatic Model Assessment of Insulin Resistance, NS-Not Significant 
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Table 2. Correlation of Serum Selenium (µg/L), dietary Selenium intake (µg/day), dietary Selenium intake per body weight 
(µg/kg/day)  in normal weight children 
Variables   Serum selenium(µg/L) Selenium intake(µg/d) selenium per 
weight(µg/kg/day) 
Age  
&  
Calorie 
Fasting Blood 
Glucose (mmol/L) 
r 0.07 -0.3 -0.1 
p NS NS NS 
Insulin (pmol/L) r -0.4 -0.2 -0.2 
p 0.006 NS NS 
HOMA-IR r -0.5 -0.2 -0.3 
p 0.002 NS NS 
HOMA-β r -0.4 -0.1 -0.3 
p 0.02 NS NS 
HOMA-β-Homeostatic Model Assessment of β cell function, HOMA-IR, Homeostatic Model Assessment of Insulin Resistance, NS-Not Significant
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Table 3. Correlation of Serum Selenium (µg/L), dietary Selenium intake (µg/day), dietary 
Selenium intake per body weight (µg/kg/day)  in obese children 
 
Variables   Serum selenium(µg/L) Selenium intake(µg/d) selenium per 
weight(µg/kg/day) 
Age  
&  
Calorie 
Fasting Blood 
Glucose (mmol/L) 
r 0.02 -0.01 0.08 
p NS NS NS 
Insulin (pmol/L) 
r -0.1 -0.1 -0.09 
p NS NS NS 
HOMA-IR 
r -0.09 -0.2 -0.1 
p NS NS NS 
HOMA-β 
r -0.2 -0.2 -0.2 
p NS NS NS 
HOMA-β-Homeostatic Model Assessment of β cell function, HOMA-IR, Homeostatic Model Assessment 
of Insulin Resistance, NS-Not Significant 
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